The role of platelets in lymphocyte recruitment during liver inflamation by Robinson, Joseph
THE ROLE OF PLATELETS IN 
LYMPHOCYTE RECRUITMENT DURING 
LIVER INFLAMATION 
 
by 
Joseph Robinson 
 
 
 
Thesis submitted to the University of Birmingham for the degree of  
Doctor of Philosophy 
 
 
College of Medical and Dental Sciences 
School of Clinical and Experimental Medicine 
The University of Birmingham 
July 2015 
 
 
 
 
 
 
 
 
 
University of Birmingham Research Archive 
 
e-theses repository 
 
 
This unpublished thesis/dissertation is copyright of the author and/or third 
parties. The intellectual property rights of the author or third parties in respect 
of this work are as defined by The Copyright Designs and Patents Act 1988 or 
as modified by any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission 
of the copyright holder.  
 
 
 
 ABSTRACT 
Platelets have long been known to be capable of mediating lymphocyte recruitment.  
However, their role in recruitment of lymphocytes to the inflamed liver remains unclear.  This 
was investigated in vivo in two murine models of hepatic injury: ischaemia reperfusion (IR) 
and concanavalin A (ConA) injury.  Intravital microscopy studies were conducted in normal or 
thrombocytopenic mice undergoing sham surgery or injury.  Hepatic recruitment of 
fluorescently labelled donor spleen derived T- and B-cells or donor platelets was determined.  
Platelet adhesion was observed in healthy and injured livers, but was not increased following 
injury when the whole region viewed microscopically in the liver was assessed.  However, in 
areas of sustained blood flow, platelet adhesion was significantly increased in IR livers.  T-cell 
adhesion was significantly increased in IR injured livers, with no increases in T- or B-cell 
adhesion following ConA injury.  In thrombocytopenic mice, a significant reduction in T- and 
B-cell adhesion was observed in both IR and ConA livers.  Blocking CD162 (PSGL-1) on T-cells 
significantly decreased their recruitment in both injury models.  Our data demonstrates 
adhesion of both T- and B-cells within the hepatic microcirculation in both injury models is 
platelet dependent.  Interestingly, lymphocyte adhesion within healthy liver was not platelet 
dependent.  Collectively, our results suggest platelets play a key role in mediating lymphocyte 
recruitment to injured liver. 
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1.  GENERAL INTRODUCTION 
 
1.1. Liver Disease and Hepatic Inflammation 
Liver disease is the United Kingdom’s 5th biggest killer and the number of cases is rising (British 
Liver Trust, 2008).  Liver disease covers a range of conditions with varying causes but a 
common feature of all liver diseases is hepatitis, or inflammation of the liver.  Liver 
inflammation is most commonly associated with viral infection (hepatitis virus A-E) but can 
also be caused by other infectious agents, toxic substances such as alcohol, autoimmune 
disorders and liver hypoxia.  Many cases of hepatitis can resolve spontaneously including most 
cases of hepatitis A and E.  However, other cases such as autoimmune hepatitis and hepatitis 
C can become chronic.  These can then progress to cirrhosis and chronic liver failure.  In certain 
cases, such as paracetamol overdose, hepatitis A or B infection or excessive alcohol intake, 
hepatocellular damage can occur rapidly leading to acute or sub-acute liver failure.  When 
liver failure does not resolve itself, treatment is limited to liver transplantation.  However, a 
shortage of donor organs in recent years has led to increased usage of marginal organs (those 
not are not ideal and include donors who are older, have diabetes, hepatitis etc.) or live donor 
transplantation (Angelico, 2005, Abbasoglu, 2008).  Regardless of the cause, liver 
inflammation results in the local accumulation of inflammatory effector cells leading to 
hepatocellular damage.  Although neutrophils have long been considered the main effector 
cell in hepatic inflammation, emerging evidence suggests other blood cells recruited by the 
liver microcirculation play a role. These include lymphocytes and platelets which will be the 
focus of the research contained within this thesis.   
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1.2. Hepatic Microcirculation 
The human liver makes up 2.5% of the body’s weight and as such is its largest organ.  It receives 
approximately 25% of the cardiac output.  The microcirculation of the liver has many functions 
including supplying the liver parenchyma with oxygen and nutrients, clearing toxins and 
foreign bodies from the circulation and also accepting the nutrients absorbed by the small 
intestine for the liver to metabolise.  The microcirculation (of any organ) also permits 
leukocyte entry in to the surrounding interstitium during inflammatory processes.  To ensure 
these various roles can be performed, the liver receives blood from two sources.  The hepatic 
portal vein drains blood from the intestine, spleen, pancreas and gallbladder and supplies 
almost 80% of the total blood flow to the liver.  The hepatic artery, a branch of the aorta, 
supplies oxygenated blood to the liver.  Within the liver, these large vessels become hepatic 
portal venules and hepatic arterioles which mix blood from both sources in hepatic capillaries 
called sinusoids. Blood entering the sinusoids is then drained into the central veins (Vollmar 
and Menger, 2009). 
It is within the sinusoids that the supply of nutrients to the hepatocytes and removal of 
metabolic products takes place.  Since smooth muscle is absent in these capillaries, blood flow 
within them is controlled by contractile sphincters composed of sinusoidal lining cells at both 
the entry and exit points (McCuskey, 2000).  The endothelium lining the hepatic 
microcirculation is markedly heterogeneous.  The endothelial cells lining the sinusoids are 
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Figure 1:1 The Hepatic Microcirculation.  Blood enters the liver via the hepatic artery providing oxygenated blood 
and the hepatic portal vein carrying blood from the intestines. The microcirculation of the liver can be divided 
into hexagonal subunits called lobules.  Within these lobules blood from the hepatic artery and portal vein mix 
in capillaries called sinusoids that have a characteristic morphological pattern. 
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functionally specialised cells that lack tight junctions as well as a basal lamina.  This facilitates 
their role in the clearance of endotoxin/bacteria, regulation of inflammation, leukocyte 
recruitment and their transmigration into the surrounding parenchyma and host immune 
responses to pathogens.  In contrast the vascular endothelial cells lining the larger portal 
venules and hepatic arterioles have a continuous basal membrane and tight junctions 
between cells (Lalor et al., 2002a).  This is appropriate to their main function of distributing 
blood evenly throughout the liver parenchyma (Lalor et al., 2006). 
Between the sinusoidal endothelial cells and hepatocytes lies a blood plasma filled area called 
the perisinusoidal space. Hepatocyte microvilli extend into this space facilitating the 
absorption of plasma components. It is also within this space that hepatic stellate cells (HSCs) 
reside. These cells perform a number of important functions. They are involved in antigen 
presentation (Viñas et al., 2003), they are the main mediators of liver fibrosis through their 
release of collagen (Bataller and Brenner, 2001), and they are important mediators of liver 
regeneration (Balabaud et al., 2004). They also contract following activation during liver injury 
increasing intrahepatic resistance and portal pressure (Rockey and Weisiger, 1996).  
 
1.3. Leukocytes in Hepatitis 
Inflammation is a localised response to pathogens, irritants or cellular damage. The liver is 
highly prone to inflammation due to its roles in metabolism of toxins and immune surveillance 
of the blood leaving the intestine.   During inflamation leukocytes invade the liver parenchyma 
after exiting from the sinusoids and the post-sinusoidal venules.  Although this is an important 
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and much needed process, unwanted or an overwhelmingly excessive activation of these 
inflammatory cells leads to liver damage.   
Leukocytes are derived from haematopoietic stem cells in the bone marrow that collectively 
make up the immune system.  They can be divided into five main subsets which can be 
separated into two distinct groups: granular leukocytes (neutrophils, basophils and 
eosinophils) and non-granular leukocytes (monocytes and lymphocytes).  Evidence suggests 
that neutrophils, monocytes and lymphocytes are the most important of these cell types in 
mediating hepatitis.  Although eosinophil recruitment is observed in several types of hepatitis, 
especially drug induced hepatitis, (Brunt et al., 1999), their role, if any, is poorly understood. 
 
1.3.1. Neutrophils in Hepatitis  
Neutrophils are phagocytic polymorphonuclear cells which account for 50-60% of the total 
circulating leukocytes in humans (Smith, 1994) and approximately 13% of circulating 
leukocytes in C57BL/6 mice (Carp et al., 1972).  They are major players of the rapidly 
responding innate immune system which is the first line of defense against initial 
environmental challenges and injury.  They are recruited to the site of inflammation within 
minutes to hours and are generally the first leukocytes to accumulate in the tissue (Kaplanski 
et al., 2003). Neutrophils play a vital role in fighting infections.  However during inflammation, 
neutrophils can inadvertently mediate cellular damage and death through production of ROS 
and release of other cytotoxic factors (Smith, 1994).  They also play a role in the recruitment 
7 
 
of other leukocytes to the site of inflammation through the release of various pro-
inflammatory cytokines (Scapini et al., 2000).   
Neutrophils have been identified as key mediators of tissue damage in a number of animal 
models of hepatitis including endotoxin induced hepatitis (Jaeschke et al., 1991), hepatic 
ischaemia-reperfusion (IR) injury (Jaeschke et al., 1990) and concanavalin A (ConA)-induced 
hepatitis (Bonder et al., 2005). The latter two models will be discussed later in Sections 1.4 
and 1.5. Hepatic accumulation and activation of neutrophils is also observed in patients with 
hepatitis (Taïeb et al., 2000, Nagore and Scheuer, 1988, Lee, 1989).  Neutrophil-mediated liver 
damage follows their activation by inflammatory chemokines and subsequent accumulation 
within the hepatic vasculature, specifically within the hepatic sinusoids.  From here they are 
able to transmigrate into the surrounding parenchyma to cause hepatocyte damage.  A 
neutrophil elastase inhibitor, Sivelestat, has been shown to confer benefit in patients 
following liver resectioning surgery (Tsujii et al., 2012). However, despite strong experimental 
and pre-clinical data, clinical trials for anti-neutrophil adhesion therapy in different organ 
injuries, including hepatic IR injury, have failed to show a significant benefit (Harlan and Winn, 
2002). This suggests other pathophysiological mechanisms, possibly involving different blood 
cells are involved in hepatitis.  
1.3.2. Monocytes and Macrophages in Hepatitis  
During acute inflammation, neutrophil recruitment is often followed by monocyte 
accumulation (Kaplanski et al., 2003).  Monocytes produce inflammatory cytokines such as 
TNF-α and IL-6 during hepatic inflammation which may contribute to both liver injury and 
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recruitment of additional inflammatory cells.  Their significant presence has been identified 
immunohistologically in liver biopsies of patients with hepatitis and when isolated were found 
to possess a very pro-migratory and activated phenotype (McClain and Cohen, 1989, Longhi 
et al., 2009). 
Macrophages are phagocytic mononuclear cells which form through differentiation of 
monocytes that have transmigrated from the circulation into tissue.  Kupffer cells are 
abundant specialised liver resident macrophages which line the walls of the hepatic sinusoids 
and make up 10-15% of the total liver cell population (Heydtmann, 2009).  They are the largest 
group of fixed macrophages in the body.  Kupffer cells have long been considered as mostly 
scavenger cells, responsible for removing particulate material from the portal blood entering 
the liver from the gut.  However, increasing experimental evidence suggests these cells may 
be implicated in the pathology of various inflammatory liver diseases including viral hepatitis, 
steatohepatitis, alcoholic liver disease and rejection of the liver following transplantation 
(Kolios et al., 2006).  Both Kupffer cells and non-liver resident macrophages appear to 
contribute directly to liver injury and hepatocyte death through release of lysosomal and 
proteolytic enzymes.  They also exacerbate injury through mediating inflammatory cell 
recruitment during hepatitis.  The latter occurs as a result of cytokine release as well as 
generation of ROS, nitric oxide (NO), interferons and other cytokines (Heydtmann, 2009, Nanji, 
2002, Schumann et al., 2000, Sass et al., 2002).  Indeed, Kupffer cells are a significant source 
of chemoattractants for cytotoxic lymphocytes, particularly CD8+ cells and can induce their 
activation (Kolios et al., 2006).    
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1.3.3. Lymphocytes in Hepatitis 
In addition to neutrophils, monocytes and macrophages, lymphocytes also play a role in 
hepatitis.  Unlike the other leukocytes, lymphocytes originate from the common lymphoid 
progenitor as opposed to the common myeloid progenitor during haematopoiesis.  In adult 
humans they make up 31% of circulating leukocytes (Hulstaert et al., 1994) whereas in mice 
they account for 54% (Domínguez-Gerpe and Rey-Méndez, 2001).  Lymphocytes can be split 
into three main groups: natural killer (NK) cells, a component of the innate immune system, 
and T-cells and B-cells, which are part of the adaptive immune system (with the exception of 
natural killer T (NKT) –cells, which bridge the two systems).   The healthy liver has a large 
resident population of lymphocytes representing 25% of non-hepatocytes.  This population 
is made up of 63% T-cells, 6% B-cells and 31% NK cells (Racanelli and Rehermann, 2006).  
These lymphocytes reside in the liver parenchyma, portal tracts and sinusoids.  The large 
population of functionally active resident lymphocytes, in addition to the liver resident 
macrophages, provides vital immune surveillance against foreign antigens, particularly those 
arriving from the gut.  Additional lymphocytes can also be recruited from the peripheral 
circulation in response to infection or injury.  Clearly, this process requires lymphocytes to be 
able to adhere to and transmigrate across the endothelial cells that line the hepatic 
microvasculature.   Studies also suggest that terminally differentiated lymphocytes can be 
removed from the body by the liver, where they are cleared by apoptosis (Crispe et al., 2000). 
Liver infiltration by lymphocytes is a certainly a feature of hepatitis, however the extent and 
type of lymphocytes involved varies from case to case.  In viral hepatitis CD8+ T-cell infiltration 
is responsible for viral clearance and disease pathogenesis (Chisari, 1997, Thimme et al., 
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2003), whereas in experimental models of ConA induced liver injury, little CD8+ T-cell 
infiltration is observed whereas high levels of CD4+ T-cell are observed (Mizuhara et al., 1994).  
Similar results are seen in the post-ischaemic liver where the majority of infiltrating T-cells are 
also CD4+ cells (Zwacka et al., 1997).  B-cell infiltration during hepatic inflammation is 
relatively poorly studied.  However, B-cell deficiency does attenuate liver fibrosis in an 
experimental, carbon tetrachloride (CCL4) induced, model of liver inflammation 
(Novobrantseva et al., 2005).  The role of lymphocytes in the two experimental models of 
injury that will be used in this thesis will be detailed later in Sections 1.4 and 1.5.  The major 
subsets of lymphocytes will be outlined in the following sections and are also summarised in 
Figure 1.2.    
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Figure 1:2 Lymphocyte Development (lymphopoiesis). Lymphocytes originate through differentiation of hematopoietic stem cells which reside in the bone marrow. 
B-cells and most NK cells mature within the bone marrow, but T-cells mature within the thymus. Following maturation lymphocytes enter the circulation and peripheral 
lymph organs.     
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1.3.3.1. T-Cell subsets: CD4+ (Thelper and Treg), CD8+, NK and NKT-cells 
T- and B-cells both originate in the bone marrow with B-cells maturing there and T-cells 
migrating to the thymus to mature and differentiate.  After leaving the bone marrow or 
thymus the naïve cells circulate between the blood and secondary lymphoid organs.  The naïve 
cells continue to circulate until they encounter their specific antigen at which point they 
become activated, proliferate and differentiate into effector cells.  T-cells (CD3+) can be 
distinguished from other lymphocytes by their surface expression of the T-cell receptor (TCR) 
found on all T-cells. The T-cell receptor is a heterodimer made up of α and β or γ and δ chains. 
The TCR associates non-covalently with CD3 signalling proteins, CD3γ, CD3δ and two CD3ε 
chains, to make up the TCR complex (Clevers et al., 1988).  This CD3/TCR protein complex is a 
defining feature of the T-cell lineage and as such anti-CD3 antibodies can be used effectively 
as T-cell markers.  T-cells can be split into a number of subsets based on their function in the 
immune system and expression of various cell surface molecules. 
The CD4+ T-cells are the most common group of T-cells which express the glycoprotein CD4.  
These are non-phagocytic cells whose main role in the immune system is to secrete a variety 
of different cytokines that can then stimulate other immune cells.  The CD4+ T-cells can be 
separated into T-helper (Th) cells and T-regulatory (Treg) cells.  Th cells function primarily to 
stimulate other immune cells e.g. stimulate B-cells to produce antibodies against antigens, 
stimulate cytotoxic cells such as macrophages to destroy pathogens etc.  Th cells can be further 
separated into subsets based on the profile of cytokines they produce.  Two of the main Th 
cell subsets are the Th1 and Th2 cells.  Th1 cells release interferon- (INF-), TNFα, interleukin 
2 (IL-2) and lymphotoxin through which they can activate macrophages and promote cell 
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mediated immunity i.e. destruction of infected or damaged cells  (Romagnani, 1999).  Th2 cells 
release IL-4, -5, -6, -10 and -13 which inhibit certain macrophage functions and induce humoral 
mediated immunity i.e. antibody production from B-cells to remove antigens (Romagnani, 
1999).  Until recently, it was thought that Th1 and Th2 were the only CD4+ T-helper cells.  
However, this  was challenged with the identification of Th17 which could contribute to 
inflammatory diseases such as rheumatoid arthritis and were defined by their production of 
the pro-inflammatory cytokine IL-17 (Furuzawa-Carballeda et al., 2007).  The sub-set field 
expanded further with the identification of IL-9 producing Th cells, termed Th9 cells, which 
have been implicated in allergic inflammation and autoimmune diseases (Kaplan, 2013).  
Follicular helper T-cells are IL-21 producing cells found in the B-cell follicles of lymphoid 
organs. They are involved in stimulation of B-cell differentiation (King et al., 2008).  Th22 cells 
are a recently characterised group of IL-22 producing CD4+ T cells (Duhen et al., 2009), thought 
to be involved in the pathogenesis of inflammatory skin disorders such as psoriasis, atopic 
eczema and allergic contact dermatitis. 
Treg cells (CD4+, CD25+, FoxP3+) act as suppressors of the immune response of other cells and 
prevent autoimmunity.  They are critical in the maintenance of immune cell homeostasis as 
they maintain order in the immune system by negatively regulating other immune cells.  
Therefore, dysfunction of Treg cells can lead to auto-immune disorders (Wing and Sakaguchi, 
2010).  They can be divided into naturally arising Treg cells, which are generated in the thymus 
and function to downregulate the overall immune system, and inducible Treg cells, which are 
generated from naïve CD4+ T-cells following activation and function to prevent immune 
responses in the gut (Wing and Sakaguchi, 2010).  Precise understanding of the role of Tregs is 
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unclear although they are thought to confer immunosuppression through release of soluble 
factors such as IL-9, IL-10 and transforming growth factor  (TGF). 
Another group of T-cells are the CD8+ T-cells which express the CD8 glycoprotein on their 
surface.  Following activation naïve CD8+ T-cells differentiate into cytotoxic T-cells (Tc).  Unlike 
Th cells, the role of CD8+ Tc cells is to kill infected, cancerous or damaged cells, which they do 
through inducing perforin/granzyme mediated apoptosis of the target cell (Trapani, 1995).  
Like Th and Treg cells, Tc cells can also secrete cytokines although in far smaller quantities 
(Mosmann et al., 1997).   
In addition to macrophages and CD8+ Tc cells, NK lymphocytes are also large cytotoxic cells 
containing numerous granules.  They are capable of killing virally infected cells and malignant 
cells. They are also capable of releasing several cytokines including INF-γ, TNF-α, CCL5 and 
CCL3 (Fauriat et al., 2010).  Human NK cells can be identified by surface expression of CD56 
and CD16 and NK cells from C57BL/6 mice can be identified by NK 1.1 and NK 1.2 expression. 
After the lungs, the liver contains the second largest population of NK cells in the body. NK 
cells account for 25-40% of hepatic lymphocytes in humans and 10-20% in mice (Tian et al., 
2013). NK cells play and important role in control of viral hepatitis (Krämer et al., 2012) and 
can inhibit liver fibrosis (Melhem et al., 2006). Suppression of NK cells by chronic alcohol 
consumption is also a contributor to the pathogenesis of alcoholic liver disease (Jeong et al., 
2008).  
Natural Killer T-cell (NKT) are another type of T-cell, so named due to similarities with NK cells 
in function and surface receptor expression.  They are CD1d restricted, express TCRαβ (often, 
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but not always, with an invariant Vα14-Jα18 TCRα chain in mice or Vα24-Jα18 in humans),  and 
generally express NK1.1 (CD161-human); some NKT cells also express CD4 or CD8 (Emoto et 
al., 2000, Pellicci et al., 2002, Godfrey et al., 2004).  In mice they are most frequent in the liver 
where they make up 50% of all mature T-cells but only account for 4% of all hepatic T-cells in 
humans (Godfrey et al., 2000). NKT cells can rapidly release high levels of TNF, IL-4 and INF-γ 
and are implicated in cancer cell killing and the immune responses to various infections 
(Godfrey et al., 2000). They also play a pathogenic role in viral hepatitis (de Lalla et al., 2004, 
Baron et al., 2002) and produce large amounts of inflammatory cytokines during concanavalin 
A induced liver injury (Yamanaka et al., 2004). Mucosal-associated invariant T (MAIT) are a 
group of  NKT like T-cells  which are MR1 restricted, often express NK1.1 (CD161), and express 
an invariant Vα19-Jα33 TCR α chain in mice or Vα7.2-Jα33 in humans (Treiner et al., 2003, 
Treiner et al., 2005, Dusseaux et al., 2011). MAIT cells are enriched within the human liver in 
which the majority of NK marker expressing T-cells have been shown to be MAIT cells (Tang 
et al., 2013). They have previously been shown to be present in the liver during hepatitis C 
infection and are known to produce the pro-inflammatory cytokine IL-17 (Le Bourhis et al., 
2013). 
1.3.3.2. B-Cells 
B-cells (CD19+) can be distinguished from other lymphocytes by their expression of the B-cell 
receptor (BCR) which is responsible for B-cell antigen recognition.  The BCR is made up of a 
membrane bound antibody and a CD79A/CD79B signal transduction moiety (Pleiman et al., 
1994). The primary function of B-cells in the immune response is antibody production (Mauri 
and Bosma, 2012).  In addition to this role, B-cells can also secrete cytokines including TNFα, 
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INFγ, IL-2, -4, -6 and -12 (Lund, 2008).  A small sub-group of B-cells which secrete the anti-
inflammatory cytokine 1L-10 has been termed regulatory B-cells (Breg).  These cells have 
proven to be important suppressors of inflammation in a number of models including colitis, 
collagen induced arthritis and autoimmune encephalomyelitis (Mauri and Bosma, 2012).  IL-
10 producing Breg cells account for only a small proportion of hepatic B-cells in stark contrast 
to the B-cells of the secondary lymphoid organs (Zhang et al., 2013). 
1.3.4. Leukocyte Adhesion Cascade 
Lymphocytes circulate continuously from blood into tissues and secondary lymphoid organs, 
and then return back to the blood to patrol the body in search for antigens, thus providing an 
effective immune surveillance.  However, during inflammation, circulating lymphocytes 
adhere to vascular endothelium in a dynamic process known as the leukocyte adhesion 
cascade (Figure 1.3).  There are three main stages to leukocyte adhesion: slow rolling, 
leukocyte activation and firm adhesion.  The neutrophil adhesion cascade has been very well 
characterised and described.  Since this thesis will be focussing on lymphocytes in the liver, 
the following section will describe the adhesion cascade specifically utilised by lymphocytes 
for hepatic recruitment.  It is apparent that there are many similarities to the adhesive events 
governing neutrophil recruitment.  However, the molecular mechanisms that control the 
recruitment of lymphocytes via the hepatic circulation, under both physiological and 
pathological conditions, have yet to be elucidated fully.  Lymphocytes can be recruited to the 
liver by adhesion to hepatic portal vessels and also sinusoidal capillaries.  However, both these 
microvessels express and utilise different adhesion molecules and cytokines for lymphocyte 
recruitment (Table 1.1). 
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1.3.4.1. Lymphocyte Capture and Rolling 
Leukocyte capture and rolling on endothelium slows the velocity of trafficking leukocytes 
giving them time to form the more stable interactions required for firm adhesion.  Leukocyte 
rolling is primarily mediated by CD62L (L-selectin), CD62E (E-selectin) and CD62P (P-selectin) 
and their counterligands such as CD162 (P-selectin glycoprotein ligand-1; (Kansas, 1996).  All 
four of these are important in mediating neutrophil rolling in other inflamed vascular beds 
(Ley et al., 2007).  In CD62L deficient mice, defects in lymphocyte rolling on the high 
endothelial venules of peripheral lymph nodes is observed (Arbonés et al., 1994).  However, 
the velocity of blood flow in the hepatic sinusoids is lower than that observed in other 
capillaries.  In rats it is around 0.28mm/s compared to 0.96mm/s in the brain and 1.07mm/s 
in the renal peritubular capillaries (Ivanov et al., 1985, Yamamoto et al., 2002).  Due to this 
low rate of blood flow, rolling therefore plays only a minimal pre-requisite role in mediating 
lymphocyte adhesion within the hepatic microcirculation (Wong et al., 1997) and occurs 
primarily in the hepatic portal venules (Sawaya et al., 1999).  Indeed, selectins are generally 
absent from sinusoidal capillaries.   
When not inflamed, the endothelial cells of the hepatic portal vessels and sinusoids 
constitutively express CD54 (intercellular adhesion molecule-1) and vascular adhesion 
protein-1 (VAP-1). However, during inflammation, a whole host of additional adhesive 
molecules are expressed including CD62E, CD62P, CD106 (vascular cell adhesion molecule-1) 
and higher levels of CD54.  The local presence of inflammatory chemokines is also increased.  
CD62P and CD162 appear most relevant in inducing lymphocyte rolling in the liver portal 
vessels.  CD62P is stored in the Weibel-Palade bodies of un-activated endothelial cells and α-
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granules of un-activated platelets, and upon their activation is translocated to the plasma 
membrane (Ley et al., 2007).   CD62P mediated leukocyte rolling is dependent on the 
leukocyte expressed high affinity CD62P ligand CD162 (Norman et al., 1995).   
On sinusoids, where selectins are absent, VAP-1 was identified by Lalor and colleagues as 
another candidate that could support lymphocyte rolling in the liver in a sialic acid dependent 
manner, although it is not as effective as selectins (Lalor et al., 2002).  In addition to selectins 
a number of other cell surface molecules are capable of supporting lymphocyte rolling.  The 
integrins CD49d/CD29 (α4β1, VLA-4) and CD49d/beta7 (α4β7, LPAM-1) have been shown to 
support lymphocyte rolling independently of selectins on CD106 and mucosal vascular 
addressin molecule 1 (MAdCAM-1) respectively (Berlin et al., 1995).  MAdCAM-1 is an 
endothelial cell addressin that was initially recognised to be key player in gut inflammation.  
However it has subsequently been identified in inflammatory liver diseases which occur as a 
result of bowel disorders.   
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Figure 1:3 The Leukocyte Adhesion Cascade. The stages of leukocyte adhesion are shown in bold, key molecules involved in each stage are listed underneath.  
MAdCAM, mucosal vascular addressin molecule 1; PI3K, phosphoinositide 3-kinase; JAM, junctional adhesion molecule; ESAM, endothelial cell-selective adhesion 
molecule.  Figure adapted from Ley et al. (2007).  
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Table 1:1 Molecules involved in the recruitment of lymphocytes to the different hepatic anatomical 
compartments. Adhesion molecules and chemokines implicated in lymphocyte recruitment via hepatic 
sinusoids and portal vessels under normal and inflamed conditions (Liaskou, 2010)  
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The integrins CD11a/CD18 (αLβ2, LFA-1) and CD11b/CD18 (αMβ2, Mac-1), in addition to CD62E, 
are required for slow rolling of leukocytes following TNFα induced inflammation (Dunne et al., 
2002, Kunkel and Ley, 1996) and in inflamed arterioles the CD11a/CD18 and CD11b/CD18 
ligand ICAM-1 is required for leukocyte rolling (Sumagin and Sarelius, 2007).  In fact at low 
shear rates CD11/CD18 and not selectins may be the dominant mediator of leukocyte rolling 
(Gaboury and Kubes, 1994). 
1.3.4.2. Lymphocyte Activation 
During rolling, lymphocytes are exposed to cytokines, released by the inflamed endothelium 
and other inflammatory cells, which trigger their activation.  Cytokines are small secreted 
peptides (5-30kDa) which exert there biological effects through interactions with specific G-
protein linked transmembrane receptors on target cells.  Chemokines are a specific group of 
cytokines which are able to induce directed chemotaxis and are classified based on their 
structure into four subfamilies: CXC, CC, CX3C and XC.  A large number of cytokines have been 
implicated in lymphocyte activation including CCL5 (RANTES), TNF-α, INF-, CXCL12 (SDF-1), 
IL-1, IL-2, IL-3, IL-4, IL-6 and IL-10 (Martino et al., 1998, Turner et al., 1995, Bleul et al., 1996, 
Haas et al., 2011).   
Some of the key players involved in activating lymphocytes in the liver are CXCL12, CCL5, CCL2 
(MCP-1), and CCL3 (MIP-1α) with their expression increasing markedly in the inflamed liver 
(Lalor et al., 2002). Within the liver vasculature the profile of chemokine expression varies 
greatly between vessel types and inflammatory states (Table 1.1), it is this pattern of 
expression that regulates selective recruitment of different lymphocyte subsets to the liver 
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during inflammation.  Increased expression of chemokines during inflammation can result in 
accumulation of lymphocytes expressing corresponding chemokine receptors within the liver. 
During hepatitis C infection the CXCR3 ligands CXCL9 and CXCL10 are expressed by sinusoidal 
endothelium and result in the selective recruitment of CXCR3 positive T-cells. Whereas, the 
CCR5 ligands CCL3 and CCL4 are expressed in portal vessels this results in selective recruitment 
of CCR5 positive T-cells to the liver (Shields et al., 1999). Indeed, both anti-CCR5 anti-CCL3 
antibodies protect against graft versus host disease associated liver injury by preventing 
selective recruitment of CCR5 positive T-cells (Murai et al., 1999) .  High levels of CXCR6 
expressing CD4 and CD8 T-cells have been observed within the inflamed human liver. The 
CXCR6 ligand CXCL16 is upregulated on inflamed bile ducts and hepatocytes and has been 
suggested to be important for the recruitment of effector T-cells within the liver (Germanov 
et al., 2008). 
Although cytokines are soluble, a significant proportion becomes bound to proteoglycans, 
such as heparin sulphate on endothelial cell.  These proteoglycans constitute the glycocalyx 
on the apical or lumenal side of the endothelial cells.  They present the chemokines, possibly 
enhancing their biological activity, to the circulating cells thereby creating a localised 
inflammatory environment (Middleton et al., 2002, Wang et al., 2005).   
Binding of cytokines to their receptors on the leukocyte can change their adhesive properties 
allowing them to firmly adhere.  The overall strength of cellular adhesion is determined by 
both the strength of the individual interactions and the total number of interactions (Carman 
and Springer, 2003).  The key mechanism by which cytokines can alter cellular adhesion is 
23 
 
through modulation of integrin interactions. Integrins are transmembrane receptors which 
mediate adhesion of cells to their surroundings.  They are made up of two non-covalently 
linked transmembrane glycoproteins known as α and β subunits.  Integrins can switch 
between low affinity, inactive forms and high affinity, active forms via conformational 
changes.  Treatment with CXCL12, CCL19 and CCL21 transiently increases the affinity of the 
integrin CD18/CD11a on lymphocytes for ICAM-1 (Constantin et al., 2000).  CCL2 activates the 
fibronectin receptors CD49d/CD29 and CD49e/CD29 on T-cells (Carr et al., 1996).  
Cytokines can also trigger changes in integrin mobility within the cell membrane.  Increased 
integrin mobility can increase the total number of integrin-ligand interaction that can occur 
(Carman and Springer, 2003). Treatment with CXCL12, CCL19 and CCL21  rapidly (within 10s) 
increases the lateral mobility of CD18/CD11a within the plasma membrane of lymphocytes 
(Constantin et al., 2000). Clustering of integrins can increase the strength of adhesion by 
increasing the number of adhesive integrins at the point of cell-cell contact.  Clustering of 
integrins can occur extremely rapidly in response to cytokines, for example immobilised 
CXCL12 can trigger sub-second clustering of CD49d/CD29 on T-cells (Grabovsky et al., 2000).  
Stimulation with cytokines can also up-regulate cell surface expression of integrins on 
leukocytes.  Up-regulation of integrin expression following cytokine stimulation is well 
described in both neutrophils and monocytes (Vaddi and Newton, 1994, Jiang et al., 1992, 
Montecucco et al., 2008, Conklyn et al., 1996).  There is limited evidence of lymphocyte up-
regulation of integrin expression in response to cytokine stimulation.  Following stimulation 
with TNF-α expression of CD11b on human lymphocytes is increased (Armstrong et al., 2001).  
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Lymphocytes can also show increased integrin expression during infection by a pathogen 
(Ueda et al., 2010). 
 
1.3.4.3. Lymphocyte Firm Adhesion 
Following activation lymphocytes firmly adhere to the endothelium, this process is primarily 
mediated by integrins and their ligands (Ley et al., 2007).  Integrins can bind to endothelium 
expressed members of the immunoglobulin superfamily: a group of proteins which all have an 
immunoglobulin-like domain (Barclay, 2003).  The immunoglobulin superfamily members 
CD54, CD102 (ICAM-2), CD106 and MAdCAM can all be expressed on endothelium within the 
liver (Scoazec et al., 1994, Steinhoff et al., 1993, Grant et al., 2001).    
CD54 is constitutively expressed on hepatic sinusoidal endothelial cells and at low levels on 
hepatic portal vascular endothelial cells (Scoazec et al., 1994).  Its expression on sinusoidal 
endothelial cells is significantly increased during inflammation (Steinhoff et al., 1993, Volpes 
et al., 1990).  Lymphocyte adhesion to CD54 is mediated by the integrin CD11a/CD18 (LFA-1) 
(Dustin and Springer, 1988). In the non-inflamed liver, CD102 is strongly expressed on the 
endothelium of hepatic portal arteries and weakly expressed on sinusoidal endothelium, a 
similar expression pattern is observed in the inflamed liver (Steinhoff et al., 1993).  
Lymphocyte binding to CD102 is also mediated by the integrin CD11a/CD18 (Binnerts et al., 
1994).  
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In the normal liver, CD106 is expressed at very low levels on vascular endothelium and not at 
all on sinusoidal endothelium (Steinhoff et al., 1993).  During inflammation its expression on 
both hepatic vascular, portal and sinusoidal endothelium is increased (Steinhoff et al., 1993, 
García-Monzón et al., 1998).  Lymphocyte adhesion to endothelium expressed CD106 is 
mediated by the lymphocyte expressed integrin CD49d/CD29 (van Dinther-Janssen et al., 
1991).  MAdCAM-1 is generally only expressed on gut endothelium and is responsible for 
targeting lymphocytes to the gut trough interaction with the lymphocyte expressed integrin 
CD49d/beta7 (integrin α4β7) (Hamann et al., 1994). However, in certain inflamed states 
MAdCAM-1 is expressed by hepatic endothelium leading to recruitment of mucosal 
lymphocytes (Grant et al., 2001). 
Non-integrin mediated interactions are also involved in firm adhesion.  CD58 (LFA-3) is 
constitutively expressed at low levels on hepatic sinusoidal endothelium and, like CD54, during 
inflammation its expression is up-regulated (Volpes et al., 1990, Steinhoff et al., 1993).  T-cell 
expressed CD2 (LFA-2) can bind CD58 with a low affinity, these interactions serve to 
strengthen cellular adhesion (van der Merwe et al., 1994, Shao et al., 2005). 
Expression of cell adhesion molecules on the surface of endothelial cells may not, on its own, 
be sufficient to support leukocyte adhesion.  The endothelial glycocalyx is a layer of 
glycoproteins, glycosaminoglycans, proteoglycans and soluble plasma proteins which extends 
≈500nm into the vascular lumen (Weinbaum et al., 2007). As the thickness of glycocalyx far 
exceeds the dimensions of the endothelial cell adhesion molecules it is likely to act as a barrier 
to leukocyte adhesion (Mulivor and Lipowsky, 2002).  However, glycocalyx shedding can occur 
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in disease states such as IR injury, inflammation and acute hyperglycaemia (Nieuwdorp et al., 
2006, Mulivor and Lipowsky, 2004).  Components of the endothelial glycocalyx may also be 
involved in leukocyte adhesion.  CD44 is a glycoprotein expressed on both lymphocytes and 
hepatic endothelium (Couvelard et al., 1993, Joensuu et al., 1993).  It can support firm 
adhesion through binding either hyaluronic acid or the integrin CD49d/CD29 (Nandi et al., 
2004, McDonald et al., 2008).  Compared to other tissues hyaluronic acid is present at very 
high concentrations in both the non-inflamed and inflamed liver sinusoids (McDonald et al., 
2008). CD44 interactions with hyaluronic acid have been shown to be import in neutrophil 
recruitment to the inflamed liver and lymphocyte recruitment to other inflamed tissues 
(McDonald et al., 2008, Milinkovic et al., 2004, Stoop et al., 2002). 
In addition to endothelium, leukocytes can also adhere to components of the endothelial 
extracellular matrix (ECM).   During liver inflammation endothelial denudation can occur 
leaving the ECM exposed (Tiegs et al., 1992).  Lymphocytes can adhere to the ECM component 
fibronectin through the integrins CD49d/CD29 and CD49e/CD29 (Szekanecz et al., 1992, van 
de Wiel-van Kemenade et al., 1992).  This interaction appears to be important in the 
recruitment of T-cells to areas of inflammation (Rodriguez et al., 1992, Hfrshkoviz et al., 1994).  
Activated T-cells are also able to adhere to both type I and type IV collagen through the 
integrins CD49a/CD29 and CD49b/CD29 (de Fougerolles et al., 2000).  
1.3.4.4. Lymphocyte Intravascular Crawling and Transmigration 
Once a leukocyte has become firmly adherent it can then crawl along the endothelium or 
transmigrate trough the endothelium and into the tissue.  Crawling along the inside of the 
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blood vessel allows leukocytes to position themselves for transmigration, in monocytes and 
neutrophils this is mediated by CD11b/CD18 and CD54 (Ley et al., 2007). Lymphocyte 
intravascular crawling appears to be mediated by high affinity CD11a/CD18 (Shulman et al., 
2009).  Transmigration occurs most commonly at the junctions between endothelial cells 
(paracellular transmigration) but there is also evidence for leukocytes, including lymphocytes, 
migrating trough a single endothelial cell (transcellular transmigration) (Feng et al., 1998, 
Millan et al., 2006).  Transmigration is mediated by a number of molecules including integrins, 
endothelial cell-selective adhesion molecule (ESAM), PECAM-1 (CD31), CD99 and junctional 
adhesion molecules (JAMs) (Ley et al., 2007). 
 
1.4. Platelets in Hepatitis 
In addition to leukocyte accumulation in the liver, a few studies have identified hepatic 
platelet accumulation in a number of models of liver inflammation including lymphocytic 
choriomeningitis virus infection (Lang et al., 2008), hepatic IR injury (Cywes et al., 1993), ConA-
induced liver injury (Massaguer et al., 2002) and lipopolysaccharide induced liver injury (Eipel 
et al., 2004).  Tamura and colleagues reported that platelet-endothelial interactions occurred 
earlier than leukocyte responses after hepatic IR injury and that, interestingly, adhesion of 
platelets required the presence of activated Kupffer cells.  Indeed, half of the adherent 
platelets located were attached to Kupffer cells (Tamura et al., 2012). Several recent studies 
by Iannacone and colleagues have reported that the intrahepatic recruitment of CD8+ T-cells 
was critically dependent on platelets, particularly after acute viral hepatitis (Iannacone et al., 
2005).  
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1.4.1. Role of Platelets in Inflammation 
Platelets are discoid shaped blood cells between 0.5-3µm in size.  They are formed by 
cytoplasmic fragmentation of precursor megakaryocytes found within the bone marrow.  The 
major role of circulating platelets in the vasculature is to maintain haemostasis or prevent 
blood loss at sites of vessel injury through the formation of platelet plugs or thrombi.  They do 
this by adhering at sites of vascular injury, becoming activated and subsequently aggregating 
to form a thrombus.  Further to their role in maintaining haemostasis, platelets also play a 
diverse role in many other physiological and pathological processes.  This includes emerging 
evidence for platelets contributing to angiogenesis, tumour metastasis, lymphangiogenesis, 
tissue regeneration, wound repair and in maintaining vascular integrity (McNicol and Israels, 
2008).   However, it is their role as immune cells that can initiate and accelerate many vascular 
inflammatory conditions that has received a lot of recent attention.  Indeed, platelets are 
linked to the pathogenesis of many inflammatory diseases such as atherosclerosis, malaria 
infection, transplant rejection, inflammatory bowel disease, IR injury and rheumatoid arthritis.  
They carry out this inflammatory role through direct interactions with leukocytes and 
endothelial cells and/or through release of soluble and vesicular inflammatory factors.  The 
next sections describe how platelets can adhere to damaged and intact blood vessels to either 
form aggregates/thrombi or platelet-endothelial interactions respectively. 
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1.4.2. Platelet Adhesion, Activation and Aggregation 
Platelet adhesion to the subendothelium, exposed after vascular damage, initiates thrombus 
formation and haemostasis.  In order to carry out this process, platelets express high 
concentrations of integrins and other glycoproteins on their membrane surface.  Similarly to 
the leukocyte adhesion cascade, thrombus formation also involves platelet tethering/rolling, 
activation, firm adhesion and an additional aggregation step. 
 
1.4.2.1. Platelet Adhesion to Exposed Subendothelial Matrix 
In the uninjured vasculature, platelets show no physical interaction with endothelial cells.  The 
intact, non-activated endothelium prevents platelet adhesion and controls platelet reactivity 
through inhibitory and modulating mechanisms involving NO, cyclooxygenase-2 (COX-2) and 
prostacyclin (PGI2).  However, disturbances in vascular integrity leading to loss or denudation 
of endothelium, exposes the underlying extracellular matrix (ECM) proteins.  Adhesive rolling 
interactions of platelets with these proteins is the first step of haemostasis.  Platelets can 
adhere to many components of the ECM including immobilised von Willebrand factor (VWF), 
collagen, laminin and fibronectin (Ruggeri and Mendolicchio, 2007) using a number of specific 
platelet glycoproteins and integrins.   
Platelet rolling or tethering occurs via the interaction of the platelet glycoprotein CD42b 
(GPIbα; part of the GPIb-IX-V receptor complex) with immobilised VWF (Girma et al., 1986, 
Huizinga et al., 2002).  These initial weak interactions allow platelets to remain attached to 
the vessel wall despite the high shear forces generated within the vascular lumen of arteries 
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and arterioles.  Within the sub-endothelial matrix, VWF is immobilised primarily to collagen 
type I, III and VI filaments (Rand et al., 1997).  However, soluble VWF in plasma can also bind 
to other ECM components including sulfatides (Roberts et al., 1986), heparin (Fujimura et al., 
1987), fibrin (Hada et al., 1986) and even to VWF already bound in the sub-endothelial matrix 
(Savage et al., 2002).  The binding of CD42b to VWF has a fast off-rate and is therefore 
insufficient to mediate stable adhesion but rather maintains the platelet in close contact with 
the surface. Indeed, interactions between CD42b and immobilised VWF typically slow platelet 
velocity to less than 2% of their free flow velocity allowing slower forming but more stable 
adhesive bonds to occur (Ruggeri and Mendolicchio, 2007).   At shear rates of greater than 
500-800s-1 for human blood (Savage et al., 1998) and 2000-5000s-1 for mouse blood 
(Konstantinides et al., 2006) only CD42b-VWF interactions have sufficiently rapid on-rate to 
initiate platelet adhesion.  
In addition to collagen-bound VWF, platelets are also capable of adhering directly to collagen 
itself (Saelman et al., 1994).  Indeed, among the various constituents of the subendothelial 
matrix, collagen is the most abundant vessel wall protein and the most thrombogenic. 
Collagen not only supports weak platelet adhesion, but also acts as a powerful activator of 
platelets which leads to their subsequent firm adhesion and aggregation (Nieswandt and 
Watson, 2003, Watson, 1999, Nievelstein et al., 1988). Platelets express a number of collagen 
receptors including the CD49b/CD29 (integrin α2β1, VLA-2; GPIa/IIa), GPVI, CD36 (GPIV) and 
p65 (Ruggeri and Mendolicchio, 2007).  Of these, CD49b/CD29 and GPVI are the most 
important, with blockade of either resulting in significantly reduced platelet adhesion and 
aggregation (Sarratt et al., 2005).  
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ECM fibronectin can also support platelet adhesion as blocking it on exposed arterial sub-
endothelium or its depletion markedly reduces platelet adhesion, delays thrombus formation 
and produces an unstable thrombus  (Houdijk and Sixma, 1985, Ni et al., 2003).  Platelet 
adhesion to fibronectin is mediated by the platelet receptors CD41/CD61 (integrin αIIbβ3, 
GPIIb/IIIa,), CD49e/CD29 (integrin α5β1, VLA-5) and GPIbα (Beumer et al., 1995).  Circulating 
fibrinogen, produced by the liver, is cleaved by thrombin to form insoluble fibrin (Blomback et 
al., 1978). Both fibrin and fibrinogen also act as a substrate for platelet adhesion through 
binding of CD41/CD61 (Hantgan et al., 1990, Savage et al., 1996).  At low shear rates of 600-
900s-1, arrest on fibrinogen and not GPIbα-VWF interactions is the primary initiator of platelet 
adhesion (Savage et al., 1996) 
1.4.2.1. Platelet Activation 
Under normal conditions platelet activation is inhibited by NO and PGI2 and also the 
endothelial ecto-ADPase CD39 (Furie and Furie, 2008).  However, the tethering events 
described above allow platelet surface signalling receptors to establish contact with exposed 
collagen, which acts as a potent activator of platelets.  Platelet activation is characterised by 
their shape change from discoid to spiculated spheres, a shape more conducive to platelet 
aggregation.  Activation also results in α and dense granule release of additional secondary 
activators such adenosine diphosphate (ADP) and thromboxane A2 (TXA2).  The ultimate aim 
of these activatory signalling events is to up-regulate platelet integrins that will enable the 
platelet to establish firm adhesion with the vessel wall followed by thrombus growth. 
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Platelet GPVI appears to be the main signalling receptor mediating platelet activation  through 
a tyrosine kinase-based signaling pathway that involves the kinase Syk and phospholipase Cγ2 
(PLCγ2) (Inoue et al., 2003) Indeed GPVI deficient platelets do not aggregate in response to 
collagen (Kehrel et al., 1998).  There is also evidence that CD49b/CD29-collagen interactions 
can also lead to partial platelet activation (Nakamura et al., 1999).  Binding of collagen by 
either GPVI or CD49b/CD29 results in the activation of the dominant aggregatory platelet 
integrin CD41/CD61 (Kehrel et al., 1998, Nakamura et al., 1999). CD42c (GPIb)-VWF 
interactions can also lead to activation of platelets (Kroll et al., 1991).  This occurs through 
activation of phospholipase-C which leads to activation of protein kinase-C and an increase in 
intracellular calcium which promotes aggregation and platelet secretion (Kroll et al., 1991).   
Platelets can be activated by other pathways in addition to those mentioned above.  Thrombin 
is a serine protease which acts as a platelet activator through the G-protein-linked protease 
activated receptors PAR1, PAR3 and PAR4 (Coughlin, 2000).  Cleavage of the N-terminal of the 
PAR receptors by thrombin leads to activation of phospholipase-Cβ leading to activation of 
protein kinase-C and an increase in intracellular calcium (Coughlin, 2000). Prothrombin is 
cleaved to form thrombin at the site of vascular injury by factor-X which is activated by a 
factor-VIIa and tissue factor complex (Coughlin, 2000). Both factor-X and factor-VIIa are 
produced in the liver and are present in the plasma (Olson et al., 1966).  Tissue factor is 
constitutively expressed in the vascular adventitia (Drake et al., 1989), by arterial smooth 
muscle following injury (Marmur et al., 1993) and by cytokine activated endothelial cells 
(Zucker et al., 1998). Vascular injury therefore allows factor-VIIa and factor-X to come into 
contact with tissue factor leading to prothrombin cleavage.   
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Platelet activation by potent agonists such as thrombin or collagen causes the secretion of 
ADP from platelet dense granules where it is stored.  ADP also activates platelets through its 
interaction with its G protein–coupled receptors P2Y12, P2Y1 and P2X1 receptors (Gachet, 2001, 
Mahaut-Smith et al., 2011).  This amplifies the platelet response to other agonists (Andre et 
al., 2003).  Clinically utilised drugs such as Clopidogrel block activation of P2Y12. 
1.4.2.2. Thrombus Formation 
Following initial platelet adhesion and activation, platelets aggregate in increasing numbers 
to form a thrombus.  Thrombi are composed primarily of platelets, fibrin and trapped 
erythrocytes and leukocytes. The developing thrombus binds unstimulated platelets from the 
circulation and a proportion of these become activated - some platelets remain un-activated 
and may become detached (Dubois et al., 2007).  Platelet activation leads to an increase in 
platelet-platelet affinity which stabilises the thrombus (Furie and Furie, 2008). Platelet-
platelet interactions are mediated by CD41/CD61 on platelets through a fibrinogen bridge 
(Goto et al., 1998) or at high shear rates by CD41/CD61 and GPIbα through a VWF bridge (De 
Marco et al., 1986, Goto et al., 1998).  The dominant role of the integrin CD41/CD61 in 
mediating thrombus growth is evident by the clinically available CD41/CD61 inhibitors such as 
abciximab, eptifibatide and tirofiban that are used as potent anti-platelet drugs.  The rolling, 
adhesion, activation and subsequent aggregatory events of platelets are summarised in Figure 
1.5. 
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1.4.2. Platelet-Endothelial Cell Interactions 
In recent years it has also become increasingly evident that endothelial denudation is not an 
absolute pre-requisite to allow platelet attachment to the arterial wall.  Damaged or inflamed 
endothelium is known to develop properties that render it pro-adhesive for platelets 
(Massberg et al., 1999, Massberg et al., 1998, Frenette et al., 1998). Platelets not only can roll 
on ECM components, but similarly to leukocytes, can also roll on intact but activated 
endothelium.  This is dependent primarily on endothelial CD62P interacting with CD162 
constitutively expressed on platelets (Frenette et al., 2000).  Activated platelets are also able 
to firmly adhere to endothelium using platelet CD41/CD61 binding endothelial adhesion 
molecules  CD51/CD61 (αvβ3), CD54 and GPIbα (Bombeli et al., 1998).  This interaction uses 
soluble fibrinogen, fibronectin or VWF as bridging molecules. The fact that platelets can 
adhere to subendothelial and endothelial layers suggests they are crucial to haemostasis as 
well as to an inflammatory response (Wagner and Burger, 2003).   
Platelets can potentially regulate leukocyte recruitment through activation of endothelial 
cells.  Interactions between CD40L on activated platelets and CD40 on endothelial cells up-
regulates endothelial expression of the adhesion molecules CD62E, CD54 and CD106  and 
induces release of the cytokines CXCL8 (IL-8) and CCL2 by the endothelial cells (Henn et al., 
1998). It has been suggested that this interaction is an important mediator of inflammation in  
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Figure 1:4 Platelet adhesion and aggregation on the ECM components such as collagen. The CD42b-vWF interaction mediates platelet tethering thereby enabling 
GPVI interaction with collagen. This triggers the shift of platelet integrins to a high-affinity state and release of ADP and TXA2 (not shown). In parallel, tissue factor 
locally triggers thrombin formation which also contributes to platelet activation. GPCR, g-protein coupled receptor; vWF, von Willebrand factor; GP, glycoprotein. 
Adapted from Varga-Szabo et al. (2008) and Jackson and Schoenwaelder (2003).
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disease states such as inflammatory bowel disease, and atherosclerosis (Danese et al., 2003, 
Phipps, 2000). 
1.4.3. Platelet-Leukocyte Interactions 
Leukocytes and platelets are well known to directly interact with each other.  Even in the 
normal circulation about 3% of lymphocytes are conjugated to platelets.  ADP activation of 
platelets increases conjugation to CD8+ T-cells (from 3% to 7%) and NK cells (from 3% to 12%) 
but has little effect on conjugation of CD4+ T-cells or B-cells (Li et al., 2006).  CD8+ T-cell 
release of interferon- (IFN) is augmented in response to binding CD40 on its surface to CD40L 
(CD154) expressed on the platelet in a mouse model of adenoviral infection (Elzey et al., 2003).  
In the same study, Elzey and colleagues also demonstrated that B-cells required B-cell CD40 
to interact with platelet CD40L in order to switch from IgM/IgD production to production of 
IgG and other Ig isotypes. This was demonstrated eloquently by transfusing activated wild type 
platelets into CD40L-/- mice (Elzey et al., 2003).  Lymphocyte activation could also increase 
conjugation to platelets of CD4+ T-cells (from 3% to 12%) and CD8+ T-cells (from 3% to 15%), 
but had little effect on the percentage of B-cells and NK cells conjugated to platelets (Li et al., 
2006).  Neutrophils also form circulating complexes with platelets.  About 15% of circulating 
neutrophils are conjugated to platelets (Tuttle et al., 2003). These neutrophils, derived from 
healthy individuals, have been shown to exhibit a greater expression of the integrin subunit 
CD11b, a greater capacity for phagocytosis and ROS release than non-platelet attached 
neutrophils (Peters et al., 1999).  These collective findings are indicative that neutrophils and 
lymphocytes within platelet-leukocyte complexes represent an activated subset of cells, 
where their function is enhanced by the attachment of platelets (Figure 1.6). 
37 
 
In vitro studies have demonstrated that immobilised platelets are capable of supporting the 
rolling and adhesion of leukocytes.  T-cells and NK-cells can both roll on and adhere to 
immobilised activated platelets under physiological flow in a CD62P dependant manner 
(Diacovo et al., 1996b, Sheikh et al., 2004).  Firm adhesion of NK cells on activated platelets is 
mediated by NK cell expressed integrins CD11a/CD18 (LFA-1) and CD11b/CD18 (Mac-1) 
binding to CD102 (ICAM-2) expressed on platelets (Sheikh et al., 2004, Diacovo et al., 1994).  
Platelets also support T- and B-cell rolling and adhesion on immobilised collagen under arterial 
flow in a CD62P, CD40L and CD41/CD61 dependent manner (Hu et al., 2010).  CD62P 
dependent lymphocyte rolling on platelets also occurs in vivo.  Platelets immobilised on the 
high endothelial venules of peripheral lymph nodes have also been shown to mediate 
lymphocyte capture and rolling (Diacovo et al., 1996c).  Neutrophils also manifest CD62P 
dependent rolling on activated platelets as well as CD11a/CD18 and CD11b/CD18 mediated 
firm adhesion to platelet expressed CD102 and platelet bound fibrinogen (Diacovo et al., 
1996a, Weber and Springer, 1997). 
Occlusion of vessels by platelet aggregates may also result in entrapment of leukocytes behind 
the thrombus without the need for receptor mediated interactions.  Indeed, microvascular 
plugging by aggregates of platelets is frequently observed during inflammation in the liver 
following ischaemia (Cywes et al., 1993, Nakano et al., 2008), in the colitic gut (Miele et al., 
2009) and during acute renal failure (Clarkson et al., 1970).     
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Figure 1:5 Platelet mediated leukocyte recruitment and activation.  Platelets (green) are capable of mediating leukocyte (orange) recruitment through direct 
interactions with endothelial cells and leukocytes and through release of inflammatory factors.  The major mediators of these interactions are listed in grey.  Occlusion 
of capillaries due to platelet aggregation may also result in entrapment of lymphocytes.  PMP, platelet micro-particle; VEGF, vascular endothelial growth factor; PAF, 
platelet activating factor. 
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1.4.4. Platelet Released Factors 
In addition to mediating leukocyte recruitment through direct cell contact, platelets also 
release a range of soluble factors which can act upon both leukocytes and the endothelium.  
Activated platelets release a number of soluble factors including cytokines and growth factors.  
The α-granules of platelets contain a number of cytokines capable of regulating lymphocyte 
function.  CXCL12 (SDF-1α), a powerful lymphocyte chemoattractant, is released by activated 
platelets.  Indeed, platelets are a major source of CXCL12 at sites of vascular injury (Bleul et 
al., 1996, Massberg et al., 2006).  Activated platelets also release CCL5 (RANTES) which acts as 
a chemoattractant for CD4+ T-cells but not CD8+ T-cells (Kameyoshi et al., 1992, Schall et al., 
1990).  Platelets are also the sole source of CXCL4 (PF4), an important regulator of T-cell 
proliferation, which stimulates proliferation of Treg cells but inhibits proliferation of non-
regulatory CD4+ T-cells (Liu et al., 2005).     
Activated platelets also release several non-cytokine mediators of lymphocyte function such 
as vascular endothelial growth factor (VEGF) which enhances recruitment of T-cells 
(Wartiovaara et al., 1998, Zhang et al., 2010).  Platelet serotonin release modulates a range of 
lymphocyte functions (Holmsen and Weiss, 1979), namely promoting proliferation of T-cells, 
B-cells and NK cells as well as NK cell cytotoxicity (Iken et al., 1995, Aune et al., 1994, 
Hellstrand and Hermodsson, 1993).  Serotonin can also elicit anti-inflammatory effects.  In a 
CD8+ dependent model of viral hepatitis, platelet derived serotonin delayed CD8+ T-cell 
invasion, prolonging virus persistence and aggravating the injury (Lang et al., 2008).  Platelet 
activating factor (PAF) is also capable of stimulating lymphocyte migration (McFadden et al., 
1995, Chignard et al., 1980).    
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Further to their effects on lymphocytes, many of the molecules released following platelet 
activation can also mediate activation of other leukocytes and endothelial cells.  For example 
platelet released IL-1β is a potent activator of endothelial cells and CXCL4, CXCL7 and CXCL8 
can mediate neutrophil recruitment (Zarbock et al., 2007).  Clearly a significant number of 
platelet-derived soluble factors exist that can modify the leukocyte and vascular response 
during inflammation 
 
1.4.5. Platelet Microparticles 
In addition to soluble factors, activated and apoptotic platelets can shed membrane vesicles 
called platelet microparticles (PMPs) from their surface into the circulation.  These are 
membrane fragments of 0.1µm-1µm in diameter (Diamant et al., 2004).  Although initially 
considered as cell debris, a central role in haemostasis has been identified for PMPs.  Plasma 
PMP numbers are significantly increased in a number of disease states including rheumatoid 
arthritis (Knijff-Dutmer et al., 2002), atherosclerosis (Nomura et al., 2000) and cancer (Kim et 
al., 2003).  They express a number of platelet receptors including CD62P, GPIbα, CD41/CD61  
and CD31 (PECAM) (Diamant et al., 2004). 
There is good evidence that PMPs can mediate cell-cell interactions of blood cells through 
binding to their membrane.  This can occur through binding of PMP expressed CD62P to its 
ligand on that cell (Janowska-Wieczorek et al., 2001, Forlow et al., 2000).  Jy and colleagues 
presented seminal data that PMPs can ‘coat’ neutrophils and induce their activation, as 
measured by increased integrin CD11b (M) expression, induce neutrophil aggregation and 
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increase their phagocytic activity (Jy et al., 1995).  Neutrophil aggregation is normally 
mediated by CD62L and CD162 (Guyer et al., 1996).  However, in the absence of CD62L, 
neutrophil bound PMPs can support neutrophil aggregation, most likely through PMP 
expressed CD62P and neutrophil expressed CD162 (Forlow et al., 2000).  Additionally PMPs 
on haematopoietic stem cells can increase their adhesion  to endothelium and engraftment in 
lethally irradiated mice (Janowska-Wieczorek et al., 2001). Although PMPs can bind to 
lymphocytes, the binding efficacy is at much lower levels than that seen with neutrophils (Jy 
et al., 1995).  However, it is not currently known whether lymphocyte bound PMPs can 
modulate lymphocyte-endothelial interactions.   
PMPs can also modulate leukocyte adhesion through delivery of inflammatory cytokines to 
the local endothelial environment. Monocyte recruitment can be mediated by CCL5 
deposition on endothelium by PMPs in an GPIbα and CD41/CD61 dependent process (Mause 
et al., 2005). 
 
1.5. Platelet-Lymphocyte Interactions in Hepatitis 
It is clear from the literature that both lymphocytes and platelets can contribute to the 
pathology of a number of inflammatory liver conditions.  It is also well known that platelets 
can actually mediate the recruitment of inflammatory leukocytes, with the evidence stronger 
for neutrophils and emerging for lymphocytes.   However, very little is known about the role 
of platelets in mediating recruitment of lymphocytes in hepatitis.   Certainly recruitment of Tc 
cells in a mouse model of hepatitis B virus infection is platelet dependant and liver injury in 
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this model is reduced following platelet depletion but not after treatment with the 
anticoagulant warfarin (Iannacone et al., 2005).  Recruitment of Tc cells to the liver was also 
greatly reduced by treatment with the anti-platelet drugs aspirin and clopidigrel in mice 
infected with a hepatotropic, replication deficient adenovirus (Iannacone et al., 2007). 
Platelets have also been shown to co-localise within the sinusoids following hepatic IR injury 
(Khandoga et al., 2006a).  
However, evidence of the role of platelets in recruiting lymphocytes to non-viral mediated 
liver inflammation remains limited.  Although T-cells are considered prime candidates in 
hepatitis, no studies have directly investigated whether B-cells are recruited post-injury and 
whether platelets can influence their presence in the liver.  The dynamics of the recruitment 
of both these cells types, and their spatial-temporal correlation, is also not characterised in 
vivo.  In this thesis, the contributory role of platelets in mediating lymphocyte recruitment to 
the murine liver will be investigated in two distinctly different inflammatory injuries of the 
liver, namely the hepatic IR injury and the concanavalin A (ConA) injury models.   
 
1.6. Hepatic Ischaemia-Reperfusion (IR) Injury 
Hepatic IR injury is a clinically important problem; it is a feature of both liver re-sectioning 
surgery and cadaveric liver transplantation (Serracino-Inglott et al., 2001).  It is associated with 
post-operative morbidity and mortality and is increasingly known to impact on the functioning 
of many remote organs.  Although significant damage does occur during ischaemia it is the 
reperfusion of the liver with oxygenated blood that results in the majority of the injury 
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(Eltzschig and Collard, 2004). IR injury refers to tissue damage caused paradoxically when 
blood flow is returned to the tissue after a period of restricted blood flow (greek. isch- 
restriction, haema- blood). Lack of oxygen and nutrients creates a condition in which the 
restoration of blood flow results in inflammation and oxidative damage through generation of 
ROS.  Reperfusion therefore exacerbates the ischaemic injury.  Indeed, in the liver, the level 
of hepatic damage seen after 3 hours of ischaemia and 1 hour of reperfusion is much greater 
than after 4 hours of ischaemia alone (Eltzschig and Collard, 2004). 
Initially, ischaemia causes metabolic disturbances within cells resulting in dysregulation of 
energy pathways and ROS release. At the outset, and within 15 minutes, hepatic cells 
experience a loss of ATP, rise of intracellular sodium and cell oedema (Eltzschig and Collard, 
2004, Fondevila et al., 2003, Kamiike et al., 1982). Ischaemic metabolic failure of the 
mitochondrial respiratory chain leads to the generation of hydroxyl radicals during reperfusion 
through an increased rate of hydrogen peroxide (H2O2) production. Evidence suggests that 
hepatocytes and Kupffer cells are also important origins of oxidative stress, although the latter 
appear to play a minor role as depleting Kupffer cells fails to attenuate IR injury (Fondevila et 
al., 2003).  
Hepatic sinusoidal perfusion failure is also common during the post-reperfusion phase, 
resulting in microcirculatory failure (Jaeschke, 2003). The vascular tone of the hepatic 
sinusoids is a result of a delicate balance between vasodilatory molecules (such as NO and 
PGI2) and vasoconstrictory molecules (such as endothelin-1; ET-1). Any imbalance between 
these factors during IR results in dysregulation of vascular tone and sinusoidal blood flow, 
44 
 
promoting mechanical leukostasis. Indeed, pharmacological restoration of vascular tone 
following IR has been shown to improve blood flow and attenuates injury (Shiraishi et al., 
1997). 
Injury is also exacerbated by the substantial endothelial recruitment of platelets.  Up to one 
third of circulating platelets were found adherent in the rat isolated liver perfused with 
platelets after a period of ischaemia (Sindram et al., 2000). These platelets form 
microaggregates and appear activated when examined by electron microscopy (Cywes et al., 
1993). Platelets can induce apoptosis in sinusoidal endothelial cells during tissue reperfusion 
which can be prevented by blocking their adhesion (Sindram et al., 2000). As a result of both 
the oxidatively stressed environment and the vascular mechanical disturbances during IR, 
hepatic microvessels display marked neutrophil accumulation, at least in part as a 
consequence of increased capture by endothelial cell adhesion molecules. During the 
reperfusion phase, neutrophil activation occurs which also results in the generation of further 
damaging ROS (Martí et al., 2004). Leukocyte recruitment is additionally amplified by the 
release of cytokines from the injured tissue, such as TNF-α and IL-1. During IR injury, plasma 
levels of TNF-α and IL-1 are raised within 5 minutes of the reperfusion phase (Toledo-Pereyra 
and Suzuki, 1994). Both TNF-α and IL-1 mediate activation of the pro-inflammatory 
transcription factor NF-κB which leads to the generation of further cytokines and chemokines, 
as well as synthesis of adhesion molecules.  Hypoxia itself activates a number of additional 
transcription factors, such as hypoxia-inducible-factor-1α (HIF-1α). Hypoxic induction of HIF-
1α drives a robust release of CXCL12, establishing a chemokine gradient for inflammatory cell 
recruitment (Ceradini et al., 2004). 
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Reperfusion also sees a dramatic increase in inflammatory cell numbers within the liver.  
Neutrophils are the major mediators of the inflammatory injury that occurs during reperfusion 
(Jaeschke et al., 1990).  They accumulate in the liver vasculature in response to a number of 
inflammatory mediators including TNF-α, CCL3, CXCL2 (MIP-2), CXCL1, CXCL8 (IL-8), activated 
compliment factors, PAF and cytokine-induced neutrophil chemoattractant amongst others 
(Jaeschke, 2006).  Their adhesion is mediated by endothelial adhesion molecules interacting 
with integrins on their surface.  Under basal conditions, sinusoidal endothelium expresses low 
levels of CD54 and CD106, with no expression of any of the selectin family members (Lalor and 
Adams, 1999).  Following insult, levels of CD54 and CD106 are raised, and although some 
vessels express CD62E and CD62P, selectins are largely absent from the sinusoids (Wang et 
al., 1999, Adams et al., 1996, Grant et al., 2001). Other endothelial adhesion molecules such 
as MAdCAM-1 can be detected under certain specific inflammatory conditions and could play 
a role in IR injury (Ando et al., 2007). Additionally, VAP-1 is constitutively expressed in the liver 
and is one of the few endothelial beds to exhibit constitutive expression (Lalor and Adams, 
1999). VAP-1 has been shown to play an important role in lymphocyte recruitment to rat and 
murine liver allografts (Martelius et al., 2004) and during inflammation in cerebral IR injury 
(Xu et al., 2006), but it is unclear whether it has any role in hepatic IR injury.  Once neutrophils 
have accumulated within the hepatic vascular they extravasate into the surrounding 
parenchyma and induce cytotoxic effects (Jaeschke and Smith, 1997).  Killing of hepatocytes 
by activated neutrophils is mediated by both ROS production and neutrophil derived 
proteases (Jaeschke, 2006).     
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1.6.1. Lymphocytes and Hepatic IR Injury  
Although the major effector cell associated with hepatic IR injury is the neutrophil, recent 
studies have identified a critical role for lymphocytes, particularly T-cells, in the 
pathophysiology of IR injury, with their presence detected post-reperfusion in various organs 
including the brain (Yilmaz et al., 2006), lung (de Perrot et al., 2003) and heart (Yang et al., 
2006).  Previously thought to be “passive observers” in the inflammatory response, there is 
now an overwhelming body of literature demonstrating the role of T-cells as direct mediators 
of IR injury.   
 
1.6.1.1. T-cells and Hepatic IR Injury  
Significant involvement of T-cells in hepatic IR injury was first demonstrated in 1997 in a report 
showing their accumulation in reperfused liver (Zwacka et al., 1997).  This immunohistological 
study demonstrated peripheral CD4+, but not CD8+, T-cells were recruited as early as 1 hour 
post-reperfusion.  This rapid recruitment was suggestive of lymphocytes promoting activation 
of the inflammatory cascade rather than being recruited inadvertently as a consequence of it.  
Indeed, lymphocyte recruitment preceded the influx of any appreciable numbers of potently 
inflammatory neutrophils, whose subsequent recruitment was dependent upon IL-17, a 
cytokine preferentially expressed and secreted by activated CD4+ T cells and Kupffer cell 
activation (Zwacka et al., 1997, Le Moine et al., 2000, Kuboki et al., 2009).  The fast reponse 
of lymphocytes and their ability to recruit neutrophils was further demonstrated in mice 
lacking CD4+ T-cells in which hepatic neutrophil accumulation was significantly decreased. 
Interestingly, however, both neutrophil oxidative burst activity and liver injury was 
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significantly increased.  (Caldwell et al., 2005).  Furthermore, the use of immunomodulators 
that sequestered peripheral blood T cells (eg. FTY720)  into lymphoid organs, was associated 
with improved hepatic structure and function and overall survival (Mizuta et al., 1999, 
Anselmo et al., 2002, Martin et al., 2010).  Hepatic IR injury conducted in CD4-/- mice was also 
associated with improved histological scores, reduced neutrophil infiltration and 
improvements in sinusoidal perfusion (Khandoga et al., 2006a). 
Binding of CXCR3 by its ligands CXCL9, 10 and 11 released during IR injury appears to be at 
least partially responsible for T-cell activation during IR injury (Zhai et al., 2006).  Antibody 
blockade of CXCR3 in a rat model of liver transplant significantly reduced both CXCR3+ CD4+ 
T-cell accumulation within the liver and also liver injury (Zhai et al., 2006).  In addition to 
cytokines matrix metalloproteinase-9 is required for T-cell recruitment and transmigration 
during hepatic IR injury (Khandoga et al., 2006b).  There is also some evidence in other organs 
for antigen mediated activation of T-cells during IR injury however, it remains unclear if this 
occurs during hepatic IR injury (Caldwell et al., 2007). 
 
1.6.1.2. B-cells and Hepatic IR Injury  
The other major cell of the adaptive immune system is the B-cell.  Activated B-cells primarily 
function in antibody production and antigen presentation.  However, due to their ability to 
secrete the potently anti-inflammatory cytokine IL-10 and the pro-inflammatory cytokines IL-
6, CXCL8 and TNFα, the role of a positive and negative regulator of inflammation has been 
ascribed to this cell (Hamze et al., 2013). In IR injuries of the gut and hind-limb, B-cell produced 
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IgM is responsible for activation of the classical complement pathway resulting in injury 
(Zhang et al., 2004, Austen Jr et al., 2004).  Burne-Taney and colleagues demonstrated reduced 
injury scores following renal IR injury in mice unable to develop peripheral mature B-cells 
(Renner et al., 2010, Burne-Taney et al., 2003).  In the kidney IgM release by B-cells 
exacerbated injury independently of compliment.  However, IL-10 release by B-cells appeared 
to have protective effects (Renner et al., 2010).  This dual role of B-cells in renal IR injury may 
account for findings that B-cell depletion can increase or decrease renal IR injury (Renner et 
al., 2010, Burne-Taney et al., 2003).  IgM also plays a pathogenic role in myocardial IR injury 
(Zhang et al., 2006).  Further demonstrations of a B-cell pathogenic role was shown in IR 
injured intestine, heart and skeletal muscle  (Linfert et al., 2009).  
Despite frequent histological observations of B-cells at inflammatory sites, there is little 
known about the recruitment kinetics of circulating B-cells to IR injured liver, even though the 
liver has a very large resident B cell population (Novobrantseva et al., 2005). They have been 
observed to home to the liver following parasitic hepatic infection (Moore et al., 2012) and 
are known to contribute to liver fibrosis, a late presenting feature of hepatic IR injury 
(Novobrantseva et al., 2005, Cheng et al., 2008). 
 
Collectively, these studies are consistent with an emerging pivotal role for lymphocytes in IR 
injury. However, the question remains as to how they are recruited to the ischaemically 
injured sinusoidal microcirculation in vivo. The importance of Kupffer macrophages has been 
demonstrated intravitally whereby their depletion using gadolinium chloride resulted in 
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reduced T-cell recruitment (Hanschen et al., 2008). However, lymphocytes have also long 
been known to roll and adhere under flow conditions to immobilised platelets in vitro and to 
captured platelets in high endothelial venules of peripheral lymph nodes in vivo (Sheikh et al., 
2004, Diacovo et al., 1996c).  Platelets are also recruited in abundance during hepatic IR injury  
(Khandoga et al., 2003) and more recently have been demonstrated to recruit T-cells following 
hepatitis B infection (Iannacone et al., 2005, Sitia et al., 2012). However, the role of platelets 
in non-viral or non-antigen induced T-or B-cell recruitment to the liver is not clear.   
 
1.7. Concanavalin-A Induced Liver Injury 
In order to compare the mechanisms of lymphocyte recruitment in a primarily neutrophil 
mediated liver injury (hepatic IR injury) to a primarily lymphocyte mediated liver injury, studies 
within this thesis have also utilised an acute mouse model of ConA induced hepatitis.  ConA is 
a lectin originally isolated from the jack bean (Canaualia ensi-formis) which triggers T-cell 
activation and proliferation in vitro (Palacios, 1982).  Following intravenous injection with 
ConA at doses greater than 1.5mg/kg, mice develop a severe T-cell dependant liver injury 
within 8 hours (Tiegs et al., 1992).  It has been used as a model for T-cell mediated hepatitis 
including autoimmune hepatitis, viral hepatitis and fulminant hepatitis (Trautwein et al., 1998, 
Ajuebor et al., 2005, Diao et al., 2004).  ConA induced liver injury is characterised by leukocyte 
and platelet recruitment followed by endothelial detachment, hepatocyte death and 
obstruction of the microcirculation (Tiegs et al., 1992, Massaguer et al., 2002). 
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The injury appears to be mainly mediated by CD4+ T cells as injection of anti-CD4, but not anti-
CD8, mab significantly reduces injury (Tiegs et al., 1992).  Significant numbers of CD4+ T, and 
much fewer CD8+ T-cells, infiltrate the liver following ConA injection (Mizuhara et al., 1994).  
NKT cells are also required for induction of ConA injury (Kaneko et al., 2000, Toyabe et al., 
1997) through osteopontin release, which triggers neutrophil activation and infiltration into 
the liver (Diao et al., 2004).  ConA injury is dependent on the activation of circulating T-cells 
by ConA (Mizuhara et al., 1994).  In the liver, ConA binds to mannose receptors on sinusoidal 
endothelial cells resulting in the liver specific activation of T-cells (Knolle et al., 1996).  
Although, like sinusoidal endothelial cells, Kupffer cells bind ConA in vitro, they do not 
significantly bind ConA in vivo (Knolle et al., 1996).  The activation of T-cells in the liver leads 
to increases in several cytokines involved in inflammation including: CXCL9 (MIG), CCL20 
(MIP3A), CXCL5 (ENA-78), CXCL11 (I-TAC), CXCL10 (IP-10), CCL3 (MIP1A), INF-γ, TNF-α, IL-12, 
IL-2 and IL-10 (Jaruga et al., 2004, Ajuebor et al., 2004, Gantner et al., 1995, Tagawa et al., 
1997, Louis et al., 1997).  In INF-γ-/- mice there is a significant reduction in injury caused by 
ConA injection when compared to wild type mice and hepatocyte apoptosis is also significantly 
reduced (Tagawa et al., 1997). 
ConA injury is associated with increased expression of a number of endothelial cell adhesion 
molecules in the liver including CD54, CD106 and VAP1 (Jaruga et al., 2004, Bonder et al., 
2005).  Injury is reduced in CD62L-/- and CD54-/- mice and is greatly reduced in double knockout 
mice when compared to wild type controls.  These  reductions in injury correlate to a decrease 
in number of CD4+ T-cells but not CD8+ T-cells or neutrophils within the liver (Kawasuji et al., 
2006).  Th1 and Th2 adhesion within the liver sinusoids following ConA injection is mediated 
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by VAP1 and CD49d/CD29 respectively (Bonder et al., 2005). ConA injury is also severely 
impaired in mice lacking P-selectin (Massaguer et al., 2002) which mediates leukocyte rolling 
within the ConA injured liver (March et al., 2005).  
 
1.8. Summary 
Given the emerging evidence for the role of the adaptive immune system in the pathology of 
inflammation in the liver, this study examined intravitally the dynamics of circulating T- and 
B-cell recruitment.  Furthermore, whether this was mechanistically dependent on platelets 
was also investigated.  Platelets have long been known to be capable of mediating lymphocyte 
adhesion and platelet accumulation within the liver is a common feature of liver inflammation.  
However, to date little is known about the role of platelets, their microparticles or their 
releasate as mediators of lymphocyte recruitment in hepatic inflammation.  Determining the 
mechanisms of lymphocyte recruitment to the hepatic microcirculation during inflammation 
is an important first step in developing strategies to limit their invasion of the liver.   In the 
first study of its kind, the kinetics and mechanisms of lymphocyte recruitment following IR 
injury and ConA-induced liver injury was compared.     
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1.9. Aims and Hypotheses 
This thesis aimed to test the following hypotheses:  
1. Platelets, their microparticles or their releasate can enhance lymphocyte adhesion to 
endothelial cells or immobilised endothelial counterligands in vitro. 
 
2. T- and B-cell recruitment to the hepatic microvasculature is significantly increased 
following IR and ConA liver injuries. 
 
3. Platelet recruitment to the hepatic microvasculature is significantly increased 
following injury. 
 
4. T- and B-cell recruitment to the injured hepatic vasculature is platelet dependent. 
 
5. Lymphocytes are recruited to the liver via similar mechanisms in ConA and IR injury.
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CHAPTER 2 
 
MATERIALS AND METHODS 
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2. MATERIALS AND METHODS 
2.1. Materials 
All antibodies were sourced from the suppliers listed in Table 2.1 and used at the stated 
concentrations.  Materials commonly used in this thesis are listed in Table 2.2; materials 
mentioned in the text were obtained from the indicated supplier unless stated otherwise. 
2.2. Methods 
2.2.1. Animals 
Animal experiments were conducted with the prior approval of the United Kingdom Home 
Office and local ethics committee in accordance with the Animals (scientific procedures) Act  
of 1986 under project licence 40/2749 (held by Dr. Neena Kalia) for intravital studies and 
project Licence 30/2721 (held by Prof. Steve Watson) for terminal bleeding.  Tissue samples 
were obtained from colitis mice which were generated under project licence 40/3226 (held by 
Dr. Bertus Eksteen) and transferred to project licence 40/2749 for intravital experiments 
(carried out by  prior to tissue isolation.  For all 
animal experiments 8-12 week old male C57BL/6 mice were obtained from  (  
) and housed in the  
with ad libitum access to food and water.  The mice were allowed to rest for at least one week 
prior to experimentation following their arrival at the . 
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Table 2.1 Antibodies used in this thesis  
        
Antibody Conj Clone Host Target Isotype Supplier Conc 
(mg/ml) 
        
Anti-CD19 PE eBio 1D3 Rat Mouse IgG2a,κ eBioscience 0.2 
        
Anti-CD3e PE 145-2C11 Armenian 
hamster 
Mouse IgG eBioscience 0.2 
        
Anti-CD19 NA MB19-1 Mouse Mouse IGAκ eBioscience 0.5 
        
Anti-CD3e biotin 145-2C11 Armenian 
hamster 
Mouse IgG ebioscience 0.5 
        
Anti-CD41 NA MwReg30 Rat Mouse Rat IgG1, 
κ 
BD 
biosciences 
0.5 
        
Anti-Rat IgG 
(H+L) 
 
Alexa 
Flour 
555 
Polyclonal Goat Rat IgG Life 
technologies 
2 
        
Streptavidin Alexa 
Flour 
647 
NA NA Biotin NA Life 
technologies 
1 
        
Anti-Mouse 
IgG (H+L) 
Alexa 
Fluor 
488 
Poly clonal Rabbit Mouse IgG Life 
technologies 
2 
        
Anti-CD16/32 NA 93 Rat Mouse IgG2a, λ Biolegend 0.5 
Anti-CD18 FITC M18/2 Rat Mouse IgG2a, κ eBioscience 0.5 
        
Anti-CD49d FITC R1-2 Rat Mouse IgG2b, κ eBioscience 0.5 
        
Rat IgG2a, κ 
isotype 
control 
 
FITC eBR2a 
 
Rat Mouse IgG2a, κ eBioscience 0.5 
        
Armenian 
hamster IgG 
isotype 
control 
PE eBio299Arm Armenian 
hamster 
Mouse IgG eBioscience 0.2 
        
Rat IgG2a κ 
isotype 
control 
PE eBR2a Rat Mouse IgG2a, κ eBioscience 0.2 
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Antibody Conj Clone Host Target Isotype Supplier Conc 
(mg/ml) 
        
Anti CD42b NA Xia.B2 Rat Mouse IgG2a emfret 0.5 
        
Platelet 
depletion 
antibody 
(anti CD42b)  
NA Polyclonal/ 
Cocktail 
(R300) 
Rat Mouse IgG emfret 0.5 
        
Rat IgG1 κ 
isotype 
control 
NA eBRG1 Rat Mouse IgG1 κ eBioscience 0.5 
        
Anti CD162 NA 4RA10 Rat Mouse IgG1 κ BD 
biosciences 
0.5 
        
CD8a PE 53-6.7 Rat Mouse IgG2a κ eBioscience 0.2 
        
CD4 PE GK1.5 Rat Mouse IgG2b κ eBioscience 0.2 
        
Anti CD62L FITC MEL-14 Rat Mouse IgG2a κ eBioscience 0.2 
        
Anti CD44 PE IM7 Rat Mouse IgG2b κ Biolegend 12.5 
        
Ly-6G PE RB6-8C5 Rat Mouse IgG2b κ eBioscience 0.2 
        
CD19 NA 6D5 Rat Mouse IgG2a Life 
technologies 
0.2 
        
Armenian 
hamster IgG 
isotype 
control 
biotin eBio299Arm 
 
Armenian 
hamster 
Mouse IgG eBioscience 0.2 
        
Mouse IgA 
isotype 
control 
 
NA NA Mouse Mouse IgA  κ eBioscience 0.2 
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Table 2.2 Materials frequently used in this thesis 
    
Materials Abbreviation Manufacturer Location 
    
Acetone - Fisher Scientific Leicestershire, UK 
    
Alexa-647 Bovine Serum Albumin - Life 
Technologies 
Paisley, UK 
    
Bovine Serum Albumin BSA Sigma Poole, UK 
    
5’6-carboxyfluorescein diacetate 
succinimidyl ester 
CFDA-SE Life 
Technologies 
Paisley, UK 
    
Cell Tracker Orange (5-(and-6)-(((4-
Chloromethyl)Benzoyl)Amino)Tetramethylrh
odamine) 
CMTMR Life 
Technologies 
Paisley, UK 
    
Concanavalin A ConA Sigma Poole, UK 
    
Dimethyl Sulphoxide DMSO Sigma Poole, UK 
    
DMEM (4.5g/l glucose) - Sigma Poole, UK 
    
D-valine MEM - Stratech Newmarket, UK 
    
Ethylenediaminetetraacetic acid EDTA Sigma Poole, UK 
    
Fluorescein isothiocyanate isomer I–Celite FITC on celite Sigma Poole, UK 
    
Heat Inactivated Fetal Calf Serum FCS Sigma Poole, UK 
    
Heparin (multiparin) - CP 
Pharmaceuticals 
Wrexham, UK 
    
2% Gelatin (Type I from porcine skin) - Sigma Poole, UK 
    
Ketamine Hydrochloride (Vetalar V) - Pfizer Kent, UK 
    
L-Glucose - Sigma Poole, UK 
    
L-Glutamine - Sigma Poole, UK 
    
Non-essential Amino Acids Solution - Life 
Technologies 
Paisley, UK 
    
Penicillin/Streptomycin P/S Life 
Technologies 
Paisley, UK 
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Materials Abbreviation Manufacturer Location 
    
Phosphate Buffered Saline PBS Sigma Poole, UK 
    
Prostacyclin - Sigma Poole, UK 
    
Propridium Iodide PI eBioscience Hatfield, UK 
    
Saline - MacoPharma Middlesex, UK  
    
Thrombin - Sigma Poole, UK 
    
 Trypan Blue  - Sigma Poole, UK 
    
Trypsin EDTA solution - Sigma Poole, UK 
    
MEM Vitamin Solution - Life 
Technologies 
Paisley, UK 
    
Xylazine Hydrochloride (Xylacare 2%) - Animalcare York, UK 
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2.2.2. Cell Isolation and Culture 
2.2.2.1. Endothelial Cell Culture 
Immortalised colonic endothelial cells (kindly provided by Professor Alexander, USA) were 
isolated as previously described from the Immortomouse (Ando et al., 2005). The cells were 
expanded at 33⁰C and 5% CO2 in endothelial growth media (D-Valine MEM, 10% foetal calf 
serum (FCS), 1% penicillin streptomycin (P/S), 1% L-glutamine, 1% non-essential amino acids, 
1% vitamin mix and 10 units/ml interferon γ).  At confluence, cells were dissociated with 
trypsin-EDTA washed with growth media and split 1 in 3.  For static adhesion assays the cells 
were de-immortalised by transferring them to experiment media (450ml DMEM (4.5g/l 
glucose), 1% FCS, 1% P/S) splitting them one in six and allowing them to grow to confluence 
over 2-5 days at 37⁰C and 5% CO2.  All tissue culture plastics were treated with a 2% gelatine 
solution before use to aid cell adhesion.   
2.2.2.2. Lymphocyte Isolation 
For some experiments lymphocytes were isolated from the inguinal lymph nodes of sacrificed 
C57BL/6 mice on the day of use.  The lymph nodes were pushed through a CD-1 mesh size 100 
screen (Sigma) into ice cold PBS containing 2% FCS using the plunger from a 5 ml syringe.  The 
screen was then washed thoroughly with 2% FCS in PBS and the resulting cell suspension 
collected.  The suspension was then spun at 400g for 10 minutes and the pellet was responded 
in 1ml of 2% FCS in PBS.  The cell suspension was stored on ice until use. 
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For other experiments T-cells, B-cells, CD4+ T-cells or CD8a+ T-cells were isolated through 
negative selection magnetic activated cell sorting (MACS).  MACS has been frequently used to 
isolated lymphocytes for intravital microscopy studies (Worbs et al., 2007, Ogino et al., 2004, 
Chtanova et al., 2014).  Negative selection kits were used to limit the possible effects of 
isolation on lymphocyte function (Šafařıḱ and Šafařıḱová, 1999).  The B cell isolation kit, Pan T 
cell isolation kit II, CD4+ T cell Isolation Kit II and CD8a+ T cell Isolation Kit II were used as per 
the manufacturer’s protocol (Miltenyi Biotec, Surrey, UK).  Spleens were taken from C57BL/6 
mice and pressed through CD-1 mesh size 100 screens into ice cold MACS buffer (PBS, pH7.2 
supplemented with 0.5% bovine serum albumin (BSA) and 2mM EDTA).  The cell suspension 
was then passed through a 7.5µm filter to remove cell clumps, counted and centrifuged at 
300g for 10 minutes.  The cells were resuspended in MACS buffer at 2.5x109cells/ml.  10µl of 
the required biotinylated antibody cocktail (Table 2.3) was added per 40µl of cell suspension 
and incubated at 4⁰C for 10 minutes.  After incubation with the antibody cocktail 20µl of anti-
biotin MicroBeads and 30µl of MACS buffer per 40µl cell suspension was added and the cells 
were incubated for a further 10 minutes at 4⁰C.  1ml of MACS buffer was added and the cells 
were centrifuged at 400g for 10 minutes.  The cell pellet was resuspended in 500µl of MACS 
buffer and run through an MS or LS MACS column in a MiniMACS or MidiMACS separator 
respectively (Miltenyi Biotec).  The column was washed 4 times with MACS buffer and the 
eluted cells collected.  The purity of the isolated cells was checked through flow cytometric 
identification of the cell specific markers CD3ε (T-cells), CD19 (B-cells), CD4 and CD8a (Section 
2.2.3). 
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Table 2.3 MACS antibody cocktails 
  
Kit Antibody Cocktail against 
  
B Cell Isolation Kit CD43, CD4, Ter-119 
  
Pan T cell Isolation Kit II CD11b, CD11c, CD19, CD45R, CD49b CD105, MHC class II, Ter-119 
  
CD4+ T Cell Isolation Kit II CD8a, CD11b, CD11c, CD19, CD45R, CD49b, CD105, MHC Class II, 
Ter-119 
  
CD8a+ T Cell Isolation Kit II CD4, CD11b, CD11c, CD19, CD45R, CD49b, CD105, MHC Class II, 
Ter-119 
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2.2.2.3. Platelet Isolation 
In order to isolate platelets isoflourane anesthetised mice were terminally CO2-narcosed.  A 
laparotomy was performed and blood was taken from the descending aorta into 100µl of acid 
citrate dextrose (ACD; 120mM sodium citrate, 110mM glucose, 80mM citric acid).  The blood 
was added to 200µl of Tyrode’s Buffer (134mM NaCl, 0.34mM Na2HPO4, 2.9mM KCl, 12mM 
NaHCO3, 20mM HEPES, 1mM MgCl2, 5mM glucose; pH 7.3 at 37⁰C)  and centrifuged at 200g 
for 5 minutes.  The platelet rich plasma (PRP) and the top third of erythrocytes were removed 
and centrifuged again at 200g for 6 minutes.  PRP was retained and a further 200µl of Tyrode’s 
buffer was added to the remaining erythrocytes which were then centrifuged again at 200g 
for 6 minutes.  The PRP from this spin was pooled with that of the previous spin, 10ng/ml of 
prostacyclin was added to prevent aggregation and the platelets were pelleted through 
centrifugation at 1000g for 6 minutes.  The pellet was resuspended in Tyrode’s buffer, platelet 
counts were obtained using a coulter counter (Beckman Coulter, High Wycombe) and the 
platelets were diluted to the required concentration with Tyrode’s buffer.  Platelets were left 
to rest for at least 30 minutes after the addition of prostacyclin prior to their use in 
experiments to ensure no prostacyclin remained. 
2.2.2.4.  Lymphocyte Staining 
For adhesion assays and intravital studies lymphocytes were fluorescently labelled with either 
CMTMR or CFDA-SE, both of which are cytoplasmic dyes which enter the cell through 
diffusion.  Once in the cell they are converted to cell-impermeant reaction products 
preventing them from leaving.  CMTMR and CFDA-SE were dissolved at 10mM in DMSO, 
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divided into single use aliquots and stored at -20⁰C.  Cells were stained by incubating them in 
a solution of 10µM CFDA-SE or 5µM CMTMR in PBS for 40 minutes at room temperature in 
the dark.  These staining concentrations have previously been used to label lymphocyte for 
intravital microscopy experiments (Gunzer et al., 2004, Jones et al., 2003). 
2.2.2.5. Platelet Staining 
Platelets were also fluorescently labelled for use in adhesion assays and intravital studies.  The 
initial steps of staining follow the platelet isolation protocol above up to the point of 
centrifugation at 1000g.  After centrifugation the platelets were resuspended in 1ml Tyrode’s 
buffer with 10µM CFDA-SE and incubated in the dark at room temperature for 20 minutes.  
10ng/ml of prostacyclin was added, and the platelets were pelleted through centrifugation at 
1000g for 6 minutes.  The pellet was resuspended in Tyrode’s buffer, platelet counts were 
obtained using a coulter counter, and the platelets were diluted to the required concentration 
with Tyrode’s buffer.  Platelets were left to rest for at least 30 minutes after the addition of 
prostacyclin prior to their use in experiments.  This method of staining platelets has previously 
been shown not to cause platelet activation (Holyer, 2010). 
2.2.3. Flow Cytometry 
Flow cytometry was used to measure the purity of cell separations and changes in surface 
receptor expression on cells following treatment.  5x105 cells in 100µl FACS buffer (2% FCS, 
0.01% sodium azide in PBS) were incubated for 20min on ice with a 1:50 dilution of the 
required antibody (Table 2.1).  If a secondary antibody was required this was added at a 
dilution of 1:50 and incubated for a further 20min on ice.  Cells were then centrifuged at 400g 
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for 10 minutes and resuspended in 300µl FACS buffer.  The samples were then loaded into a 
FACSCalibur flow cytometer (BD) and analysed with Summit 4.0 (DakoCytomation; Colorado, 
USA). Flow cytometry plots in this thesis were produced using Flowing Software 2.5.1 
(University of Turku, Finland) and Summit 4.0.   
2.2.4. Static Adhesion Assays 
These assays were conducted to determine the effects of (i) adherent platelets on subsequent 
lymphocyte adhesion and (ii) incubating lymphocytes with platelets, cytokines and H2O2 on 
their subsequent adhesion.  Static adhesion assays were carried out on both colonic 
endothelial cells and immobilized ligands (CD54, CD106 and MAdCAM-1).  Three different 
types of assay were carried out.  Firstly, naïve and thrombin activated (5 minute incubation in 
0.2U/ml thrombin) CFSE-labelled platelets (2x107platelets/ml) in Tyrode’s were incubated on 
the ligands or endothelium for 20 minutes followed by 3 washes with PBS.   
In the second assay the ligands or endothelium were incubated with platelets as above,  the 
wells were then washed 3 times with PBS and then incubated for 20 minutes with lymphocytes 
(1x106lymphocytes/ml) in PBS followed by a further 3 washes with PBS (Figure 2.1 A).   
In the final assay the lymphocytes (1x106lymphocytes/ml) were incubated with a pre-
treatment (Table 2.4) for 5 or 30 minutes. For this, thrombin activated platelet supernatant 
was produced by incubation of washed platelets with 0.2U/ml thrombin in Tyrode’s buffer for 
5 or 30 minutes, the platelets were then spun down (1500g, 15 minutes) and the supernatant 
isolated. Platelet micro particles (PMPs) were produced by incubation of 3x108 washed 
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platelets/ml with 2U/ml thrombin for 30 minutes at 37°C. Platelets were then spun down 
(1500g, 15 minutes) and the resulting supernatant was centrifuged again at 1800g for 30 
minute. The supernatant was discarded and the pellet (PMPs) was resuspended in an 
equivalent volume of Tyrode’s. Following pre-treatment the cells were added to endothelium 
or immobilised ligands at a concentration of 1x106lymphocytes/ml and incubated for a further 
20 minutes (Figure 2.1 B). 
Following each of the assays, cells were fixed overnight in 5% formalin at 4⁰C then washed 3 
times in PBS prior to imaging with an Olympus IX81 inverted microscope fitted with a 20X 
objective lens (Olympus, UK).  5 images were taken per well in a pre-defined pattern (Figure 
2.2) starting at the centre of the well.  To eliminate bias, images were analysed using blind 
counting software developed by Dr Kavanagh (University of Birmingham). 
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Figure 2:1 Schematic of static adhesion assays.  Assays were conducted to determine the effects of (A) adherent platelets (green) on subsequent lymphocyte (orange) 
adhesion and (B) incubating lymphocytes with platelets, cytokines and H2O2 on their subsequent adhesion. 
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Table 2.4 Static adhesion assay pre-treatments 
  
Pre-treatment Name Description 
  
Thrombin 0.2U/ml thrombin 
  
Naïve Platelets 2x107 platelets/ml 
  
Thrombin activated Platelets 2x107 platelets/ml + 0.2U/ml thrombin 
  
Thrombin activated Platelet 
Supernatant 
The supernatant of 2x107 platelets/ml + 0.2U/ml thrombin  
  
Platelet micro particles (PMPs) Released following activation of 3x108 platelets/ml  with 
2U/ml thrombin for 30 minutes at 37ᵒC 
  
CXCL1 (KC) 25 ng/ml CXCL1 (PeproTech; London, UK) 
  
CXCL12 (SDF) 25 ng/ml CXCL12 (PeproTech;  London, UK) 
  
CCL5 (RANTES) 25 ng/ml CCL5 (PeproTech; London, UK) 
  
H2O2 100µM H2O2 
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Figure 2:2 Pre-defined imaging pattern.  For intravital studies, adhesion assays and immunofluorescent staining 
5 fields of view were imaged following this pre-defined pattern.
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2.2.4.1. Ligand Static Adhesion Assay 
For ligand static adhesion assays, 96 well plates were treated with 50µl of 3% BSA or 10µg/ml 
recombinant murine CD54, CD106 or MAdCAM-1 for 1 hour at room temperature.  The 
treatments were then removed and the remaining uncoated plastic was blocked by incubation 
with 50µl of 3% BSA for a further hour. This concentration was determined as the minimum 
concentration that could block activated platelet (5 minutes, 0.2U/ml thrombin) adhesion to 
tissue culture plastic. The wells were then washed three times with PBS and the assays were 
carried out as above adding 100µl of cell suspension to each well. 
2.2.4.2. Endothelial Static Adhesion Assay 
Immortomouse colonic endothelial monolayers in 24 well plates were washed with PBS and 
incubated at 37⁰C for 4 hours in experiment media with or without 10ng/ml TNF-α.  The wells 
were then washed three times with PBS and the assays were carried out as above adding 500µl 
of cell suspension to each well. 
2.2.4.3. Stamper Woodruff Assays 
Gut sections were taken from sham, IR injured and colitis mice.  IR injury was induced by 
clamping of the superior mesenteric artery for 45 minutes followed by 2 hours of reperfusion, 
for uninjured controls sham surgery was carried out.  Colitis was induced by replacement of 
drinking water with water containing 3% dextran sodium sulphate for 5 days (MW 36000-
50000, MP Biomedicals, UK), sham controls were given normal drinking water.  The terminal 
Ileum and terminal jejunum were taken from IR injured mice and the descending colon was 
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taken from colitis mice. Gut sections were then cut lengthways along one side and laid flat, 
mucosal side, up on a cork board.  The tissue samples were then snap frozen in liquid nitrogen 
and stored at -80⁰C.  Prior to use the top 60µm of the mucosal side of the sections was 
removed using a cryostat in order to expose the vasculature.  Tissue sections were then fixed 
in acetone for 20 minutes, air dried and stored at -20⁰C. 
On the day of use tissue sections were placed at room temperature for 20 minutes to allow 
them to thaw.  The surfaces of the sections were than washed 3 times with PBS.  100µl of PBS 
containing 2x106 naïve or activated (0.2U/ml; 5 minutes) CFSE labelled platelets or 100,000 
lymphocytes were then placed onto the sections for 20 minutes in the dark in a humidified 
box.  The cell suspension was then removed and the sections were washed 3 times with PBS.  
The sections were fixed with acetone for 20 minutes and air dried before imaging. 
Images were captured with an Olympus IX81 inverted microscope fitted with a 20X objective 
lens.  5 images were taken per section in a pre-defined pattern (Figure 2.2) starting at the 
centre of the section.  To eliminate bias images were analysed using blind counting software 
developed by Dr Kavanagh (University of Birmingham).  
2.2.5. In vivo Studies 
2.2.5.1. Surgical Preparation 
Anaesthesia was induced through intraperitoneal injection of ketamine (100mg/Kg) and 
xylazine hydrochloride (10mg/Kg) delivered in 0.9% saline solution.  Anaesthesia was 
monitored through regular testing of the pedal reflex and maintenance anaesthesia was 
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delivered intra-arterially as required.  The trachea and right common carotid artery were 
cannulated using heparinised polyethylene portex tubing (Smiths Medical, Hythe, UK) in order 
to assist breathing and allow introduction of anaesthetic, cells and antibodies.  Skin was 
removed for the abdomen and a midline laparotomy was performed by cutting along the 
avascular linea alba.  The left and right rectus abdominis muscles were then removed using a 
cautery exposing the liver.  The falciform ligament and round ligament of the liver were cut 
freeing the liver from its attachment to the diaphragm. 
2.2.5.2. Hepatic Ischemia Reperfusion 
As total hepatic ischemia for periods of greater than 45 minutes results in 100% mortality 
(Kavanagh, 2009) injury was induced through partial hepatic ischemia. Ischemia of the left and 
median lobes of the liver was induced through application of an atraumatic vascular clamp to 
the hepatic artery and portal vein supplying these lobes for 90 minutes (Figure 2.3 A).  
Ischemia was confirmed by colour change of the left and median liver lobes (Figure 2.3 B).  
Sham animals were prepared in the same way as injured animals except the vascular clamp 
was not applied.  After 90 minutes ischemia the clamp was removed and intravital 
observations carried out. 
2.2.5.3. Concanavalin A induced Liver Injury 
ConA was dissolved in sterile saline, divided into single use aliquots and stored at -20⁰C until 
use.  To induce injury a dose of 20mg/kg was introduced via the carotid cannula (Tiegs et al., 
1992).  For uninjured vehicle control mice an equivalent volume of sterile saline was 
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B 
 
Figure 2:3 Ischemia of the liver was induced through application of a vascular clamp.  IR injury was induced 
through clamping of the blood supply to the left and median lobes but not the right lobe of the liver (A; adapted 
from Cook (1965)).  Ischemia was confirmed through a colour change of the tissue (B).  
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introduced into the carotid artery.  Injury was then allowed to develop for 2 or 4 hours prior 
to intravital observation. 
2.2.5.4. Induction of Thrombocytopenia 
For some experiments platelet depleted mice were used.  R300 is a cocktail of monoclonal 
CD42b antibodies which, when injected into mice, cause profound irreversible 
thrombocytopenia in an Fc-receptor independent manner (Nieswandt et al., 2000).  
Thrombocytopenia was induced by a dose of 1.5mg/Kg R300 antibody introduced via the 
carotid cannula.  After 1 hour liver injury or sham surgery was carried out.  Thrombocytopenia 
was confirmed using an ABX Pentra 60 automated blood counter (Horiba; Northampton, UK).  
Platelet depletion with this antibody does not affect the number of other blood cells in 
circulation (Holyer, 2010). 
2.2.5.5. CD162 Blocking 
For CD162 blocking experiments lymphocytes were incubated in 200µl of 20µg/ml CD162 
blocking antibody (4RA10) or rat IgG1κ for 20 minutes at 4⁰C (Engelhardt et al., 2005).  
Complete blocking was confirmed using flow cytometry. 
2.2.5.6. Intravital Microscopy 
15 minutes prior to the end of injury induction the left lobe of the liver was exteriorised onto 
a petri dish and the mouse was transferred to the stage of an Olympus IX81 inverted 
microscope.  The microvasculature of the liver was then viewed through a 20X objective.  
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For monitoring of T-cell and B-cell recruitment 0.5x106 fluorescently labelled (section 2.2.2.4) 
T-cells and B-cells were injected into the carotid artery 2 or 4 hours post ConA injection or at 
the point of clamp removal for IR injury as previously described (Chimen et al., 2015). For 
some experiments cells were injected directly into the portal vein at 60 minutes post 
reperfusion.  Following cell injection a random field was selected every 10 minutes and imaged 
for 20 seconds.  5 additional fields of view in a pre-defined pattern were then imaged for 20 
seconds each (Figure 2.2). 
To monitor the effect of PMP pre-treatment on lymphocyte adhesion in the injured liver, 
1.8x106 CFDA-SE labelled inguinal node lymphocytes were treated with PMPs for 5 minutes 
using the same method used for adhesion assays (section 2.2.4). These cells were then 
injected into the carotid artery prior to 90 minutes partial hepatic ischemia. Following 
reperfusion one random field was imaged every 10 minutes for 2.5 hours.   
For monitoring of platelet recruitment CFDA-SE labelled platelets were injected into the 
carotid artery either 5 minutes before application of the clamp for IR injury or 2 or 4 hours 
post ConA injection.  One field of view was randomly selected every 10 minutes over 2 hours 
and imaged for 1 minute.  After each minute of imaging 5 additional fields of view in a 
predefined pattern were captured in order to ensure that the random field was 
representative. 
For labelling of endogenous platelets and lymphocytes 20µl of rat anti mouse CD41 antibody 
(platelet specific), biotin conjugated Armenian hamster anti mouse CD3e (T-cell specific), and 
mouse anti mouse CD19 antibody (B-cell specific) were incubated for 5 minutes with 40µl 
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alexa 488 anti mouse antibody, alexa 555 anti rat antibody, and alexa 647 streptavidin. IgG 
controls for the primary antibodies were prepared in the same way. In a separate experiment 
a rat anti mouse CD19 antibody was also used, 20µl of the antibody was incubated with 40µl 
alexa 488 anti rat for 5 minutes. In another experiment 8µl of PE conjugated rat anti mouse 
Lye6G (neutrophil specific) was made up to 100µl with PBS. The antibody cocktails were 
injected 10 minutes prior to induction of ischemia or sham surgery to allow time for the 
antibody to circulate. Following 90 minutes of ischemia one field of view was imaged for 2 
minutes every 10 minutes for 2.5 hours. 
2.2.5.7. Analysis of Intravital Experiments 
Intravital data was analysed using Slidebook V software (3i; Göttingen, Germany).  Free 
flowing and adherent cells/platelets were counted blind to remove possibility of bias, to do 
this file names were obfuscated using software developed by Dr Kavanagh (University of 
Birmingham).  Free flowing cells/platelets were defined as cells that were present in the field 
of view but were not static or were static for less than 20 seconds.  Adherent cells/platelets 
were defined as cells that were static for at least 20 seconds.  Cells/platelets at the edge of 
the field of view that were not entirely within the field of view were not counted.  Out of focus 
cells/platelets (lacking a punctate, ovoid appearance) were not counted.  Platelet velocity was 
calculated using the manual single particle tracking feature of Slidebook software.  The 
velocities of at least the first 5 free flowing platelets to enter the field of view which were 
visible for more than one time point were measured.  To calculate the area of CD41 antibody 
staining the masking feature of Slidebook software was used (Figure 2.4), ‘masks’ were drawn 
over points   
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Figure 2:4 Quantification of fluorescence using Slidebook’s masking tool.  A mask (blue) was drawn over areas 
of fluorescence (red) with a pixel intensity of greater than 180.  Scale bar = 100µm. 
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in the Cye3 channel with intensities greater than 180.  This intensity range was chosen as it 
excluded background fluorescence. 
2.2.5.8. Laser Doppler Measurements 
In order to measure perfusion of the liver during injury measurements were taken using a 
moorVMS-LDF laser Doppler blood flow monitor (Moor instruments; Devon, UK), 
measurements were taken prior to injury and then every hour post injury.  Measurements 
were taken at five random locations for every time point.  During laser Doppler measurements 
the room was kept dark to reduce interference from outside light, damp gauze was placed 
under the liver lobe to minimise movement due to respiration. 
2.2.5.9. Visualisation of Perfusion 
In order to visualise areas of flow within the hepatic vasculature 100µl FITC-BSA or 100µl 
2.5mg/ml Alexa-647 BSA were injected intra arterially.  It was then possible to visualise the 
BSA within the liver using intravital microscopy.  When introduced systemically the BSA is 
retained within the vasculature, provided that the integrity of the vessel is not disturbed (Kalia 
et al., 2002).  It does not enter areas of the vasculature without flow.  To produce FITC-BSA 
170mg 10% FITC on celite was conjugated to 1g BSA by mixing the FITC, BSA and 10ml of 
bicarbonate buffer (0.6g Na2CO3, 3.7g NaHCO3, 100ml distilled water, pH 9.0) overnight at 4⁰C.  
This was then centrifuged at for 10 minutes at 16000g and conjugated/unconjugated BSA 
separated by dialysis (12,000MW cut off; Spectrum Laboratories, CA, USA).  Prepared FITC-
BSA was split into single use aliquots, frozen and stored until use. 
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2.2.5.10. Immunofluorescent Staining of Tissue Sections 
Following injury or sham surgery livers were snap frozen in liquid nitrogen and stored at -80⁰C.  
10µm sections of the livers were taken using a cryostat, mounted on slides and fixed in 
acetone for 20 minutes.  Sections were then incubated with 1:50 dilutions of CD42b, CD41 or 
IgG2a antibody for 3 hours at 4⁰C and washed 3 times in PBS.  Sections were then incubated 
with a 1:50 dilution of Alexa 488 rabbit anti rat antibody for 1 hour at 4⁰C.  Sections were then 
washed 3 times with PBS and dehydrated for 5 minutes in 95% ethanol.  Sections were then 
imaged with a fluorescence microscope fitted with a 20X objective lens (EVOS microscope; 
AMG; Washington, USA).  5 images were taken per section in a pre-defined pattern (Figure 
2.2) starting at the centre of the section.  To eliminate bias images were analysed using blind 
counting software developed by Dr Kavanagh (University of Birmingham).   
2.2.5.11. Plasma Alanine Aminotransferase Tests 
Following intravital experiments blood samples were taken from the mice into 100µl ACD.  The 
blood was then centrifuged at 2000g for 20 minutes at 4⁰C.  The plasma fraction was then 
removed and stored at -80⁰C.  In order to quantitate the level of injury alanine 
aminotransferase (ALT) activity tests were carried on the plasma samples by the clinical 
chemistry department at Birmingham Women’s Hospital (UK) using an Olympus Au400 
analyser. 
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2.2.5.12. Blood Counts 
At the end of some intravital experiments blood samples were taken from the mice into 100µl 
ACD.  The samples were analysed using an ABX Pentra 60 automated blood counter to obtain 
erythrocyte, leukocyte and platelet counts. 
2.2.6. Statistics  
Statistical tests were carried out using GraphPad Prism 5 software (GraphPad; San Diego, 
USA).  Serial data was analysed using two-way ANOVA.  Static adhesion assay data and some 
flow cytometry data was analysed using one-way ANOVA with Dunnet’s post-hoc tests.  
Survival curves were analysed using Mantel-Cox tests with Bonferroni corrections for multiple 
comparisons.  All remaining data was compared using unpaired student’s t-tests.  p-values of 
<0.05 (*), <0.005 (**) and <0.001 (***) were considered significant. 
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3. PLATELET MODULATION OF LYMPHOCYTE ADHESION IN VITRO 
 Introduction and Hypotheses 
It is well established that immobilised activated platelets can support rolling and adhesion of 
lymphocytes under physiological flow in a CD62P, CD11a/CD18 and CD11b/CD18 dependant 
manner (Diacovo et al., 1996b, Sheikh et al., 2004).  Lymphocytes can also adhere to activated 
endothelium, a process which is mediated by endothelial cell expressed adhesion molecules 
such as CD54, CD106 and MAdCAM-1 (van Dinther-Janssen et al., 1991, Dustin and Springer, 
1988, Grant et al., 2001).  However, little is known about whether platelets can modify directly 
or indirectly lymphocyte adhesion to cell adhesion molecules or endothelial cells.  There are a 
number of ways in which platelets could potentially modulate lymphocyte adhesion.  Platelets 
may act as a bridge between the endothelial surface and the lymphocyte. Indeed, this has 
previously been shown to mediate the capture of lymphocytes from flow on the high 
endothelial venules of peripheral lymph nodes (Diacovo et al., 1996c).  Platelets also release 
a number of factors including cytokines and PMPs which may modulate lymphocyte adhesion 
(Zarbock et al., 2007, Diamant et al., 2004).  Platelet adhesion on endothelium can also result 
in endothelial activation via the CD40/CD154 pathway (Henn et al., 1998).  The experiments 
in this chapter aim to assess the effect of platelets and platelet released factors on lymphocyte 
adhesion to immobilised cell adhesion molecules and endothelium in vitro.    
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For the work included in this chapter we hypothesised that: 
1. Adhesion of lymphocytes to endothelium and immobilised cell adhesion molecules is 
increased following their incubation with activated platelets or their releasate. 
2. Adhesion of lymphocytes on immobilised cell adhesion molecules is increased following 
their incubation with PMPs. 
3. Expression of integrins on lymphocytes is increased following their incubation with 
activated platelets or their releasate. 
 Methods 
The methods used in this chapter are discussed in detail in Chapter 2 and were used to 
investigate in vitro whether lymphocyte adhesion to immobilised endothelial counter-ligands 
could be modulated by (i) pre-incubation with platelets (ii) previously adherent platelets (iii) 
pre-incubation with PMPs or factors released from activated platelets.  Briefly, murine 
lymphocytes were isolated from the inguinal lymph nodes and platelets from the whole blood 
of C57BL/6 mice.  Static adhesion assays were carried out on endothelium, immobilised cell 
adhesion molecules and intestinal tissue sections to determine the effects of adherent 
platelets on subsequent lymphocyte adhesion and incubating lymphocytes with platelets or 
platelet releasate on their subsequent adhesion.  Lymphocyte expression of CD49d and CD18 
following incubation with platelets or platelet releasate was determined by flow cytometry.   
To investigate whether PMPs affect lymphocyte adhesion, lymphocytes were incubated with 
PMPs generated through thrombin stimulation of washed platelets and their adhesion to 
83 
 
endothelial counter ligands was quantitated.  Flow cytometry was used to determine whether 
PMPs form conjugates with lymphocytes using antibodies against the platelet specific marker 
CD41. 
 Results 
3.3.1. 3% BSA is Sufficient to Block Platelet Adhesion to Tissue Culture Plastic 
In static adhesion assays using protein coated tissue culture plastic, BSA can be used to block 
uncoated plastic.  Previously, a concentration of 1% BSA has been used in this lab to block 
tissue culture plastic for static adhesion assays.  Large numbers of adherent platelets were 
observed on untreated tissue culture plastic (Figure 3.1 A) as well as on tissue culture plastic 
blocked with 1% BSA, indicating incomplete blocking of the plastic (Figure 3.1 B).  3% BSA was 
found to almost completely block activated platelet adhesion to tissue culture plastic (Figure 
3.1 C).  3% BSA was therefore used for blocking in all future static adhesion assays on 
immobilised protein. 
3.3.2. Activation with Thrombin Significantly Increases Platelet Adhesion on Immobilised 
Cell Adhesion Molecules 
To determine whether platelet activation increases platelet adhesion to cell adhesion 
molecules naïve and activated platelets were incubated under static condition on immobilised 
CD54, CD106 and MAdCAM-1 for 20 minutes and their adhesion was quantitated.  Platelet 
activation significantly increased platelet adhesion to both CD54 (Figure 3.2 A-C; p<0.01) and 
MAdCAM-1 (Figure 3.2 G-I; p<0.01).  Adhesion of activated platelet to CD106 was also greater 
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than that of naïve platelets although this difference did not reach significance (Figure 3.2 D-F; 
p>0.05).  Activated platelet adhesion was highest on CD54 (adherent cells / field of view: 
88±25), 4 times greater than the number of adherent platelets observed on MAdCAM-1 
(adherent cells / field of view: 22±6), few adherent platelets were observed on CD106 
(adherent cells / field of view: 2±1). 
3.3.3. T-cells Make Up the Majority of Cells in Lymph Node Cell Isolates 
For the following experiments in which lymphocyte adhesion was investigated, lymphocytes 
were isolated via mechanical digestion of inguinal lymph nodes taken from C57BL/6 mice.  
Flow cytometry showed these cell isolates to be made up of 76±1% T-cells (Figure 3.3 A; CD3ε+ 
cells) and 26±3% B-cells (Figure 3.3 B; CD19+ cells). NK cells were undetectable in this 
population of murine inguinal lymph node cells (Figure 3.3 C; NK1.1+ cells). 
3.3.4. Adherent Activated Platelets Significantly Enhance Lymphocyte Adhesion to 
Immobilised Cell Adhesion Molecules 
In order to investigate whether adherent platelets can affect lymphocyte adhesion to cell 
adhesion molecules naïve or activated platelets where added to the immobilised ligand and 
non-adherent platelets washed away.  Lymphocytes were then added and their adhesion after 
20 minutes quantitated.  There was significantly greater adhesion of lymphocytes to CD54 
(Figure 3.4 A; p<0.05) and MAdCAM-1 (Figure 3.4 E; p<0.05) when activated platelets had 
previously been incubated on the ligands compared to lymphocytes on their own.  Naïve 
platelets had no significant effect on adhesion to CD54 (Figure 3.4 A; p>0.05) or MAdCAM-1 
(Figure 3.4 E; p>0.05).  On CD106 no adhesion of lymphocytes was observed in the absence of 
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platelets; however, some adhesion did occur when the immobilised ligand had previously 
been incubated with naïve and activated platelets (Figure 3.4 C).  The vast majority of adherent 
lymphocytes were not bound to platelets (Figure 3.4 D & F). 
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Figure 3:1 3% BSA is sufficient to block platelet adhesion to tissue culture plastic.  CFSE labelled activated platelets (0.2U/ml thrombin; 5 minutes) were incubated 
on untreated tissue culture plastic (A)   and tissue culture plastic blocked with 1% (B) and 3% BSA (C).  Blocking the plastic with 3% BSA greatly reduced the number of 
adherent platelets observed.  n=1, scale bars=100µm.  
A Untreated  B 1% BSA  C 3%BSA 
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Figure 3:2 Thrombin significantly increases platelet adhesion to cell adhesion molecules.  Adhesion of naïve 
and activated (0.2U/ml thrombin; 5 minutes) platelets after 20 minutes incubation on immobilised cell adhesion 
molecules was quantitated.  Activation significantly increased platelet adhesion on CD54 (A) and MAdCAM-1 (G) 
but not CD106 (D).  Images show CFDA-SE stained naïve/activated platelets on CD54 (B/C) CD106 (E/F) and 
MAdCAM (H/I).  Data presented as mean ±SEM, n=5, **p<0.01 (t-tests), scale bars=100µm. 
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Figure 3:3 T-cells make up the majority of cells in lymph node cell isolates.  Flow cytometry was carried out on 
lymph node cell isolates to analyse their composition. Representative plots are shown. Isolates were found to 
contain 76±1% T-cells (A; CD3ε+ cells; n=4) and 26±3% B-cells (B; CD19+ cells; n=4); NK cells were undetectable 
(C; NK1.1+ cells; n=4).  Black lines: isotype controls, red lines: antibody against relevant cell marker, blue gates: 
cell marker positive cells,. 
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Figure 3:4 Adherent activated platelets significantly increase lymphocyte adhesion to immobilised cell 
adhesion molecules.  The presence of activated (0.2U/ml thrombin; 5 min) adherent platelets significantly 
increased lymphocyte adhesion on immobilised CD54 (A) and MAdCAM-1 (E) but not CD106 (C).  Representative 
images are shown of lymphocyte (red arrowheads / colourless cells) adhesion in the presence of activated 
adherent platelets (white arrowheads / green cells) on CD54 (B), CD106 (D) and MAdCAM-1 (F).  Data presented 
as mean ±SEM, n=5, *p<0.05 **p<0.01 (one-way ANOVA with Dunnett’s post-tests), scale bars=100µm. 
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3.3.5. Incubation with Platelets or Activated Platelet Supernatant Significantly Enhances 
Lymphocyte Adhesion to Immobilised Cell Adhesion Molecules 
Lymphocytes were pre-incubated with thrombin (control) naïve platelets, thrombin activated 
platelets or thrombin activated platelet releasate for 5 or 30 minutes to determine whether 
this modified their subsequent adhesion. Although increases in lymphocyte adhesion to CD54 
were observed after 5 and 30 minutes incubation with activated platelets and platelet 
releasate, this did not reach statistical significance between treatments (Figure 3.5 A; p>0.05). 
Incubation with the releasate of thrombin activated platelets for 5 and 30 minutes increased 
lymphocyte adhesion to CD106 but reached statistical significance at 5 minutes only when 
compared to incubation with thrombin alone (Figure 3.5 B; p<0.01). Similarly, incubation with 
the releasate of thrombin activated platelets increased lymphocyte adhesion to MAdCAM-1, 
which was significantly different at 5 minutes (Figure 3.5 C; p<0.001) and 30 minutes (Figure 
3.5 C; p<0.05).  Incubation for 5 minutes with naïve platelets also significantly increased 
lymphocyte adhesion to MAdCAM-1 when compared to untreated cells (Figure 3.5 C; p<0.05).   
3.3.6. Incubation with PMPs Significantly Increased Lymphocyte Adhesion to Immobilised 
Cell Adhesion Molecules 
As activated platelet releasate was shown to significantly increase lymphocyte adhesion to 
cell adhesion molecules the effect of purified PMPs, vesicles released from activated platelets, 
on lymphocyte adhesion was investigated.  Incubation with PMPs for 5 minutes significantly 
increased lymphocyte adhesion to CD54 (Figure 3.6 A; p<0.05) and MAdCAM-1 (Figure 3.6 C; 
p<0.05) and to CD106 following 30 minutes incubation (Figure 3.6 B; p<0.05).  In order to 
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determine if PMPs were physically interacting with the membrane of the lymphocytes flow 
cytometry was used to look for the presence of the platelet specific marker CD41.  Flow 
cytometry following incubation with PMPs did not detect CD41 on the surface of lymphocytes 
(Figure 3.6 D; p>0.05).  To determine if this was due to the low concentration of PMPs 
lymphocytes were incubated with 10 times the concentration of PMPs; this also did not result 
in surface CD41 expression (Figure 3.6 E; p>0.05). 
3.3.7. Neither Endothelial Activation nor Platelet Activation Significantly Alters Platelet 
Adhesion to Endothelium 
As previously adherent platelets or incubation with platelets or platelet releasate enhanced 
lymphocyte adhesion to immobilised cell adhesion molecules found on endothelial cells, 
further experiments were carried out to determine if platelets could also enhance lymphocyte 
adhesion on endothelial monolayers as well.  Firstly, platelet adhesion to untreated and TNFα 
stimulated murine colonic endothelial cells using static adhesion assays was investigated.  
Considerable adhesion of naïve platelets was observed on untreated endothelial cells.  
Although increased adhesion of thrombin activated platelets was observed on untreated 
endothelial cells, this did not reach statistical significance (Figure 3.7; p>0.05).  TNF-α 
stimulation of the endothelium also had no effect on the adhesion of naïve or activated 
platelets (Figure 3.7; p>0.05). 
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3.3.8. The Presence of Adherent Platelets does not Significantly Affect Lymphocyte 
Adhesion to Endothelium 
As adherent platelets significantly enhanced lymphocyte adhesion to cell adhesion molecules 
their effect on lymphocyte adhesion to endothelium was also investigated.  The presence of 
adherent platelets on the endothelium had no significant effect on lymphocyte adhesion to 
endothelium (Figure 3.8; p>0.05).  Stimulation of the endothelium with TNF-α also had no 
significant effect on lymphocyte adhesion to endothelium (Figure 3.8; p>0.05). 
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Figure 3:5 Incubation with platelets or activated platelet supernatant significantly enhances lymphocyte 
adhesion on immobilised cell adhesion molecule.  The adhesion on CD54 (A), CD106 (B) and MAdCAM-1 (C) of 
untreated lymphocytes (-) and lymphocytes incubated for 5 or 30 minutes with thrombin (+T), platelets (P), 
platelets and thrombin (+T+P) or thrombin activated platelet releasate (+T+PR) was quantitated.  Data presented 
as mean ±SEM, n≥4, **p<0.05 compared to 5 minute +T, ***p<0.001 compared to 5 minute +T, ●p<0.05 
compared to -, #p<0.05 compared to 30 minute +T (one-way ANOVA with Bonferroni post-tests). 
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Figure 3:6 Lymphocyte adhesion on immobilised cell adhesion molecules was significantly increased following 
incubation with PMPs.  The adhesion of untreated lymphocytes (-) and lymphocytes incubated with PMPs for 5 
and 30 minutes on immobilised CD54 (A), CD106 (B) and MAdCAM-1 (C) was quantitated.  Panels D and E   show 
representative flow cytometry plots, black line: isotype control, red lines: untreated lymphocytes with CD41 
antibody, blue line: PMP treated lymphocytes (D) or lymphocytes treated with a 10X concentration of PMPs (E) 
with CD41 antibody.  Data presented as mean ±SEM, n≥3, *p<0.05 (one-way ANOVA with Dunnett’s post-tests 
(A, B & C) and t-tests (D&E)). 
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Figure 3:7 Neither endothelial activation nor platelet activation significantly alters platelet adhesion on 
endothelium.  Activation of platelets (0.2U/ml; 5 minutes) and/or endothelium (10ng/ml; 4 hours) had no 
significant effect on platelet adhesion to endothelium after 20 minutes incubation.  Data presented as mean 
±SEM, n≥5 (two-way ANOVA). 
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Figure 3:8 The presence of adherent platelets does not significantly affect lymphocyte adhesion on 
endothelium.  The presence of adherent naïve or activated (0.2U/ml thrombin; 5 min) platelets had no significant 
effect on lymphocyte adhesion to endothelium after 20 minutes.  Data presented as mean ±SEM, n≥3 (two-way 
ANOVA). 
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3.3.9. Incubation with Platelets has no Significant Effect on Lymphocyte Adhesion to 
Endothelium 
As incubation with platelets increased lymphocyte adhesion to immobilised cell adhesion 
molecules their effect on lymphocyte adhesion on endothelium was investigated.  No 
significant difference in lymphocyte adhesion was observed following incubation with 
platelets for either 5 or 30 minutes (Figure 3.9; p>0.05).  TNF-α stimulation of the endothelium 
had no significant effect on lymphocyte adhesion, although there was a trend for increased 
lymphocyte adhesion when endothelium had been activated (Figure 3.9; p>0.05). 
3.3.10. Thrombin Activation and Tissue Injury Increase Platelet Adhesion to Gut Tissue  
Interestingly, the static adhesion assay data presented so far demonstrated that platelets 
could modulate lymphocyte adhesion to immobilised endothelial cell adhesion molecules but 
this effect was not reproduced on endothelial cells themselves. Further assays were carried 
out to determine whether platelets modulated lymphocyte adhesion on frozen sections of 
gastrointestinal tissue (Stamper Woodruff assays). Firstly, platelet adhesion to sham and IR 
injured jejunum and ileum was assessed as well as platelet adhesion to sham and colitis 
injured colon tissue.  Generally, there was a trend for naïve and activated platelets to adhere 
more so on injured tissue sections than healthy sham sections but this did not always attain 
statistical significance.  Certainly adhesion of naïve platelets was significantly greater on IR 
ileum than sham ileum sections (Figure 3.10 D; p<0.05).  The most adhesion of platelets was 
observed on ileum tissue rather than jejunum or colon.  Also, thrombin activation significantly 
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increased adhesion of platelets on sham jejunum (Figure 3.10 A; p<0.01) and colitis injured 
colon (Figure 3.10 G; p<0.01) sections. 
3.3.11.  Incubation with Platelets Increases Lymphocyte Adhesion to Ileum 
Interestingly, untreated lymphocytes did not adhere to any of the intestinal sham or injured 
tissue sections.  However, a very small number of lymphocytes did adhere to ileal sections 
after they were incubated with platelets or thrombin activated platelets, but this failed to 
reach statistical significance between sham and IR injured ileum (Figure 3.11; p>0.05).  
Adhesion to other tissue sections was not modified by the presence of naïve or activated 
platelets.  
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Figure 3:9 Incubation with platelets has no significant effect on lymphocyte adhesion on endothelium.  The adhesion on untreated and TNF-α stimulated (10ng/ml; 
4 hours) colonic endothelium of untreated lymphocytes (-) and lymphocytes incubated for 5 or 30 minutes with thrombin (+T), platelets (P) or platelets and thrombin 
(+T+P) was quantitated.  Data presented as mean ±SEM, n≥3 (two-way ANOVA). 
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Figure 3:10 Thrombin activation and tissue injury increase platelet adhesion to gut tissue.  Sham and Ischemia 
reperfusion (IR) injured ileum (A) and jejunum (D) sections and sham and colitis colon (G) sections were 
incubated with naïve and activated CFSE labelled platelets and their adhesion quantitated.  Images show naïve 
(B) and activated (C) platelets (geen) on sham jejunum; naïve platelets on sham ileum (E) and IR Ileum (F) and 
naïve platelets (H) and activated platelets (I) on colitis colon.  Data presented as mean ±SEM, n≥4, *p<0.05 
**p<0.01 (one-way ANOVA with Bonferroni post-tests). 
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Figure 3:11 Lymphocytes adhere to ileal tissue sections following incubation with platelets.  Lymphocytes were 
incubated with platelets (+P) or platelets and thrombin (+P+T) for 5 minutes.  Adhesion of the lymphocytes to 
Sham and Ischemia reperfusion (IR) injured ileum sections was then quantitated.  Data presented as mean ±SEM, 
n≥3, (one-way ANOVA with Bonferroni post-tests). 
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3.3.12. Incubation with Platelets had no Significant Effect on CD18 or CD49d Expression on 
Lymphocytes 
In order to determine how platelets increase lymphocyte adhesion, their effect on lymphocyte 
integrin expression was investigated using flow cytometry.  Both CD18 (Figure 3.12) and 
CD49d (Figure 3.13) were expressed on both T-cells and B-cells.  However, incubation with 
thrombin, platelets or thrombin and platelets for 5 or 30 minutes had no significant effect on 
either CD18 (Figure 3.12; p>0.05) or CD49d (Figure 3.13; p>0.05) expression on T-cells or B-
cells. 
The results outlined above are also summarised in Table 3.1.
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Figure 3:12 Incubation with platelets or thrombin had no effect on lymphocyte CD18 expression.  Lymphocytes 
were incubated with platelets (+P) thrombin (+T) or platelets and thrombin (+P+T) for 5 or 30 minutes.  CD18 
expression on T-cells (CD3ε+) and B-cells (CD19+) was then quantitated using flow cytometry. Panels show 
representative flow cytometry plots, black line: isotype control, red lines: untreated lymphocytes with CD18 
antibody, blue line: treated lymphocytes with CD18 antibody.  n≥3, (t-tests).  
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Figure 3:13 Incubation with platelets or thrombin had no effect on lymphocyte CD49d expression.  
Lymphocytes were incubated with platelets (+P) thrombin (+T) or platelets and thrombin (+P+T) for 5 or 30 
minutes.  CD49d expression on T-cells (CD3ε+) and B-cells (CD19+) was then quantitated using flow cytometry.  
Panels show representative flow cytometry plots, black line: isotype control, red lines: untreated lymphocytes 
with CD49d antibody, blue line: treated lymphocytes with CD49d antibody.  n≥3, (t-tests). 
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 ICAM-1 VCAM-1 MAdCAM-1 Stimulated Endothelium Intestinal Sections 
 
Naïve Platelets No adhesion 
 
No adhesion No adhesion  60-80 platelets Generally, there was a 
trend for naïve / activated 
platelets to adhere to 
injured tissue, with most 
adhesion observed on 
ileum (10-40 platelets).   
     
Activated Platelets   100 platelets  
p<0.01 
 1-2 platelets   
NS  
 20 platelets 
p<0.01 
 100 platelets 
NS 
      
Lymphocytes No adhesion 
 
No adhesion No adhesion  20 lymphocytes No adhesion 
      
Lymphocytes when naïve 
platelets already adherent  
 1-2 lymphocytes  
NS 
No adhesion No adhesion   30 lymphocytes   
NS 
NOT INVESTIGATED 
      
Lymphocytes when 
activated platelets already 
adherent  
 4 lymphocytes 
p<0.05 
No adhesion   20 lymphocytes   
p<0.01 
No increase NOT INVESTIGATED 
      
Lymphocytes incubated 
with thrombin 
No adhesion (but thrombin 
can increase lymphocyte 
adhesion with long incubations). 
No adhesion (but thrombin 
can increase lymphocyte 
adhesion with long incubations). 
No adhesion (but thrombin 
can increase lymphocyte 
adhesion with long incubations). 
 
No increase  1-2 lymphocytes adhere 
to injured ileum when 
incubated with activated 
platelets  
     
Lymphocytes incubated 
with naïve platelets 
No adhesion 
 
No adhesion 
 
  20 lymphocytes  
p<0.05 
No increase 
     
Lymphocytes incubated 
with activated platelets 
 10 lymphocytes  
NS (5 mins) 
No adhesion 
 
  15 lymphocytes NS 
(5 mins) 
No increase 
     
Lymphocytes incubated 
with activated platelet 
releasate 
 15 lymphocytes  
NS (5 mins) 
 15 lymphocytes 
p<0.01 (5 mins) 
  50 lymphocytes  
p<0.001 (5 & 30 mins) 
NOT INVESTIGATED 
      
Lymphocytes incubated 
with PMPs generated after 
activation of platelets  
  40 lymphocytes  
p<0.05 (5 mins) 
 
  30 lymphocytes  
p<0.05 (30 mins) 
 
  60 lymphocytes  
p<0.05 (5 mins) 
NOT INVESTIGATED NOT INVESTIGATED 
Table 3.1 Summary of results from all in vitro studies highlighting platelet, lymphocyte and platelet modified lymphocyte adhesion to endothelial counterligands, 
endothelium and intestinal tissue sections.  Generally, it seems as if platelets are better able to modify lymphocyte adhesion to ICAM-1 and MAdCAM-1 rather than 
endothelium and tissue sections.  NS = Not significant.  Endothelium was stimulated with TNFα. 
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 Discussion 
Recent evidence suggests lymphocytes may play a role in inflammatory disorders. The 
mechanisms by which they are recruited are not clear.  Platelets and their micro particles 
(PMPs) are known to mediate recruitment of inflammatory leukocytes, particularly 
neutrophils.  However, their ability to influence lymphocyte adhesion is unclear.  The data 
presented in this chapter provides clear evidence for platelet modulation of lymphocyte 
adhesion in vitro.  The results demonstrated that previously adherent activated platelets 
increased lymphocyte adhesion to endothelial counter-ligands, namely CD54 and MAdCAM-1.  
These results were also repeated when lymphocytes were pre-incubated with platelet 
releasate and PMPs. Modified adhesion did not appear to be related to platelets inducing an 
increased expression of adhesion molecules on lymphocytes.  Interestingly, lymphocyte 
adhesion to endothelial monolayers could not be modified by any of the platelet treatments 
tested.  These results suggest that peripherally circulating activated platelets may be able to 
modify lymphocyte adhesion in vivo when endothelial cell adhesion molecules are expressed 
at high density.  Clearly this will have pathophysiological consequences. 
The experiments presented in this chapter firstly tested platelet adhesion to endothelial 
counterligands.  As expected adhesion of naïve platelets to CD54, CD106 and MAdCAM-1 was 
low.  Following activation with thrombin, platelet adhesion to ICAM-1 was greatly increased.  
This is likely to be mediated by platelet adhesion to ICAM-1 bound fibrinogen (Bombeli et al., 
1998). Fibrinogen would be present in this assay as it is found within α-granules which are 
released by platelets following activation. Adhesion to MAdCAM-1 was also greatly increased 
following platelet activation.  This was unexpected as platelets do not express the receptors 
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usually associated with adhesion to MAdCAM-1, namely CD62L, CD49d/beta7, and 
CD49d/CD29.  This may be non-specific binding or mediated by an as yet unknown receptor.  
Unsurprisingly platelet adhesion to VCAM-1 was very low as platelets are not known to 
express the VCAM-1 binding integrins CD49d/beta7 and CD49d/CD29.   
More importantly, we demonstrated that both activated previously adherent platelets and 
incubation with platelets or platelet releasate significantly enhance lymphocyte adhesion to 
immobilised cell adhesion molecules.  Interestingly incubation with activated platelet 
releasate appeared to result in a greater increase in platelet adhesion than incubation with 
activated platelets for the equivalent length of time.  Although the presence of activated 
platelets on ligand increased subsequent lymphocyte adhesion to CD54 and MAdCAM-1, 
incubation with platelet releasate increased adhesion to VCAM-1 as well.  This suggests that 
it is factors released from activated platelets that result in the increase in lymphocyte 
adhesion observed in these static adhesion assays.  This is also supported by the observation 
that in these experiments few direct lymphocyte-platelet conjugates were observed.  This is 
in agreement with previous findings that only about 3% of lymphocytes (be they T-cells, B-
cells and NK-cells) are conjugated to platelets in the peripheral circulation, with only a slight 
rise in this percentage following platelet activation (Li et al., 2006).  Indeed, it has been 
demonstrated that lymphocytes have a considerably lower potential to form heterotypic 
aggregates, with other cells such as platelets, than monocytes and granulocytes (Li et al., 
1999). This is not to say that platelets cannot modify lymphocyte adhesion through direct 
interactions with platelets.  Certainly, under flow conditions, platelet-lymphocyte conjugates 
have been shown to influence lymphocyte adhesion (Diacovo et al., 1996b, Sheikh et al., 2004, 
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Hu et al., 2010).  It is possible that both mechanisms are important in the recruitment of 
lymphocytes during inflammation. 
It is likely that one of the factors in activated platelet releasate that affect lymphocyte 
adhesion are PMPs.  Indeed,  Jy et al. (1995) presented seminal data that PMPs can ‘coat’ 
neutrophils and induce their activation, as measured by increased integrin CD11b (M) 
expression and phagocytic activity.  However the effect of PMPs on lymphocyte adhesion has 
not been previously described.  In the current study, purified PMPs increased lymphocyte 
adhesion to CD54, CD106 and MAdCAM-1.  PMPs are known to bind to lymphocytes albeit at 
much lower levels than to neutrophils (Jy et al., 1995).  To confirm lymphocyte coating with 
PMPs, flow cytometry was used to detect the platelet specific marker on the lymphocytes.  
This is a glycoprotein integrin subunit found specifically on platelets (and megakaryocytes). It 
forms half of the CD41/CD61 complex that interacts with fibrinogen and thus plays an 
important role in platelet aggregation and adhesion to endothelium.  However, in our 
experiments, CD41 was not found on lymphocytes treated with PMPs generated by treating 
platelets with 2U/ml thrombin for 30 minutes.  This may indicate that PMPs were not coating 
the surface of the lymphocytes or alternatively, the number of CD41 molecules present on 
lymphocytes were too low to detect.  This may be a result of low numbers of PMPs being 
present.  Future studies could focus on using higher doses of thrombin or alternative agonists 
to see if this leads to the detection of PMPs on lymphocytes.  Indeed, recent studies from the 
Kalia lab have shown that calcium ionophore generated more than double the number of 
PMPs than thrombin as determined by flow cytometry and nanoparticle tracking.  
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Furthermore, increased efficacy of coating of mesenchymal stem cells was observed when 
higher number of PMPs were generated (unpublished results). 
As the releasate of platelets stimulated with 0.2U/ml thrombin for 5 minutes is unlikely to 
contain high concentrations of PMPs (Matzdorff et al., 1998) it is expected that other factors, 
such as platelet released cytokines, also contribute to the observed effects of this releasate 
on lymphocyte adhesion. Activated platelets are known to release a number of well-known 
regulators of lymphocyte recruitment and migration including the chemokines CCL5 (RANTES) 
and CXCL12 (SDF-1α) and also VEGF, and PAF (Bleul et al., 1996, Massberg et al., 2006, Szabo 
et al., 1997, Kameyoshi et al., 1992, Webb et al., 1998, Zhang et al., 2010, McFadden et al., 
1995, Chignard et al., 1980).  These factors appear to primarily influence lymphocyte adhesion 
through mediating increases in surface integrin expression.  Certainly RANTES has been shown 
to induce de novo expression of adhesion molecules such as CD11b and CD62L or upregulate 
expression of integrins such as CD49d on human lymphocytes (Szabo et al., 1997).  In contrast, 
in the current study flow cytometry did not detect changes in the expression of CD49d or CD18 
– these differences could simply be due to murine rather than human lymphocytes being 
tested.  It is also possible for increased lymphocyte adhesion to be mediated independently 
of changes in integrin expression.  Indeed SDF-1α induces clustering of integrins such as VLA-4 
on the surface of human lymphocytes has been shown to result in enhanced avidity for 
endothelial CD106 (Grabovsky et al., 2000). 
Interestingly, the number of lymphocytes observed to adhere on CD106, either following pre-
incubation with platelets or subsequent to platelet adhesion, was considerably lower than 
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that observed on CD54 or MAdCAM-1.  This was an unexpected result as the cells used in this 
study did express CD49d, half of the CD106 binding integrins CD49d/beta7 and CD49d/CD29 , 
and lymphocytes have previously been shown to adhere to CD106  (Chan et al., 2000).  This 
result may be due to a low density of CD106 coating on the tissue culture plastic as lymphocyte 
adhesion on immobilised CD106 is heavily dependent on this density. In a study by Chan et al. 
(2000) lymphocyte adhesion was found only to occur at CD106 densities of greater than 100 
molecules/µm2. Unfortunately, due to the method of coating used in our work it is not 
possible to know the density at which the plates were coated with CD106. Lalor et al. (1997) 
found that coating plastic with 10µg/ml CD106, the same as used in our experiments,  
supported lymphocyte rolling but not firm adhesion under flow; however, a concentration of 
100µg/ml was found to be sufficient for lymphocyte arrest (Chan et al., 2000).  
In contrast to lymphocyte adhesion on cell adhesion molecules, platelets had no significant 
effect on lymphocyte adhesion to colonic endothelium. It may be the case that in the absence 
of platelets, maximal lymphocyte adhesion was already achieved and therefore adhesion 
could not be further increased by addition of platelets. Carrying out further experiments under 
flow instead of static conditions may reduce lymphocyte adhesion sufficiently for platelets to 
have a modulatory effect on their adhesion. Interestingly, TNF-α stimulation of the 
endothelium had no effect on lymphocyte adhesion or platelet adhesion.  These results are 
similar to those seen previously in the lab with haematopoietic and mesenchymal stem cells 
(Yemm, 2013).  One possible reason for this is that 4 hours stimulation was not a sufficient 
period of time for up-regulation of adhesion molecule expression to occur.  MAdCAM-1 
expression on these cells only increases following 24 hours of TNF-α stimulation (Ando et al., 
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2005). However, 4 hours stimulation is sufficient to increase CD54 expression and neutrophil 
adhesion on colonic endothelium (Goebel, 2006). Another possibility is that the endothelium 
was already in an activated state due to the INF-γ in its culture media (Thornhill and Haskard, 
1990). 
Both naïve and activated platelets were found to adhere to the endothelial monolayers.  It is 
well known that activated platelets can adhere to endothelium and that this adhesion is 
mediated by platelet CD41/CD61 through its binding of fibrinogen, fibronectin and VWF which 
can then become bound by the endothelial adhesion molecules CD51/CD61, CD54 and CD42b 
(Bombeli et al., 1998). Platelet activation with thrombin and endothelial stimulation with 
TNF-α had no effect on the adhesion of platelets on endothelium.  Naïve platelets do not 
adhere to endothelium under normal physiological conditions so this adhesion is likely an 
artefact of the static nature of this assay. 
Finally, this chapter assessed platelet modulation of lymphocytes to frozen sections of injured 
gut.  Adhesion of platelets to tissue sections was significantly increased by both platelet 
activation and IR injury of the tissue.  This is consistent with previous work carried out in the 
Kalia lab which showed platelet accumulation does occur in the small intestine following IR 
injury in vivo (Holyer, 2010).  This is likely due to endothelial denudation caused by the IR 
injury, which subsequently exposes extracellular matrix components such as collagen that 
platelets can adhere to (Grootjans et al., 2010, Ruggeri and Mendolicchio, 2007).  Interestingly 
untreated lymphocytes did not adhere to injured or uninjured tissue sections despite adhering 
to cell adhesion molecules and cultured endothelial cells.  However, following incubation with 
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naïve and activated platelets some adhesion was observed on ileum sections, supporting our 
hypothesis that incubation with platelets can increase lymphocyte adhesion. 
As direct adhesion of lymphocytes to platelets did not appear to be required for the increased 
lymphocyte adhesion observed on cell adhesion molecules, it was hypothesised that platelets 
were modulating lymphocyte integrin expression.  Both T-cells and B-cells were found to 
express CD18, which is a subunit of the CD54 binding integrins C11a/CD18 and CD11b/CD18, 
and CD49d, which is a subunit of the MAdCAM-1 and CD106 binding integrins CD49d/beta7 
and CD49d/CD29.  Although platelets were capable of modulating lymphocyte adhesion in 
static adhesion assays on CD54 and MAdCAM-1, treatment with naïve and thrombin activated 
platelets had no significant effect on CD18 or CD49d expression.  Although the increases in 
lymphocyte adhesion observed do not appear to be due to platelet modulation of lymphocyte 
integrin expression, they may be due to modulation of lymphocyte integrin function through 
integrin activation or integrin mobility changes.  For example the platelet released cytokines 
CXCL12 and CCL5 can induce subsecond clustering of CD49d/CD29 on lymphocytes leading to 
increased rolling and tethering on endothelium (Grabovsky et al., 2000). 
The results presented in this chapter clearly show that platelets are able to modulate the 
adhesion of lymphocytes in vitro.  Previous work on the role of platelets in lymphocyte 
adhesion has shown that a direct interaction between platelets and lymphocytes is a key 
mediator of lymphocyte adhesion.  The evidence presented in this chapter indicates that 
factors released by activated platelets are also important mediators of lymphocyte adhesion.  
Platelet released PMPs appear to be a strong candidate for the factor which modulates 
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lymphocyte adhesion although other factors such as platelet released cytokines are also likely 
to play a role.  The cells used in the adhesion assays were a mixed population of lymphocytes 
taken from the inguinal lymph nodes.  It is therefore not possible to define which subsets of 
lymphocytes were actually adhering in these experiments.  However, as T-cells made up the 
majority of the isolated cells and appeared to have greater levels of CD18 and CD49d 
expression than B-cells it is probable that the majority of adherent cells were T-cells. The 
following chapters will address whether platelet modulation of T- and B-cells adhesion occurs 
in vivo in models of liver inflammation.  
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4. LYMPHOCYTE RECRUITMENT TO THE LIVER DURING ISCHEMIA REPERFUSION INJURY IS 
MEDIATED BY PLATELETS 
4.1. Introduction and Hypotheses 
Hepatic IR injury is a clinically relevant problem that occurs following a transient cessation of 
blood flow to the liver.  This results in accumulation of inflammatory cells and platelets within 
the hepatic microvasculature.  The majority of the injury is thought to be caused by a 
neutrophil mediated inflammatory response following reperfusion (Jaeschke et al., 1990, 
Eltzschig and Collard, 2004).  However, there is a growing body of evidence that lymphocytes, 
particularly T-cells, are also important mediators of hepatic IR injury.  Their presence has also 
been detected post-reperfusion in various other organs including the brain, lungs, intestine 
and heart (Linfert et al., 2009).  Previously thought to be “passive observers” in the 
inflammatory response, there is now an overwhelming body of literature demonstrating the 
role of T-cells as direct mediators of IR injury (Linfert et al., 2009).  Indeed, depletion of 
circulating T-cells significantly reduces hepatic injury following 60 and 150 minutes ischaemia 
(Anselmo et al., 2002).  Furthermore, in mice lacking CD4+ T-cells, hepatic neutrophil 
accumulation is significantly reduced (Caldwell et al., 2005).   
The other major cell of the adaptive immune system is the B-cell.  Activated B-cells primarily 
function in antibody production and antigen presentation.  However, due to their ability to 
secrete the potently anti-inflammatory cytokine IL-10 and the pro-inflammatory cytokines IL-
6, IL-8 and TNF, the role of a positive and negative regulator of inflammation has been 
ascribed to this cell (Hamze et al., 2013).  Despite frequent histological observations of B-cells 
at inflammatory sites, there is little known about the recruitment kinetics of circulating B-cells 
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to IR injured liver, even though the liver has a very large resident B-cell population 
(Novobrantseva et al., 2005).  Burne-Taney and colleagues demonstrated reduced injury 
scores following renal IR injury in mice unable to develop peripheral mature B-cells (Burne-
Taney et al., 2003). Further demonstrations of their pathogenic role was shown in IR injured 
intestine, heart and skeletal muscle (Linfert et al., 2009). However, no studies have currently 
assessed the spatial and temporal kinetics of peripheral B-cells in acute hepatic IR injury, 
although they have been observed to home to the liver following parasitic hepatic infection 
(Moore et al., 2012) and are known to contribute to liver fibrosis, a late presenting feature of 
hepatic IR injury (Novobrantseva et al., 2005). 
Collectively, these studies are consistent with an emerging pivotal role for lymphocytes in IR 
injury.  However, the question remains as to how they are recruited to ischaemically injured 
sinusoidal microcirculation in vivo.  Platelets are also recruited in abundance during hepatic IR 
injury and more recently have been demonstrated to recruit T-cells to the liver during 
hepatitis B infection (Iannacone et al., 2005, Sitia et al., 2012). However, the role of 
platelets in non-viral or non-antigen induced T- or B- cell recruitment to the liver has not been 
investigated in detail.  
The data presented in the previous chapter suggests that platelets, in particular activated 
platelets, can increase the adhesion of lymphocytes in vitro under static conditions.  In hepatic 
IR injury significant numbers of activated platelets are found within the liver (Cywes et al., 
1993) which may play a role in lymphocyte recruitment.   Given the emerging evidence for the 
role of the adaptive immune system in hepatic IR injury, this chapter examined intravitally the 
dynamics of circulating T- and B-cell recruitment in vivo and investigated whether this was 
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mechanistically dependent on platelets.  The experiments in this chapter aimed firstly to 
develop a method for monitoring the trafficking of lymphocytes and platelets in vivo within 
the murine hepatic microcirculation.  Data are presented in this chapter comparing 
lymphocyte recruitment in the IR injured and uninjured hepatic microvasculature.  Further to 
this, data comparing lymphocyte recruitment in the hepatic microcirculation in both normal 
and platelet depleted mice are presented. 
For the work included in this chapter we hypothesised that: 
1. Lymphocyte recruitment to the liver is increased following IR injury. 
2. Lymphocyte recruitment in IR injured liver is reduced following platelet depletion. 
3. Lymphocyte recruitment to the IR injured liver is dependent on lymphocyte 
expressed CD162 (PSGL-1). 
4. Treatment with PMPs can increase lymphocyte recruitment to the IR injured liver.  
4.2. Methods 
The methods used in this chapter are described in detail in Chapter 2.  Briefly, lymphocyte and 
platelet recruitment to the injured liver was monitored in the anaesthetised mouse using 
fluorescent intravital microscopy.  Injury was induced by clamping off the blood supply to the 
left and median lobes of the liver for 90 minutes.  The clamp was then removed to allow 
reperfusion.  Platelet and lymphocyte trafficking were tracked via two methods: (i) 
endogenous platelets, T-cells and B-cells were labelled by injection of fluorescent antibodies 
against CD41, CD3ε and CD19 respectively in mice undergoing intravital experimentation  (ii) 
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fluorescently labelled donor cells were injected into the systemic circulation of recipient mice 
undergoing intravital experimentation.  For the latter, T-cells and B-cells were isolated from 
the spleen of donor mice using MACS and platelets were isolated from the whole blood.  For 
some experiments, purified CD4+ and CD8+ T-cells were used, which were again isolated  from 
the spleen of donor mice and purified using MACS.   
To investigate if platelets play a role in lymphocyte recruitment, in some experiments systemic 
platelets were depleted prior to injury by injection of a mix of platelet-depleting CD42b 
antibodies.  Platelets may mediate the recruitment of lymphocytes by direct interactions 
between CD62P on the platelet and CD162 on the lymphocyte.  Therefore, in other 
experiments CD162 on the surface of lymphocytes was blocked via incubation with a blocking 
antibody prior to their infusion.  To investigate the role of pre-treatment with PMPs on 
lymphocyte recruitment to the IR injured liver, lymphocytes isolated from the inguinal lymph 
nodes of donor mice were incubated with PMPs generated by thrombin stimulation of washed 
platelets.   
Blood flow within the whole liver was measured using laser Doppler and areas of blood flow 
were visualised intravitally following injection of FITC-BSA.  The velocity of free flowing 
fluorescently labelled donor platelets was also used as a quantitative measure of overall blood 
flow.  At the end of the experiments, blood samples were taken for blood counts and analysis 
of serum alanine transaminase (ALT) activity.  ALT is an enzyme produced by the liver and 
released into the bloodstream following hepatocellular injury.  Liver sections obtained from 
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mice at the end of experiments were stained with fluorescent CD41 and CD42b antibodies to 
further analyse the number of platelets present.  
Static adhesion assays were carried out to determine the effects of inflammatory mediators 
on lymphocyte adhesion.  CFDA-SE labelled T-cells or B-cells isolated from the spleens of mice 
were incubated for 5 minutes with 100µM H2O2 or 25ng/ml CCL5 (RANTES), CXCL12 (SDF-1α) 
or CXCL1 and their adhesion to CD54, CD106 or MAdCAM was quantitated. 
4.3. Results 
4.3.1. IR Results in Macroscopically Visible Injury and an Increase in Serum ALT Activity 
The liver is visibly injured 2 hours after reperfusion (Figure 4.1).  Blood counts did not 
significantly change following IR injury compared to sham controls (Figure 4.2 A; p>0.05).   
Platelet depletion using a depleting antibody had no significant effect on the numbers of 
circulating leukocytes or erythrocytes in either sham or IR mice (Figure 4.2 A; p>0.05).  
However, as was desired, numbers of circulating platelets were reduced to below detectable 
levels (<1x103/mm3).  Circulating lymphocyte numbers did show a trend to go down in injured 
mice, but this did not prove to be statistically significant.  Following IR injury, survival of mice 
was not significantly different from sham treated animals up to two hours post-reperfusion 
(Figure 4.2 B; p>0.05).  There was also no significant difference between the survival of sham 
treated thrombocytopenic mice and IR injured thrombocytopenic mice (Figure 4.2 B; p>0.05).  
Depletion of platelets did appear to reduce survival of mice compared to non-
thrombocytopenic mice; however, these differences were not significant (Figure 4.2 B; 
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p>0.05).  Serum ALT activity, a biochemical marker of liver injury, was significantly increased 
in both normal (Figure 4.2 C; p<0.01) and thrombocytopenic mice (Figure 4.2 C; p<0.05) 
following IR injury when compared to that of uninjured controls.  Platelet depletion did not 
have a significant effect on serum ALT activity following injury (p>0.05).  However, following 
injury serum ALT activity did appear to be higher in thrombocytopenic mice than normal mice 
but this was not significant.   
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Figure 4:1 2 hours after ischemia the liver is visibly injured.  IR injury was induced by clamping off the blood 
supply to the left and median lobes of the liver for 90 minutes.  2 hours after rep the IR injured liver is darker 
and less uniform in colouration than the uninjured liver. 
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A 
 RBC 
(106/mm3) 
PLT 
(103/mm3) 
WBC 
(103/mm3) 
HCT 
(%) 
MPV 
(µm3) 
LYM% MON% NEU% EOS% BAS% 
Sham 9.5±0.5 768±4 3.4±0.9 36.0±1.2 5.7±0.2 83.5±6.0 3.2±0.5 8.5±1.2 0.1±0.0 5.7±5.1 
IR 8.9±0.2 782±64 4.5±0.8 33.2±1.5 5.6±0.3 75.9±7.2 4.0±1.2 19.0±8.0 0.3±0.1 0.7±0.2 
Sham Thrombocytopenic 9.5±0.7 ND 5.4±1.6 36.0±2.8 ND 83.7±1.7 10.2±1.5 8.3±2.5 0.5±0.2 0.4±0.1 
IR Thrombocytopenic 9.3±0.7 ND 3.8±0.3 34.9±2.3 ND 75.8±4.4 13.6±5.4 9.3±2.2 0.4±0.3 1.0±0.1 
RBC=red blood cells, PLT=platelets, WBC=white blood cells, HCT=haematocrit, MPV=mean platelet volume, LYM=lymphocytes, MON=monocytes, NEU=neutrophils, 
EOS=eosinophils, BAS=basophils, ND=not detected. 
 
B 
 
C 
 
 
Figure 4:2 IR injury causes a significant increase in serum ALT activiy. (A) Blood counts of mice 2hours after 90 minutes ischemia or sham surgery for both untreated 
and platelet depleted mice.  (B) Survival of mice following sham surgery or IR injury for both untreated and platelet depleted mice.  (C) Alanine transferase activity in 
serum samples taken from mice 2 hours after sham surgery or IR injury in both untreated and platelet depleted mice.  Data presented a mean ±SEM, n≥3, *p<0.05 
**p<0.01 compared to sham (one-way ANOVA with Bonferroni post-tests (A&C) and Mantel Cox tests with Bonferroni correction (B))
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4.3.2. Following Ischemia Blood Flow within the Liver Vasculature is Severely Disrupted 
Immediately following reperfusion, laser Doppler measurements show no significant 
difference in perfusion of the IR injured liver compared to the sham liver (Figure 4.3 A; p>0.05).  
However, perfusion in the IR injured liver is significantly reduced compared to the sham at 1 
hour (Figure 4.3 A; p<0.05) and 2 hours (Figure 4.3 A; p<0.01) post reperfusion.  The velocity 
of free flowing platelets can be used as a measure of the rate of blood flow (Holyer, 2010). 
The velocity of fluorescently labelled platelets within the hepatic microcirculation was 
significantly greater in IR injured animals than sham animals at the point of reperfusion and 
30 minutes post reperfusion (Figure 4.3 B; p<0.05).  This difference decreased over time, and 
by 120 minutes post reperfusion platelet velocities were almost equal between sham and IR 
injured animals.  
To parallel the above quantitative data, areas of non-perfused hepatic tissue were not 
observed in the sham animals intravitally when FITC-BSA was used to identify areas of flow 
within the microvasculature (Figure 4.3 C & E).  However, injection of FITC-BSA revealed large 
areas of non-perfused tissue, which appeared as ‘black’ vessels, both immediately following 
reperfusion (Figure 4.3 D) and 2 hours after reperfusion (Figure 4.3 F). 
Platelet depletion did not significantly affect hepatic tissue perfusion following ischaemia as 
measured by laser Doppler (Figure 4.3 H; p>0.05).  Areas of non-perfused tissue are also visible 
in platelet depleted mice immediately after ischemia (Figure 4.3 G). 
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4.3.3. Incubation with PMPs has no Significant Effect on Lymphocyte Recruitment to the IR 
Injured Liver  
As incubation with PMPs was shown to increase lymphocyte adhesion to cell adhesion 
molecules in chapter 3, the effect of incubation with PMPs on lymphocyte recruitment to the 
IR injured liver was investigated.  Incubation with PMPs was found to have no significant effect 
on lymphocyte adhesion within the post ischemic hepatic vasculature (Figure 4.4 A; p>0.05).  
Incubation with PMPs also had no significant effect on the number of free flowing lymphocytes 
in hepatic vasculature (Figure 4.4 B; p>0.05).  
4.3.4. Increased Endogenous T-cell Recruitment to the Liver Following Ischemia 
Previous studies have tracked lymphocytes in vivo by labelling donor cells and imaging their 
trafficking in recipient experimental mice.  However, not only does this require more mice to 
be used, it may also underestimate cellular events as it does not image the endogenous cells.  
To avoid these issues, and also to reduce the number of mice required for experiments even 
further, we aimed to track the recruitment of endogenous T-cells, B-cells and platelets within 
the same mouse.  Antibody labelling was used to allow the imaging of these three endogenous 
populations of cells.  Mice were injected with antibodies against CD3ε (T-cells), CD19 (B-cells) 
or CD41 (platelets) which had been conjugated to fluorescent secondary antibodies or 
streptavidin.  The results showed a significant increase in endogenous T-cell recruitment 
(Figure 4.5 A; p<0.001) but not endogenous B-cells recruitment (Figure 4.5 B; p>0.05).  
Interestingly, the number of B-cells observed within the hepatic microcirculation was far 
higher than the number of T-cells.  Approximately four endogenous T-cells were observed per 
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field of view in IR injured mice whereas 70-80 B-cells were observed in sham and IR injured 
mice.  Free flowing cells were not observed in either the injured or the sham animals.  No 
significant difference in platelet adhesion was observed between sham and IR injured livers 
(Figure 4.5 E; p>0.05).  This was quantitated as the area of liver labelled by CD41 antibody as 
it was not possible to identify individual platelets. 
4.3.5. Increased Endogenous T-cell Recruitment to the Liver Following Platelet Depletion 
In order to determine whether platelets were involved in mediating the increased endogenous 
lymphocyte recruitment to the IR injured liver, mice were depleted of systemic platelets by 
injection of a platelet depleting CD42b antibody.  Platelet depletion was confirmed using an 
automated blood counter (see data presented in Figure 4.2).  Platelet depletion had no effect 
on leukocyte or erythrocyte numbers.  Interestingly, following platelet depletion, a significant 
increase in endogenous T-cell recruitment to the injured liver was observed (Figure 4.6 A; 
p<0.001).  No significant difference in endogenous B-cell recruitment to the injured liver 
following platelet depletion was noted (Figure 4.6 B; p>0.05). 
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C 90mins sham injury D 90mins ischemia 
  
E 90mins sham injury + 120mins reperfusion F 90mins ischemia + 120mins reperfusion 
  
G throbocytopenia + 90mins ischemia H 
 
 
Figure 4:3 Following ischemia blood flow within the liver vasculature is severely disrupted.  Laser Doppler  for 
IR injured liver compared to the sham control after 150 and 210 minutes (A).  Velocities of free flowing platelets 
in the IR and sham livers were determined by intravital microscopy (B).  Images show FITC-BSA (green) within 
the hepatic vasculature following 90 minutes sham treatment (C); 90 minutes ischemia (D); 120 minutes after 90 
minutes sham treatment (E); after 90 minutes ischemia and 120 minutes reperfusion (F) and after platelet 
depletion and 90 minutes ischemia (G).  Perfusion of the IR liver in normal and platelet depleted mice measured 
by laser Doppler (H).  Data presented a mean ±SEM, n≥3, *p<0.05 **p<0.01 (one-way ANOVA with Bonferroni 
post-tests (A&B) and t-test (H)) scale bars=100µm.   
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Figure 4:4 Incubation with PMPs has no significant effect on lymphocyte recruitment to the IR injured liver.  
1.8 million CFSE stained lymphocytes were incubated for 5 minutes with PMPs or PBS (untreated) and their 
adhesion (A) and the number of free flowing cells (B) within the IR injured liver was quantitated using intravital 
microscopy.  Data presented as mean ± SEM, n≥3 (two-way ANOVA). 
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Figure 4:5 Antibody Labelling Shows an Increase in Endogenous T-cell Recruitment to the Liver Following 
Ischemia.  Mice were injected with antibodies against CD3ε, CD19 and CD41 which had been conjugated to 
fluorescent secondary antibodies or streptavidin.  Following 90 minutes ischemia or sham surgery the number 
or area of fluorescent objects within the liver was quantitated using intravital microscopy.  The number of 
adherent T-cells indicated by CD3ε antibody labelling in the sham and IR liver (A).  The number of B-cells indicated 
by CD19 antibody labelling in the sham and IR liver (B).  Images show CD3ε antibody labelling in the sham (C) and 
IR injured (D) liver at 70 minutes post reperfusion.  The area of the liver labelled by CD41 antibody in the sham 
and the IR injured liver (E).  Data presented as mean ± SEM, n≥4, ***p<0.001 (two-way ANOVA), scale 
bars=100µm. 
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Figure 4:6 Antibody labelling shows an increase in endogenous T-cell recruitment to the IR injured liver 
following platelet depletion.  Prior to the start of the experiment mice were injected with platelet depleting 
antibodies. Mice were then injected with antibodies against CD3ε and CD19 which had been conjugated to 
fluorescent secondary antibodies or streptavidin.  Following 90 minutes ischemia or sham surgery the number 
of fluorescent objects within the liver was quantitated using intravital microscopy.  The number of adherent 
T-cells indicated by CD3ε antibody labelling in the livers of normal and platelet depleted mice (A).  The number 
of B-cells indicated by CD19 antibody labelling in the IR livers of normal and platelet depleted mice (B).  Images 
show CD3ε antibody labelling in the non-platelet depleted (C) and thrombocytopenic (D) IR injured liver at 10 
minutes post reperfusion.  Data presented as mean ± SEM, n≥4, ***p<0.001 (two-way ANOVA), scale 
bars=100µm. 
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4.3.6. Antibody Labelling Does Not Appear to be the Ideal Method for Studying 
Lymphocyte and Platelet Trafficking within the Liver 
 Blood smears taken from animals at the end of these experiments appeared to show that the 
antibodies used to label T- and B-cells in vivo were labelling these specific blood cells (Figure 
4.7 A & B).  However, injection of isotype control antibodies for the CD41, CD3 ε and CD19 
antibodies revealed large amounts of non-specific antibody binding within the liver (Figure 4.7 
C, D & E).  Similar binding patterns were also seen with antibodies against other receptors 
such as the neutrophil specific marker GR1 (Figure 4.7 F).  One CD19 antibody did however 
appear to have less non-specific binding and free flowing cells could be observed with this 
antibody (Figure 4.7 G). 
As non-specific binding of antibodies appeared to be a problem within the mouse liver, cells 
isolated from donor mice were fluorescently labelled and used to monitor cell trafficking in all 
subsequent experiments.  T-cells and B-cells isolated from the spleen of donor mice using 
MACS were routinely >96% pure (Figure 4.8 A & B).  In static adhesion assays on colonic 
endothelial cells, incubation with activated platelets significantly increased adhesion of both 
T-cells (Figure 4.8 C; p<0.05) and B-cells (Figure 4.8 D; p<0.05) isolated using this technique.  
Incubation with activated platelets or activated platelet releasate had no significant effect on 
expression of  CD18, CD49d, CD62L or CD44 on the surface of these cells (Figure 4.8 E & F; 
p>0.05).
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A blood: anti CD3ε B blood: anti CD19 C liver: isotype control (CD41) D liver: isotype control (CD19) 
    
E liver: isotype control (CD3ε) F liver: anti GR1  G liver: anti CD19 (clone 6D5)  
   
 
 
 
 
Figure 4:7 Antibodies bind non-specifically within the liver vasculature.   Images show Blood taken from mice injected with: (A) anti CD3ε antibody and Streptavidin 
Alexa 647 and (B) anti CD19 antibody and anti-mouse alexa488. sham livers with: (C) rat IgG and anti-rat IgG-Alexa 555 (D) armenian Hamster IgG-Biotin and 
Streptavidin Alexa 647 (E) mouse IgA and anti-mouse Alexa-488 (F) PE anti GR1 (G) rat anti-mouse CD19 and anti-rat Alexa-488.    Scale bars=100µm  
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Figure 4:8 Adhesion of purified T-cells and B-cells can be increased by incubation with activated platelets.   
T-cells and B-cells were purified from the spleens of C57BL/6 mice using MACS.  The purity of T-cell (A; CD3ε+) 
and B-cell (B; CD19+) separations was determined by flow cytometry and found to be routinely >96%. Plots 
representative of 3 experiments;  red line: isotype control, green line: sorted cells and antibody against relevant 
marker, blue line: excluded cells and antibody against relevant marker.  T-cells (C) and B-cells (D) were incubated 
for 5 mins with thrombin (+T), thrombin activated platelets (+T+P) or thrombin activated platelet releasate 
(+T+PR) and their  adhesion on TNF-α stimulated endothelium was quantitated..  The effect  of these treatments 
on expression of CD18, CD62L, CD49d or CD44 on the surface of T-cells (E) or B-cells (F) was determined by flow 
cytometry.  Data presented a mean ± SEM, n≥3, *p<0.05 (one-way ANOVA with Dunnett’s post-tests) 
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4.3.7. Adhesion of Donor Platelets within the Hepatic Microcirculation is Increased in 
Areas of Flow Following Hepatic IR Injury 
In order to track platelet recruitment to the IR injured liver with a more accurate method than 
labelling endogenous platelets, CFSE labelled washed donor platelets were injected 5 minutes 
prior to ischaemia.  Overall there was no significant difference in the number of adherent 
platelets in the sham and IR injured livers (Figure 4.9 A; p>0.05).  Dual labelling of albumin (to 
identify blood flow) with Alexa 647 and donor platelets with CFSE, demonstrated that the 
majority of adherent platelets in the IR injured liver were found in areas of blood flow (Figure 
4.9 F).  When platelets in only areas of flow were quantitated, platelet adhesion was found to 
be significantly higher in IR injured animals than sham animals (Figure 4.9 C; p<0.05).  
Interestingly, platelet adhesion was high in sham livers too.  The number of free flowing 
platelets was found to be significantly lower in the injured liver than the sham liver (Figure 4.9 
B; p<0.001).  However in areas of flow there was no significant difference between the 
numbers of free flowing platelets (Figure 4.9 D; p>0.05).  No difference was observed between 
IR injured and sham treated animals in the number of platelets identified ex vivo within the 
kidney or the mucosa of the jejunum (Figure 4.9 G; p>0.05).  The number of platelets within 
the spleen was too great to analyse (Figure 4.9 H).  
In order to confirm these intravital findings, tissue sections were taken from the liver of mice 
2 hours after ischaemia or sham surgery.  Staining of sections with antibodies against the 
platelet markers CD41 and CD42b showed no significant difference in the number of platelets 
present between the sham liver and IR injured liver (Figure 4.10 A & D; p>0.05) corroborating 
the intravital data.  Again platelet presence was high even in the sham livers.   
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Figure 4:9 Adhesion of donor platelets within the hepatic microcirculation is increased in areas of flow 
following hepatic IR injury.  Trafficking of platelets within the hepatic microcirculation following partial hepatic 
ischemia was monitored using intravital microscopy.  The overall numbers of adherent (A) and free flowing (B) 
platelets within the sham and IR liver was quantitated. Numbers of adherent (C) and free flowing (D) platelets  in 
areas of flow only were also quantitated.  Images show platelets (green) and Alexa-647 BSA (red) in the sham (E) 
and IR (F) liver at 2 hours post reperfusion.  The number of platelets within the kidney and jejunum at 2 hours 
post reperfusion was quantitated ex vivo (G), the number of platelets with in the spleen was too great to analyse 
(H).  Data presented as mean ±SEM, n≥3, *p<0.05 **p<0.01 (two-way ANOVA), scale bars=100µm.  
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Figure 4:10 Immuno-fluorescent staining shows no difference in platelet accumulation between the sham and IR injured liver.  Tissue sections were obtained from 
the livers of mice at 2 hours post ischemia or sham surgery. Platelet number within the sham and IR livers was quantitated by staining with CD41 (A).  Platelet number 
within the sham and IR livers was also quantitated by staining with staining with CD42b(D).  Images show CD41 (green) staining on a sham liver section (B) and IR 
injured section (C) and CD42b staining (green) on a sham liver section (E) and IR injured section (F).  Data presented as mean ±SEM, n=3, (t-tests), scale bars=100µm. 
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4.3.8. Adhesion of Donor T-cells within the Hepatic Microcirculation is Increased Following 
IR Injury 
In order to track lymphocyte recruitment to the IR injured liver, CMTMR labelled donor spleen 
T-cells and CFDA-SE labelled B-cells were injected at the point of reperfusion.  T-cell adhesion 
was significantly higher in the IR injured liver than the sham liver (Figure 4.11 A; p<0.001).  
There was no significant difference in the number of free flowing T-cells between the post 
ischemic and sham livers (Figure 4.11 B; p>0.05); after injection the number of free flowing 
cells rapidly decreased.  Ex vivo analysis indicated large numbers of T-cells were becoming 
adherent in the spleen, although the number of cells present was not significantly affected by 
liver injury (Figure 4.11 E; p>0.05).   
Unlike T-cells, there was no significant difference in B-cell adhesion between the IR and sham 
liver (Figure 4.12 A; p>0.05). Interestingly, a much higher number of B-cells (10 cells/field of 
view) were identified in sham liver than T-cells (2 cells/field of view). There was also no 
significant difference in the number of free flowing B-cells between the IR injured and sham 
liver (Figure 4.12 B; p>0.05).  Similarly to T-cells the number of free flowing B-cells rapidly 
decreased following injection.  A large number of B-cells were found in the spleen ex vivo and 
the number of cells present was not significantly affected by liver IR injury (Figure 4.12 E; 
p>0.05). 
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Figure 4:11 Adhesion of donor T-cells in the hepatic microcirculation is significantly increased following IR 
injury.  T-cells isolated from the spleens of donor mice were labelled with CMTMR and injected into the carotid 
artery of mice following sham surgery or 90 minutes hepatic ischemia.  The trafficking of these cells within the 
liver was monitored using intravital microscopy.  Adherent (A) and free flowing (B) T-cells  were quantitated 
within the IR injured liver and the sham liver. Images show T-cells (red) in the sham (C) and IR injured liver (D) at 
40 minutes post reperfusion.  Ex vivo analysis of the number of T-cells in the spleen in sham and IR injured animals 
(E).  Data presented as mean ±SEM, n≥4, ***p<0.001 (two-way ANOVA (A&B) and t-test (E)), scale bars=100µm 
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Figure 4:12 Adhesion of donor B-cells in the hepatic microcirculation is not significantly different following IR 
injury.  B-cells isolated from the spleens of donor mice were labelled with CFSE and injected into the carotid 
artery of mice following sham surgery or 90 minutes hepatic ischemia.  The trafficking of these cells within the 
liver was monitored using intravital microscopy.  Adherent (A) and free flowing (B) B-cells  were quantitated 
within the IR injured liver and the sham liver. Images show B-cells (green) in the sham (C) and IR injured liver (D) 
at 40 minutes post reperfusion.  Ex vivo analysis of the number of B-cells in the spleen of sham and IR injured 
animals (E).  Data presented as mean ±SEM, n≥4, *p<0.05 (two-way ANOVA (A&B) and t-test (E)), scale 
bars=100µm. 
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4.3.9. Treatment with Inflammatory Cytokines or H2O2 had no Significant Effect on 
Lymphocyte Adhesion to CD54, CD106 or MAdCAM 
With the aim of determining whether inflammatory cytokines released during IR injury were 
responsible for the rise in T-cell adhesion seen in the IR injured liver, T-cells were treated with 
CXCL1, CXCL12 (SDF-1α) and CCL5 (RANTES) and their adhesion on CD54, CD106 and 
MAdCAM-1 was quantitated.  Although none of the pre-treatments elicited a significant effect 
on T-cell adhesion to the cell adhesion molecules, both CCL5 and CXCL1 resulted in a non-
significant increase in adhesion to CD106 and MAdCAM-1 (Figure 4.13 B & C; p>0.05).  All of 
the pre-treatments resulted in a non-significant reduction in adhesion to CD54 (Figure 4.13 A; 
p>0.05). 
In addition to inflammatory cytokines, H2O2 is also released during inflammation. H2O2 is 
released by inflammatory cells, including neutrophils, which are able to generate local H2O2 
concentrations of 200-500µM (Johnston, 1996).  Treatment of T-cells or B-cells for 5 minutes 
with physiological concentrations of H2O2 (100µM) did not significantly affect their adhesion 
to either CD54 or CD106 (Figure 4.14; p>0.05). 
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Figure 4:13 Treatment with inflammatory cytokines had no significant effect on T-cell adhesion to CD54, CD106 
or MAdCAM-1.  CMTMR labelled T-cells were incubated for 5 minute with 25ng/ml CXCL1, CXCL12 or CCL5 before 
being incubated on immobilised CD54 (A), CD106 (B) or MAdCAM-1 (C) for 20 minutes and their adhesion 
quantitated.    Data presented as mean ±SEM, n≥3 (one-way ANOVA with Dunnet’s post-tests).
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Figure 4:14 Treatment with H2O2 had no significant effect on T-cell or B-cell adhesion to CD54 or CD106.  CFDA-
SE labelled T-cells (A&B) and B-cells (C&D) were incubated for 5 minute with 100µM H2O2 before being incubated 
on immobilised CD54 or CD106 for 20 minutes and their adhesion quantitated.  Data presented as mean ±SEM, 
n≥3 (paired t-tests). 
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4.3.10. Injecting Lymphocytes into the Portal Vein at 60 Minutes Post Reperfusion Results 
in Significantly Fewer Adherent Lymphocytes in the IR Injured Liver Compared to the Sham 
Liver   
For the above intravital studies, donor lymphocytes were introduced systemically following 
infusion via the carotid artery.  However, this resulted in a much lower number of lymphocytes 
being observed in the liver than expected and also lower than that observed in the spleen.  
Similar intravital studies were again conducted but this time with cells injected into the 
hepatic portal vein.  This was performed in an attempt to increase the proportion of cells 
having an opportunity to become adherent in the liver.  The cells were also injected at 60 
minutes post reperfusion instead of immediately following reperfusion. The number of 
adherent T-cells in the hepatic microcirculation of sham mice was higher than that previously 
observed when injected via the carotid artery but the number of B-cells was lower.  However, 
this route of administration resulted in significantly fewer adherent T-cells (Figure 4.15 A; 
p<0.001) and B-cells (Figure 4.16 A; p<0.05) present in the IR injured liver compared to the 
sham.  There was no significant difference in the number of free flow T-cells (Figure 4.15 B; 
p<0.05) or B-cells (Figure 4.16 B; p<0.05) between the IR injured liver and sham liver.  Ex vivo 
analysis showed no significant difference in the number of T-cells in a cross-section of the liver 
(Figure 4.15 F; p>0.05) or the spleen (Figure 4.15 E; p<0.05) between sham and IR-injured 
animals.  Ex vivo analysis also showed no significant difference in the number of B-cells in the 
spleen (Figure 4.16 E; p>0.05) or a cross section of the liver (Figure 4.16 E; p<0.05) between 
sham and IR injured animals.  Despite the slightly increased adhesion of T-cells within the 
hepatic microcirculation it was decided that, due to the complicated nature of portal injection, 
introduction of cells through a carotid cannula would be used for all further experiments.   
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4.3.11. CD8+ and CD4+ T-cells Adhere in Equal Numbers in the Microvasculature of the IR 
Injured Liver 
As IR injury resulted in a significant increase in T-cell adhesion within the liver (section 4.3.8) 
further experiments were carried out to determine if there was a difference in adhesion 
between CD4+ and CD8+ subsets of T-cells.  Flow cytometry showed that the T-cells used in 
previous experiments were 50±5% CD4+ (Figure 4.17 A) and 42±1% CD8a+ (Figure 4.17 B).  
MACS was used to isolate purified CD4+ and CD8a+ T-cells from the spleens of donor mice. 
CD4+ T-cell isolates were found to be >92% pure (Figure 4.17 C) and CD8a+ T-cells were found 
to be >93% pure (Figure 4.17 D). Equal numbers of Purified CD4+ and CD8a+ T-cells were 
introduced into the same mouse following IR injury. The two subsets were differentiated by 
staining either CFDA-SE or CMTMR; the stain used for each subset was alternated between 
experiments to control for differences in florescence.  There was no significant difference in 
adhesion in the liver observed between the two subsets (Figure 4.18 A; p>0.05).  There was 
also no significant difference in the number of free flowing cells between the subsets (Figure 
4.18 B; p>0.05).  At 120 minutes post-reperfusion ex vivo analysis showed no significant 
difference between the number of CD8a+ and CD4+ T-cells in the spleen (Figure 4.18 E; 
p>0.05) or in a cross section of the liver (Figure 4.18 F; p>0.05). 
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Figure 4:15 Injecting T-cells into the portal vein at 60 minutes post reperfusion results in significantly fewer 
adherent lymphocytes in the IR injured liver compared to the sham liver.  T-cells isolated from the spleens of 
donor mice were labelled with CMTMR and injected into the portal vein of mice following sham surgery or 90 
minutes hepatic ischemia and 60 minutes reperfusion.  The trafficking of these cells within the liver was 
monitored using intravital microscopy.  T-cell adhesion (A) and free flowing T-cells (B) within the liver were 
quantitated. Images show T-cells (red) in the sham (C) and IR injured liver (D) at 70 minutes post reperfusion.  Ex 
vivo analysis of T-cells in a cross section of the liver (E) and the spleen (F) between in sham and IR injured animals.  
Data presented as mean ±SEM, n≥4, ***p<0.001 (two-way ANOVA (A&B) and t-test (E&F)), scale bars=100µm.    
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Figure 4:16 Injecting B-cells into the portal vein at 60 minutes post reperfusion results in significantly fewer 
adherent lymphocytes in the IR injured liver compared to the sham liver.  B-cells isolated from the spleens of 
donor mice were labelled with CFSE and injected into the portal vein of mice following sham surgery or 90 
minutes hepatic ischemia and 60 minutes reperfusion.  The trafficking of these cells within the liver was 
monitored using intravital microscopy.  B-cell adhesion (A) and the number of free flowing B-cells (B) in the sham 
and IR injured livers were quantitated.  Images show B-cells (green) in the sham (C) and IR injured liver (D) at 110 
minutes post reperfusion.  Ex vivo analysis of the number of B-cells in a cross section of the liver (E) and the 
spleen (F) in sham and IR injured animals.  Data presented as mean ±SEM, n≥4, *p<0.05 (two-way ANOVA (A&B) 
and t-test (E&F)), scale bars=100µm 
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Figure 4:17 CD4 and CD8a expression on T-cells isolated from the mouse spleen using MACS.  Flow cytometry 
was used to determine the percentage of cells expressing CD4 and CD8a from cells isolated from the spleen with 
several different MACS antibody cocktails.  Cells isolated using the pan T-cell isolation kit II were found to be 
50±5% CD4+ (A) and 42±1% CD8a+ (B).  Cells isolated with the CD4+ T-cell isolation kit II were found to be >92% 
CD4+ (C) and cells isolated with the CD8a+ T-cell isolation  kit II were found to be >93% CD8a+ (D).  Plots are 
representative of n=3.  
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Figure 4:18 CD8+ and CD4+ T-cells are recruited in equal numbers to the IR injured liver.  CD4+ and CD8a+ 
T-cells isolated from the spleens of donor mice were labelled with CFSE or CMTMR and injected into the carotid 
artery of mice following 90 minutes hepatic ischemia.  The trafficking of these cells within the liver was monitored 
using intravital microscopy.  The numbers of adherent CD4+ and CD8a+ T-cells (A) and free flowing CD4+ and 
CD8a+ T-cells (B) within the IR injured liver were counted using intravital microscopy.  Images show CD4+ (C) and 
CD8a+ (D) CFSE labelled T-cells (green) in the IR injured liver at 120 minutes post reperfusion.  Ex vivo analysis of 
the number of CD4+ and CD8a+ T-cells in the spleen (E) and a cross section of the liver (F).  Data presented as 
mean ±SEM, n≥4, (two-way ANOVA (A&B) and t-test (E&F)), scale bars=100µm.    
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4.3.12. Depletion of Platelets Significantly Reduces Lymphocyte Recruitment to the IR 
Injured Liver  
In order to determine whether platelets play a role in lymphocyte recruitment following 
hepatic ischemia platelets were depleted using antibodies prior to injury.  Fluorescently 
labelled T-cells and B-cells were then introduced into the circulation and their adhesion within 
the liver was quantitated.  Depletion of platelets was found to significantly reduce both T-cell 
(Figure 4.19 A; p<0.001) and B-cell (Figure 4.20 A; p<0.001) adhesion in the IR injured liver.  
Depletion of platelets had no significant effect on the number of free flowing T-cells (Figure 
4.19 B; p>0.05) or B-cells (Figure 4.20 B; p>0.05) within the hepatic vasculature. 
4.3.13. Depletion of Platelets has no Significant Effect on T-cell Adhesion within the Sham 
Liver 
In the uninjured liver platelet depletion had no significant effect on adhesion of T-cells (Figure 
4.21 A; p>0.05).  Platelet depletion did result in a small significant decrease in B-cell adhesion 
within the sham liver (Figure 4.22 A; p<0.01).  Depletion of platelets had no significant effect 
on the number of free flowing T-cells (Figure 4.21 B; p>0.05) or B-cells (Figure 4.22 B; p>0.05) 
within the uninjured hepatic vasculature. 
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Figure 4:19 T-cell adhesion within the IR liver is significantly reduced following platelet depletion.  0.5 million 
CMTMR labelled T-cells were introduced via the carotid artery of non-platelet depleted and platelet depleted 
mice after 90 minutes hepatic ischemia.  The trafficking of these cells within the liver was monitored using 
intravital microscopy. Adherent (A) and free flowing (B) T-cells within the thrombocytopenic and non-
thrombocytopenic IR livers were quantitated.  Images show T-cells (red) in the IR injured liver in non-platelet 
depleted (C) and thrombocytopenic mice (D) at 40 minutes post reperfusion.  Data presented as mean ±SEM, 
n≥4, ***p<0.001 (two-way ANOVA), scale bars=100µm. 
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Figure 4:20 B-cell adhesion within the IR liver is significantly reduced following platelet depletion.  0.5 million 
CFDA-SE labelled B-cells were introduced via the carotid artery of non-platelet depleted and platelet depleted 
mice after 90 minutes hepatic ischemia.  The trafficking of these cells within the liver was monitored using 
intravital microscopy.  Adherent (A) and free flowing (B) B-cells within the thrombocytopenic and non-
thrombocytopenic IR livers were quantitated. Images show B-cells (green) in the IR injured liver in non-platelet 
depleted (C) and thrombocytopenic mice (D) at 40 minutes post reperfusion.  Data presented as mean ±SEM, 
n≥4, ***p<0.001 (two-way ANOVA), scale bars=100µm. 
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Figure 4:21 Platelet depletion has no significant effect on T-cell adhesion within the sham liver.  0.5 million 
CMTMR labelled T-cells were introduced via the carotid artery of non-platelet depleted and platelet depleted 
mice 90 minutes after sham surgery.  The trafficking of these cells within the liver was monitored using intravital 
microscopy. Adherent (A) and free flowing (B) T-cells within the thrombocytopenic and non-thrombocytopenic 
sham livers were quantitated.  Images show T-cells (red) in the IR injured liver in non-platelet depleted (C) and 
thrombocytopenic mice (D) at 40 minutes post reperfusion.  Data presented as mean ±SEM, n≥4, (two-way 
ANOVA), scale bars=100µm. 
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Figure 4:22 Platelet depletion significantly reduces B-cell adhesion within the sham liver.  0.5 million CFDA-SE 
labelled B-cells were introduced via the carotid artery of non-platelet depleted and platelet depleted mice 90 
minutes after sham surgery.  The trafficking of these cells within the liver was monitored using intravital 
microscopy.  Adherent (A) and free flowing (B) B-cells within the thrombocytopenic and non-thrombocytopenic 
sham livers were quantitated. Images show B-cells (green) in the IR injured liver in non-platelet depleted (C) and 
thrombocytopenic mice (D) at 100 minutes post reperfusion.  Data presented as mean ±SEM, n≥4, **p<0.01 
(two-way ANOVA), scale bars=100µm. 
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4.3.14. Blocking CD162 (PSGL-1) on T-cells Significantly Reduces their Recruitment to the IR 
Injured Liver 
As depletion of platelets was shown to lead to a significant decrease in lymphocyte adhesion 
and lymphocytes have previously been shown to adhere to platelet expressed CD62P (Diacovo 
et al., 1996b) experiments were carried out to determine if blocking the CD62P ligand CD162 
also lead to a decrease in lymphocyte adhesion.  Flow cytometry was used to determine a 
suitable concentration for blocking all receptors on the surface of T-cells.  Increasing the 
antibody concentrations above 10µg/ml did not result in any increase in antibody binding to 
T-cell indicating that all C162 receptors were blocked (Figure 4.23 A).  The B-cells used in our 
experiments were found not to express CD162 (Figure 4.23 B).  A concentration of 10µg was 
used to block T-cells for further experiments.  Adhesion within the IR injured liver of T-cell 
incubated with the CD162 blocking antibody was significantly lower than for T-cells incubated 
with an IgG control (Figure 4.23 C p<0.01).  However, this decrease in adhesion was far smaller 
than that observed following platelet depletion.  No significant difference was observed in the 
numbers of free flowing T-cells between those incubated with the blocking antibody and those 
incubated with the IgG control (Figure 4.23 D; p>0.05).  No significant difference was observed 
ex vivo in the number of T-cells present in the spleen (Figure 4.23 F; p>0.05) and cross sections 
of the liver (Figure 4.23 G; p>0.05) between those incubated with blocking antibody and those 
incubated with control IgG.    
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Figure 4:23 Blocking CD162 on T-cells significantly reduces their adhesion within the IR injured liver.  (A) 
Representative flow cytometry plots for T-cells incubated with an IgG control (black) and CD162 antibody at 
concentrations of 5µg/ml (red), 10µg/ml (green), 20µg/ml (blue) and 30µg/ml (orange).  (B) Representative flow 
cytometry plots for B-cells incubated with IgG control (black) or CD162 antibody (blue).  The effect of incubation 
with CD162 blocking antibody on T-cells adhesion within the liver compared to the IgG control was determined 
by intravital microscopy (C).  The number of free flowing cells following incubation with blocking antibody and 
control IgG was also quantitated (D).  Images show T-cells incubated with an IgG control (E) and CD162 blocking 
antibody (F) in the liver at 60 minute post reperfusion.  Ex vivo analysis of T-cells in the spleen (G) or a cross 
section of the liver (H) at 120 minutes post reperfusion following incubation with CD162 blocking antibody or 
control IgG.  Data presented as mean ±SEM, n≥4, **p<0.01 (two-way ANOVA (C&D) and t-test (G&H)), scale 
bars=100µm. 
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 Blood Flow as determined 
by laser Doppler and 
platelet velocities 
PMP effect on 
Lymphocyte 
adhesion 
Endogenous 
platelet 
adhesion 
Endogenous T-
cell adhesion 
Endogenous B-
cell adhesion 
Donor platelet 
adhesion 
Donor   
T-cell adhesion 
Donor  
B-cell 
adhesion 
Sham livers 
 
 
 
 
  Generally seems 
to be quite high 
 Generally 
seems to be 
higher than 
endogenous  
T-cells 
 
Generally 
seems to be 
quite high 
 Generally 
seems to be 
higher than 
donor T-cells  
IR injured livers 
 
 
 
 
Laser Doppler suggests 
overall blood flow within 
liver is decreased as a result 
of injury.  Platelet velocities 
suggest the rate  of blood 
flow increases for a short 
period immediately after 
reperfusion but decreases 
with time 
 
No effect on 
lymphocyte 
adhesion 
No increase 
compared to 
sham – not the 
most sensitive 
measure of 
individual 
platelet adhesion 
 
 (p<0.001) 
compared to 
sham 
No increase 
compared to 
sham – but 
numbers much 
higher than 
endogenous  
T-cells 
 (p<0.001) 
compared to 
sham in areas 
of blood flow  
 (p<0.001) 
compared to 
sham 
No increase 
compared to 
sham – but 
numbers much 
higher than 
donor T-cells 
Sham Livers in 
Thrombocytopenic 
mice 
 
      No effect  (p<0.001) 
compared to 
sham mice 
IR injured Livers in 
Thrombocytopenic 
mice 
 
 
No effect on flow which 
remains poor  
   (p<0.001) 
compared to 
IR injured 
mice 
 
No difference 
compared to 
IR injured mice 
  (p<0.001) 
compared to 
IR injured 
mice 
 (p<0.001) 
compared to 
IR injured 
mice 
 
 
Table 4.1 Summary of results from all in vivo studies highlighting platelet, lymphocyte and platelet modified lymphocyte adhesion to sham or IR injured livers in 
vivo.  Generally, the presence of platelets within the IR injured increased but, interestingly, was high even in healthy / sham livers.  They also played a significant role 
in the recruitment of lymphocytes, specifically T-cells, to the IR injured liver.  Interestingly, platelets could modify basal B-cell presence in healthy and injured livers.  
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4.4. Discussion 
Although there is a large body of evidence to suggest that platelets can interact with various 
subsets of lymphocytes in vitro, there is little evidence to support their cross-talk in vivo.  
Indeed, the data presented in the previous chapter provided clear evidence for platelet 
modulation of lymphocyte adhesion in vitro.  The results demonstrated that previously 
adherent, activated platelets increased lymphocyte adhesion to endothelial counter-ligands.  
It is therefore possible that platelets may modulate the adhesion of lymphocytes following 
injury in vivo.  Hepatic IR injury is an important clinical problem which has been shown to be 
mediated, in part, by an inflammatory lymphocyte response.  The role that platelets may play 
in mediating lymphocyte recruitment in vivo was therefore tested using intravital microscopy 
in a mouse model of acute hepatic IR injury.  The work presented in this chapter provides, for 
the first time, direct evidence of a role for platelets in the recruitment of lymphocytes to the 
liver following hepatic IR injury in vivo. 
Blood flow within the hepatic microcirculation was severely disrupted following ischaemia and 
subsequent reperfusion.  This is a commonly described phenomenon known as ‘no-reflow’, 
caused by vasoconstriction and/or cellular aggregation (Cywes et al., 1993, Uhlmann et al., 
2000).  The latter compounds the vascular constriction, with the offending cells being 
congested red blood cells, adherent neutrophils and/or platelet microthrombi.  Platelet 
depletion was found to have no beneficial effect on blood flow within the liver immediately 
following ischaemia.  This seems to correspond with earlier findings that ‘no-reflow’ within 
the liver is mainly caused by vascular constriction rather than cellular aggregation (Uhlmann 
et al., 2000).  Injection of FITC-BSA, a means of identifying areas of perfusion, revealed areas 
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of no flow immediately after reperfusion in the IR injured liver.   However, laser Doppler 
measurements showed no overall difference in perfusion between the IR injured and sham 
livers at the same time point.  This discrepancy may be explained by the fact that an increased 
velocity of blood occurred within the perfused areas as indicated by the increased velocity of 
free flowing platelets in these areas.  Platelet velocity decreased as reperfusion continued, 
corresponding to the parallel decrease in laser Doppler measurements.   
The results in Chapter 3 indicated that PMPs could dramatically increase the adhesion of 
lymphocytes to endothelial counterligands in vitro.  However, incubating lymphocytes with 
PMPs prior to systemic injection did not increase their adhesion to the IR injured liver in vivo.  
PMPs have been identified in the peripheral circulation of patients following various diseases 
including diabetes, hypertension, arteriosclerosis and sepsis (VanWijk et al., 2003).  Indeed, a 
recent study demonstrated that PMPs could be observed in the blood within 30 minutes of 
reperfusion in mice subjected to hepatic IR injury using a protocol similar to our own model 
(i.e. 90 mins ischaemia) (Freeman et al., 2014). It is possible that some of the adhesion of 
lymphocytes that was observed following hepatic IR injury was mediated by endogenous 
circulating PMPs.   Therefore, pre-treatment with PMPs may not further increase lymphocyte 
adhesion – this may explain the results obtained.   Another possibility is that incubating 
lymphocytes with PMPs is only capable of increasing lymphocyte adhesion under static 
conditions but not under flow conditions where shear stresses are present.   Clearly more 
studies need to be done to investigate whether improving the efficacy of PMP-lymphocyte 
interactions affects lymphocyte adhesion before completely ruling out a role for PMPs.   
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Although intravital experiments primarily utilise specific labelled donor cells and monitor their 
trafficking in vivo, this chapter aimed to develop a methodology to visualise the endothelial 
interactions of the endogenous blood cells of interest.  Therefore, fluorescently tagged 
antibodies to CD3ε and CD19 were injected to visualise endogenous T-cells and B-cells 
respectively.  However, initial experiments using these antibodies demonstrated high levels 
of non-specific binding within the liver.  This non-specific binding was also present when using 
antibodies previously used successfully by the Kalia group to measure blood cell recruitment 
to other tissues including the mouse gut and kidney (Holyer, 2010, White, 2014).  This implies 
that non-specific labelling is a liver specific problem.   The liver is also known to be one of the 
main organs involved in simple antibody clearance from the circulation.  Indeed Boyle and 
colleagues demonstrated that following intravenous administration of radiolabelled antibody 
into rats, 15% of the injected dose was contained within the liver after 2 hours and remained 
there after 72 hours (Boyle et al., 1992).  Initially most of this antibody was attached to 
sinusoidal cells but was taken up by parenchymal cells with time.   Interestingly, the rapid 
hepatic clearance of antibody has been suggested to be a problem requiring consideration in 
experimental studies of immunotherapy against tumours as it limits the availability of 
antibody that can bind to the tumour (Sharkey et al., 1991).   Circulating immune complexes 
(CICs), comprised of antigen and antibody, are also cleared from the liver.  These are produced 
when an aggressive immune response towards antigen occurs.   Human CICs are delivered to 
the liver sinusoids following their attachment to red blood cells (RBCs).  Once within the liver, 
they detach from the RBCs and are cleared from the circulation by hepatic phagocytes/Kupffer 
cells.    This antibody ‘trapping’ or clearance role of the liver may explain the high levels of 
non-specific binding observed within this organ.  However, no study has previously provided 
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intravital images showing such a high non-specific antibody load following infusion within the 
mouse liver.   Given our findings, it was decided that injection of exogenously pre-labelled 
donor cells was a more appropriate method for tracking cell recruitment within the liver. 
The route of delivery used for injection of donor cells greatly affected the results obtained.  
Injection of cells into the portal vein, as opposed to the carotid artery, delivered them directly 
to the liver circulation without them having to pass through other tissues first.   It was 
anticipated that this route of delivery would provide more cells to the IR injured liver for 
adhesion.  However, interestingly when cells were injected into the portal vein, fewer 
adherent T-cells (and B-cells) were observed in the IR injured liver compared to the sham liver.  
This is in contrast to results obtained from injection of cells into the carotid which showed a 
small increase in T-cell adhesion in the IR injured liver compared to the sham liver.  The manual 
injection of cells is a relatively ’forceful’ mode of delivering cells into the systemic circulation 
- at the time of entry their velocity was likely higher than that of endogenous circulating cells.  
However, when cells are introduced via the carotid artery they have an opportunity to adjust 
their velocity to that of the circulation before they arrive at the liver.  Portal injection of cells 
resulted in large numbers of fast trafficking cells which could be observed intravitally in the 
liver sinusoids.   This may have resulted in a shorter period of time that they were exposed to 
local (and circulating) inflammatory mediators and could hence explain the reduced adhesion 
of T-cells in IR injured mice compared to sham mice. In addition to this cell infusion in these 
experiments was carried out at 60 minutes post reperfusion whereas in experiments using 
carotid injection, cells were infused immediately after reperfusion. It was hoped that by 
allowing the injury to develop for longer cellular adhesion would be increased. The later time 
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point of injection may explain the differing results between the two infusion sites as lower 
perfusion is observed in the liver 60 minutes after reperfusion compared to immediately after 
reperfusion.   Due to these results we opted to use carotid injection for all experiments. 
Following carotid introduction of washed platelets, surprisingly high numbers of adherent 
platelets were observed within the healthy, sham liver.  This was not expected as the Kalia lab 
(and others) have not previously demonstrated platelets to adhere in such high numbers in 
sham kidney, small intestine, colon or cremaster muscle vascular beds.  It is well known that 
the reticuloendothelial system, comprising macrophages of the liver and spleen, is the main 
route for phagocytic removal of damaged or unwanted circulating cells.  The liver Kupffer cells 
are particularly involved in clearing platelets and the presence of Kupffer cells within the 
sinusoidal blood vessels places them in a prime position to capture circulating platelets.  
Bearing this in mind, it could be possible that the adherent platelets seen in the sham liver are 
an artefact of or damaged by the donor platelet washing process.  Another possibility is that 
sham surgery caused damage to the liver leading to platelet activation and adhesion.  A similar 
result was seen in a study by Hoffmeister et al. (2003) following injection of washed donor 
platelets.  A significant proportion of the platelets were rapidly cleared from the circulation 
with the majority of them being found in the healthy mouse liver and the spleen.  Interestingly, 
this study showed that a greater proportion of platelets were found in the liver if platelets 
were refrigerated prior to injection rather than those stored at room temperature.  This study 
further demonstrated that clearance of platelets by the liver occurred after their ingestion by 
Kupffer cells, the major phagocytic scavenger cells of the liver.  Intravitally they showed 
platelets colocalised with hepatic sinusoidal Kupffer cells and this colocalisation was greater 
161 
 
with chilled platelets. A later study by the same group showed that following long term 
refrigeration (>48 hours) platelets are also cleared by hepatocytes (Rumjantseva et al., 2009).  
In contrast, other intravital studies using washed donor platelets have not shown such high 
numbers of adherent platelets in healthy, sham hepatic sinusoids.  Approximately 3-5 
Rhodamine-G labelled donor platelets adherent / field of view in sham animals have been 
noted previously, which is significantly lower than that observed in the current study where 
approximately  50 adherent platelets / field of view were noted (Pak et al., 2010, Ogawa et al., 
2013, Nakano et al., 2008)  However, these studies were conducted in rats and the platelets 
were labelled with Rhodamine 6G, which may explain the discrepancies.   In a more recent 
study conducted in mice, Wong et al. (2013) presented intravital images that showed high 
numbers of endogenous platelets present within the liver sinusoids under basal conditions.   
Therefore, this phenomenon may be specific to mice. 
It was expected that platelet adhesion would increase following hepatic IR injury but this 
initially did not appear to be the case.  This was probably due to the reduced blood flow 
detected overall in the injured liver as determined by laser Doppler.   Also, when platelet 
adhesion was quantitated in a field of view, in IR livers this area comprised regions of both 
blood flow and complete stasis.  This data was being compared to sham mice in which the 
whole field of view had blood flow.  Therefore, to make comparisons more meaningful, 
additional analysis was conducted in which platelet adhesion was counted but only in areas 
of flow.  This then demonstrated a significant increase in platelet adhesion between IR and 
control mice, with almost 100 platelets adherent in a field of view in injured mice at 30 
minutes post-reperfusion compared to 50 in sham mice. When free flowing platelets were 
162 
 
analysed in this way, similar numbers were observed between the injured and uninjured liver.  
In other intravital studies, adhesion of washed platelets was also shown to increase following 
ischemia.  Increases in these studies were more remarkable than the current study which can 
be explained by the fact that previously published work used a 20 minute ischaemic period 
which would have  resulted in less severely disrupted flow than our 90 minute ischaemic phase 
(Pak et al., 2010, Nakano et al., 2008, Ogawa et al., 2013).   Although we demonstrated an 
increase in adhesion of donor platelets, which comprised approximately 5% of the circulating 
platelet population, most likely the actual platelet recruitment was much higher due to 
adhesion of endogenous platelets too.  The role of this significant platelet presence within the 
injured liver in mediating lymphocyte adhesion was assessed.   
Adhesion of both T-cells and B-cells was observed within the sham liver, with presence of the 
latter being greater.  Naïve, memory and activated T-cells are known to continuously migrate 
from the lymph nodes via the blood and through the liver under normal conditions (Luettig et 
al., 1999).  It has also been clearly demonstrated that activated lymphocytes can be cleared 
by the liver, particularly activated CD8+ T-cells which are selectively retained within normal 
liver.  This event is primarily mediated by CD54 expressed on sinusoidal endothelium and 
Kupffer cells (Mehal et al., 1999).  This normal migration to and clearance of lymphocytes by 
the liver may explain the adhesion of T-cells and B-cells within the sham liver in our 
experiments.  Sham surgery is also likely to result in some minor activatory damage to the liver 
which may lead to adhesion of lymphocytes.  It is interesting that sham liver show high platelet 
and lymphocyte (particularly B-cell) adhesion.  This may also be explained by the unique slow 
blood velocity found within sinusoidal capillaries which can intermittently stop completely due 
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to occlusion of the sinusoidal lumen by Kupffer cells.   The tortuous structure of the sinusoids 
may also allow continuous contact between circulating cells and sinusoidal endothelium and 
thus increase the chances of adhesion.  The distribution of adhesion molecules in the sinusoids 
is also unique as unlike other non-inflamed vessels, liver sinusoids constitutively express 
abundant ICAM-1 without the need for induction by inflammatory cytokines (Lalor et al., 
2002b, Panes et al., 1995).   They also express vascular adhesion protein-1 (VAP-1) which 
mediates selective adhesion of CD8+ T-cells (Lalor et al., 2002b).   All of the above increase the 
likelihood of firm interactions between circulating cells and sinusoidal endothelium even 
under non-inflamed conditions in the liver.   
Following induction of IR injury, a small but nevertheless sustained significant increase in T-cell 
adhesion was observed.   This has previously been reported although all initial experimental 
studies were immunohistochemical in nature (Zwacka et al., 1997).  Although the increase in 
T-cell adhesion in the current study was small, it is worth noting that it was quantitated in a 
smaller area of the liver as perfused regions were reduced compared to sham.   Recruitment 
was also a rapid response occurring within 1 hour of reperfusion.  Indeed, others have shown 
histologically that lymphocyte infiltration occurs long before any appreciable neutrophil 
accumulation (Caldwell et al., 2005).  In vitro studies suggested that this increase may not have 
been mediated by well-known inflammatory mediators including CXCL1, CXCL12 (SDF-1α), 
CCL5 (RANTES) or H2O2 as pre-treatment with them did not increase T-cell adhesion to any of 
the endothelial cell adhesion molecules tested under static conditions.  Interestingly, of these 
inflammatory factors both CCL5 and CXCL12 are known to be released by platelets (Massberg 
et al., 2006, Kameyoshi et al., 1992).   No difference in adhesion between CD4+ and CD8a+ T-
164 
 
cells following hepatic IR injury was identified.  This is contrary to the work of Zwacka et al. 
(1997) which showed significant liver infiltration by CD4+ T-cells but very little infiltration by 
CD8+ T-cells following hepatic IR injury.  This discrepancy may be explained by the injection of 
heparin to prevent clotting in the experiments carried out by Zwacka et al. (1997). Also our 
work used a different mouse strain from the BALB/c mice used in this study.  Furthermore, in 
our experiments CD4+ and CD8a+ cells were injected in equal numbers whereas the circulating 
T-cells quantitated in the study was Zwacka and colleagues were predominantly CD4+ (Zwacka 
et al., 1997, Chen and Harrison, 2002). 
It was not previously know whether B-cells are recruited following hepatic IR injury.  However, 
B-cells are recruited to other tissues such as the kidney and intestine following IR injury (Linfert 
et al., 2009).  The results presented in this chapter show that B-cells are not recruited to the 
IR injured liver in numbers greater than the un-injured liver.  However, it is plausible that B-
cell recruitment may occur at a later time point as in the kidney B-cell accumulation does not 
peak until three days post injury (Jang et al., 2010).  B-cell adhesion may also have been higher 
if the area of endothelium available for adhesion was higher – this was not the case as blood 
flow was severely disrupted in the IR livers as evidenced by areas of complete blood flow 
stasis. 
Following platelet depletion remarkable decreases in both T-cell and B-cell adhesion was 
observed in the IR injured liver.  Indeed, T-cell adhesion was lowered to values below that 
observed basally in sham mice.  Iannacone et al. (2005) described a similar drop in T-cell 
recruitment following platelet depletion in a mouse model of hepatitis B infection.  Khandoga 
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et al. (2006a) found that platelets and CD4+ T-cells localise in the post-ischaemic liver.  
However, this is the first time a role for platelets in recruiting lymphocytes to the IR injured 
liver has been reported.  It is also the first time that a role for platelets in the recruitment of 
B-cells to liver inflammation has been reported.   
Clearly, the decreased lymphocyte presence may have been due to decreased liver injury in 
the absence of platelets.  However, it was surprising that platelet depletion did not decrease 
injury to the liver as measured chemically by serum ALT activity.  Similarly Nocito et al. (2007) 
found that neither platelet depletion nor functional inhibition of platelets with Clopidigrel 
affected serum aspartate transaminase activity (a marker of liver damage) for 48 hours after 
60 minutes partial liver ischaemia.  Indeed it appears that in our model, platelet depletion may 
even increase liver injury as evidenced by a non-significant increase in ALT levels in platelet 
depleted injured mice compared to injured mice with platelets.  This may have been through 
increased haemorrhage within the liver in the absence of platelets, allowing for greater 
infiltration of the liver by other populations of inflammatory cells.  It may also be due to a 
reduction in the recruitment of subsets of lymphocytes which may play anti-inflammatory or 
protective roles during IR injury.  For example, Caldwell and colleagues demonstrated 
histologically that CD4−/− mice, lacking CD4+ T lymphocytes and a deficiency in helper T-cells,  
exhibited increased liver injury (raised ALT levels;  widespread hemorrhagic necrosis, 
parenchymal cell destruction) despite reduced neutrophil recruitment (Caldwell et al., 2005).  
They showed that this was possibly due to the fact that neutrophils from CD4-/- mice had a 
higher oxidative burst activity.  
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To assess whether adherent platelets recruited lymphocytes through physically interacting 
with them and thus bridging them to the endothelium, T-cells were pre-treated with an anti-
CD162 blocking antibody prior to injection.  This showed that T-cell recruitment appeared to 
be partially governed by interactions between CD62P the counter-receptor for lymphocyte 
CD162.  As platelets within the IR injured liver express P-selectin (Esch et al., 2010), and direct 
platelet-T-cell interactions are mediated by CD62P (Diacovo et al., 1996b, Sheikh et al., 2004), 
it is plausible that physical interactions between the two cells are part of the mechanism by 
which platelets recruit T-cells to the IR injured liver. Although vascular endothelial cells 
express CD62P, sinusoidal endothelial cells do not, therefore endothelial cell expressed CD62P 
is unlikely to play a role in lymphocyte recruitment in our model (Lalor et al., 2002b).  A role 
for CD62P has previously been shown in neutrophil infiltration of the IR injured liver and 
blocking of CD62P results in a reduction in liver damage (Dulkanchainun et al., 1998, Garcia-
Criado et al., 1995).  The reduction in adhesion was not as large as that observed following 
platelet depletion and the B-cells used in our experiments did not express CD162 at all which 
suggests other mechanisms such as platelet released cytokines may be involved in lymphocyte 
recruitment.  Nocito et al. (2007) found that platelet depletion, but not the anti-platelet drug 
Clopidigrel, reduced the infiltration of neutrophils in the IR injured liver.  As Clopidigrel did not 
affect the expression of pro-inflammatory mediators they concluded from these results that 
platelet released cytokines were required for neutrophil recruitment. 
Interestingly platelet depletion did not affect T-cell adhesion within the un-injured liver but 
did decrease B-cell adhesion – albeit this was a far smaller reduction than that seen with T-
cells in the injured liver.  These results imply that the adhesion of lymphocytes within injured 
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and un-injured liver relies on different mechanisms, being either partially platelet dependent 
or completely platelet independent.  It remains unclear why basal B-cell presence within the 
liver is somewhat platelet dependent, but in light of our data highlighting a significant platelet 
presence in sham livers, it may not be so surprising.   
The data presented in this chapter have shown for the first time a key role for platelets as 
mediators of lymphocyte recruitment following hepatic IR injury.  In order to determine if the 
importance of platelets in lymphocyte recruitment is conserved across other injury models, 
the next chapter will investigate the role of platelets in lymphocyte recruitment following 
ConA induced liver injury.  This injury model is well accepted to be lymphocyte dependent and 
it is anticipated that a greater lymphocyte recruitment will be induced than that seen following 
IR injury.  This will hopefully allow us to determine whether the ability of platelets to modify 
lymphocyte recruitment varies depending on the severity of lymphocyte involvement.   
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5. LYMPHOCYTE RECRUITMENT TO THE LIVER DURING CONCANAVALIN A INDUCED INJURY 
CAN BE MODULATED BY PLATELETS 
5.1. Introduction and Hypotheses 
Concanavalin A (ConA) is a plant lectin from jack bean (Canaualia ensiformis), known to 
activate T lymphocytes in vitro.  ConA induces liver specific injury in mice and is widely used 
as a reliable experimental model of acute T-cell mediated diseases on the hepatitis spectrum, 
including auto-immune hepatitis, viral hepatitis and fulminant hepatitis (Trautwein et al., 
1998, Ajuebor et al., 2005, Diao et al., 2004). The cells involved in mediating the injury are 
primarily CD4+ T-cells that migrate specifically to the liver within hours of exposure, but NK T-
cells have also been implicated in the injury (Kaneko et al., 2000, Toyabe et al., 1997) as have 
neutrophils (Bonder et al., 2004) and Kupffer cells (Schumann et al., 2000).  These cells have 
been shown to play roles in a number of human liver diseases, including autoimmune, viral, 
alcoholic, and IR injury.   After recruitment, T-cells release high levels of pro-inflammatory 
cytokines that induce the development of the hepatic lesions.  Indeed, in vitro it has been 
reported that lymphocytes are capable of exerting direct cytotoxicity against ConA–treated 
hepatocytes.  
Tiegs and colleagues were the first to describe this experimental model of liver injury (Tiegs et 
al., 1992).  In their seminal study, ConA resulted in T-cell stimulation and particularly IL-2 
release in vivo.  The resultant liver injury could be prevented by immunosuppressive drugs, 
such as cyclosporin A (FK506).  The lymphocyte pathology of this injury was further confirmed 
by the fact that immunodeficient mice (SCID or athymic nude mice) failed to develop hepatitis 
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on ConA challenge, with CD4+ T-cells identified as the major effector cell in this model.  Many 
studies thereafter have demonstrated that ConA causes systemic release of cytokines such as 
TNFαα, GM-CSF, IL-2, and IFNy.  
Hokari and colleagues demonstrated that activation of T-cells with ConA for 48 hrs prior to 
their injection led to their highly significant retention within the healthy rat liver (Hokari et al., 
1999).  They further demonstrated that interactions between CD11a/CD18 and CD54 
accounted for the activated lymphocyte accumulation in hepatic sinusoids.  Since reduced 
accumulation within the intestinal Peyer's patches and the spleen was observed, the authors 
concluded that ConA activation diminished lymphocyte entry into lymphoid tissue but 
enhanced their transit through non-lymphoid sites such as the liver.  This makes this a useful 
experimental model to examine the role that platelets may play in mediating lymphocyte 
recruitment to the liver.       
The work presented in the previous chapters indicates that platelets are important mediators 
of lymphocyte recruitment both in vitro and in a murine hepatic IR injury model.  Accumulation 
of platelets within the hepatic microvasculature has been previously observed during ConA 
induced liver injury (Massaguer et al., 2002).  It is therefore possible that these platelets play 
a role in the recruitment of lymphocytes to the liver during ConA injury.  In this current 
chapter, data is presented comparing platelet and lymphocyte adhesion in the hepatic 
microvasculature following both ConA and vehicle control treatment.  Further to this, data 
comparing lymphocyte recruitment in the hepatic microcirculation in both normal and platelet 
depleted mice is also presented. 
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For the work included in this chapter, it was hypothesised that: 
 Lymphocyte recruitment to the liver is increased following ConA injury. 
 CD4+ but not CD8+ T-cells are recruited to the liver following ConA injury. 
 Lymphocyte recruitment is significantly reduced following platelet depletion. 
 T-cell recruitment to the liver following ConA injury is dependent on lymphocyte 
expressed CD162.  
5.2. Methods 
The methods used in this chapter are described in detail in chapter 2.  Briefly, injury was 
induced by introduction of ConA via a carotid artery cannula at a dose of 20mg/kg; injury was 
then allowed to develop for 2-4 hours prior to intravital observations.  T-cells and B-cells were 
isolated from the spleen of donor mice using MACS and platelets were isolated from the whole 
blood of donor mice through centrifugation.  These cells were then labelled using fluorescent 
dyes and their trafficking within the liver was monitored using intravital microscopy.  Some 
experiments used purified CD4+ and CD8+ T-cells which were isolated from the spleens of 
donor mice using MACS.  To investigate if platelets play a role in lymphocyte recruitment 
platelets were depleted prior to injury by injection of a platelet depleting CD42b antibodies.  
In some experiment CD162 on the surface of T-cells was blocked by incubation with a blocking 
antibody for 20 minutes. 
Blood flow within the liver was measured using laser Doppler.  FITC-BSA was injected to 
visualise areas with flow and the velocities of free flowing platelets were used as a measure 
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of rate of flow. Blood samples were taken at the end of experiments in order to conduct blood 
counts.  Serum samples were isolated at the end of experiments in order to measure the level 
of injury through analysis of serum ALT activity. 
5.3. Results 
5.3.1. Markers of Liver Injury are Increased Following ConA Administration 
Within 2 hours of ConA injection the liver was visibly inflamed and sometimes appeared 
darkened with a spotty haemorrhagic appearance due to vascular congestion (Figure 5.1 A).  
The spleen also became strikingly enlarged and darker in colour (Figure 5.1 B).  4 hours after 
the injection of ConA there were significant reductions in the numbers of circulating 
erythrocytes (p<0.001) and platelets (p<0.001) and in haematocrit (p<0.001) compared to the 
vehicle controls (Figure 5.2 A).  Treatment with ConA also resulted in a decrease in circulating 
leukocytes although this difference did not reach significance (Figure 5.2 A; p>0.05).  
Treatment with ConA significantly increased the proportion of circulating leukocytes made up 
by basophils (p<0.05) but did not significantly alter the proportions of other leukocyte subsets 
(Figure 5.2 A; p>0.05).  A significant increase in mean platelet volume was also observed 
(Figure 5.2 A; p<0.01). 
Similar results were observed in platelet depleted mice treated with ConA.  Haematocrit and 
the number of circulating erythrocytes were both significantly reduced compared to the 
vehicle control (Figure 5.2 A; p<0.05).  There were also significant increases in the proportions 
of circulating leukocytes made up by monocytes and basophils (Figure 5.2 A; p<0.05).  Blood 
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counts for platelet depleted ConA mice did not significantly differ from blood counts of non-
platelet depleted ConA mice (Figure 5.2 A; p>0.05).   
Survival of ConA injured mice was significantly lower than that of mice treated with a vehicle 
control (Figure 5.2 B; p<0.05).  For example, 6 hours after ConA administration only 14% of 
mice survived.  Survival of thrombocytopenic ConA treated mice was also significantly reduced 
compared to those treated with a vehicle control (Figure 5.2 B; p<0.05).  Although platelet 
depletion did decrease the survival of ConA injured mice this decrease did not reach 
significance (Figure 5.2 B; p>0.05). 
4 hours after ConA treatment serum ALT activity was significantly increased in both normal 
(Figure 5.2 C; p<0.05) and platelet depleted mice (Figure 5.2 C; p<0.05).  Platelet depletion did 
result in increased serum ALT activity 4 hours after ConA administration; however, this 
increase was not significant (Figure 5.2 C; p>0.05). 
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Figure 5:1 Administration of ConA results in liver inflammation and splenomegaly.  2 hours after administration 
of a 20mg/kg dose of ConA the liver is visibly inflamed compared that of an animal administered with a vehicle 
control (A, liver outlined in white).  The spleen of an animal 2 hours after ConA administration is greater in size 
and darker in colour than that of a control animal (B). 
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A 
 RBC 
(106/mm3) 
PLT 
(103/mm3) 
WBC 
(103/mm3) 
HCT 
(%) 
MPV 
(µm3) 
LYM% MON% NEU% EOS% BAS% 
Vehicle 8.7±0.1 793±29 2.8±0.4 35.5±0.1 5.65±0.1 86.7±0.3 2.7±0.7 10.0±2.7 0.2±0.1 0.3±0.1 
ConA 6.6±0.1 144±22 1.8±0.3 25.2±0.7 6.4±0.2 69.3±7.8 3.7±1.0 22.9±6.9 0.3±0.0 3.8±1.5 
 *** ***  *** **     * 
Thrombocytopenic ConA 4.7±1.4 ND 1.8±0.4 17.8±5.3 ND 75.2±1.2 11.4±3.0 12.0±1.2 0.4±0.16 1.1±0.2 
 *   *   *   * 
RBC=red blood cells, PLT=platelets, WBC=white blood cells, HCT=haematocrit, MPV=mean platelet volume, LYM=lymphocytes, MON=monocytes, NEU=neutrophils, 
EOS=eosinophils, BAS=basophils, ND=not detected. 
B C 
  
 
Figure 5:2 ConA treatment significantly increased serum ALT activity and reduced survival.  Blood counts of mice 4 hours after vehicle or ConA treatment for both 
non-platelet depleted and platelet depleted mice (A).  Survival of mice following vehicle treatment or ConA treatment for both non-platelet depleted and platelet 
depleted mice (B).  Alanine transferase activity in serum samples 4 hours after vehicle or ConA treatment for both non-platelet depleted and platelet depleted mice 
(C).  Data presented a mean ±SEM, n≥3, *p<0.05 **p<0.01 ***p<0.001 compared to vehicle (one-way ANOVA with Bonferroni post-tests (A&C) and Mantel Cox tests 
with Bonferroni correction (B)) 
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5.3.2. Hepatic Blood Flow is Disrupted in ConA Induced Liver Injury 
Injection of FITC-BSA at 4 hours post-ConA treatment indicated that some areas of the liver 
were not perfused with blood (Figure 5.3 B).  However, perfusion of the liver, as measured by 
laser Doppler, did not significantly differ between the ConA injured liver and uninjured 
controls at 4 hours following treatment administration (Figure 5.3 C; p>0.05).  Using the 
velocity of platelets as a measure of flow rate, it was observed that the rate of flow within the 
ConA injured liver was significantly greater than in control livers (Figure 5.3 D; p<0.001).  
Platelet depletion had no significant effect on blood flow within the ConA injured liver at 2 
hours post ConA injection (Figure 5.3 E; p>0.05).  Cellular adhesion within the ConA injured 
liver was only observed within areas of perfusion (Figure 5.3 F) 
5.3.3. Platelets Injected at 2 Hours Post Treatment Adhere in Significantly Lower Numbers 
within the Livers of Mice Injected with ConA Compared to Vehicle Control 
In order to track platelet recruitment to the ConA injured liver CFDA-SE labelled donor 
platelets were injected 2 hours after ConA or vehicle control administration.  Platelet adhesion 
was found to be significantly reduced following ConA treatment compared to the control 
(Figure 5.4 A; p<0.001).  However, towards the end of the experiment the numbers of 
adherent platelets in ConA injured and control livers were almost equal (Figure 5.4 A).  In ex 
vivo cross sections of the liver there were fewer platelets following ConA than vehicle control 
treatment although this difference was not significant (Figure 5.4 B; p>0.05).  Due to their high 
speed it was not possible to accurately assess the number of free flowing platelets in the ConA 
injured liver. 
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Figure 5:3 Following ConA administration blood flow within the liver is disrupted.  4 hours after administration 
of a 20mg/kg dose of ConA or a vehicle control FITC-BSA was injected into the circulation and the liver was 
visualised using intravital microscopy.  In the control liver FITC-BSA entered all areas of the tissue (A), following 
ConA treatment FITC-BSA did not enter large areas of the tissue (B; dark areas).  Laser Doppler was used to 
measure perfusion of the liver in animals given ConA or a vehicle control (C). Velocities of  CFDA-SE labelled 
platelets in livers of mice treated with ConA or vehicle control were determined by intravital microscopy (D). 
Laser Doppler measurements for the ConA injured liver at 120 minutes post administration in throbocytopenic 
and non-thrombocytopenic mice. T-cells (green) and B-cells (blue) were only observed to adhere in areas of flow 
– highlighted by Alexa-674 BSA (red) – following ConA administration (F). Data presented a mean ±SEM, n≥3, 
***p<0.001 (two-way ANOVA) scale bars=100µm.   
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Figure 5:4 Platelets injected at 2 hours post treatment adhere in significantly lower numbers within the livers 
of mice injected with ConA compared to vehicle control.  1x108 CFDA-SE stained platelets were injected into the 
carotid artery of mice 2 hours after administration of ConA or a vehicle control.  Using intravital microscopy the 
number of adherent platelets within the hepatic microcirculation was monitored in the ConA injured liver and 
vehicle control treated liver (A).  Ex vivo analysis of the number of platelets in a cross section of the liver 4 hours 
after treatment administration (B).  Images show platelets (green) in the control liver (C) and the ConA injured 
liver (D) at 130 minutes post treatment administration.  Data presented a mean ±SEM, n≥3, ***p<0.001 (two-
way ANOVA (A) and t-test (B)) scale bars=100µm. 
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5.3.4. There is no Significant Difference in Adhesion of T-cells Injected 2 Hours Post 
Treatment between the Control and ConA Injured Liver 
In order to determine whether ConA injury leads to lymphocyte recruitment the trafficking of 
CMTMR stained T-cells and CFDA-SE stained B-cells  within ConA injured and control livers was 
tracked using intravital microscopy.  When T-cells were injected at 2 hours post-treatment 
administration there was no significant difference in the adhesion between ConA injured livers 
and control livers (Figure 5.5 A; p>0.05). ConA injury also had no significant effect on the 
number of free flowing cells within the liver compared to control (Figure 5.5 B; p>0.05).  The 
number of free flowing T-cells rapidly decreased within the first 10 minutes after cell injection.  
There was no significant difference between ConA injured and control livers in the numbers 
of T-cells in ex vivo liver cross sections taken at 4 hours post treatment administration (Figure 
5.5 E; p>0.05).   
Similar results were also obtained with B-cells.  There was no significant difference found in 
the numbers of adherent B-cells between ConA injured and control livers (Figure 5.6 A; 
p>0.05).  No significant difference was observed in the number of free flowing B-cells between 
the ConA injured and control livers (Figure 5.5 B; p>0.05).  Similarly to T-cells, the number of 
free flowing B-cells rapidly decreased within the first 10 minutes following cell injection. There 
was no significant difference in the numbers of B-cells observed in ex vivo liver cross sections 
between the ConA injured and control livers (Figure 5.6 E; p>0.05), however the number of 
B-cells was lower in the ConA injured livers.  
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Figure 5:5 There is no significant difference in adhesion of T-cells injected 2 hours post treatment between the 
control and ConA injured liver.  0.5x106 CMTMR stained T-cells were injected into the carotid artery of mice 2 
hours after administration of ConA or a vehicle control.  Intravital microscopy was used to monitor their 
trafficking within the liver.  Numbers of adherent cells (A) and free flowing cells (B) in control and ConA injured 
livers.  Images show T-cells (red) in the control liver (C) and the ConA injured liver (D) at 240 minutes post 
treatment administration. Numbers of T-cells in cross sections of the liver taken ex vivo 4 hours after treatment 
administration (E).  Data presented a mean ±SEM, n≥3, (two-way ANOVA (A&B) and t-test (E)) scale bars=100µm. 
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Figure 5:6 There is no significant difference in adhesion of B-cells injected 2 hours post treatment between the 
control and ConA injured liver.  0.5x106 CFDA-SE stained B-cells were injected into the carotid artery of mice 2 
hours after administration of ConA or a vehicle control.  Intravital microscopy was used to monitor their 
trafficking within the liver.  Numbers of adherent cells (A) and free flowing cells (B) in control and ConA injured 
livers.  Images show B-cells (green) in the control liver (C) and the ConA injured liver (D) at 240 minutes post 
treatment administration.  The numbers of B-cells in  cross sections of the liver taken ex vivo 4 hours after 
treatment administration (E).  Data presented a mean ±SEM, n≥3, (two-way ANOVA (A&B) and t-test (E))) scale 
bars=100µm. 
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5.3.5. Platelets Injected at 4 Hours Post Treatment Adhere in Significantly Lower Numbers 
within the Livers of Mice Treated With ConA Compared to Vehicle Control 
As no increase in platelet adhesion was observed at 2-4 hours post ConA treatment, the 
intravital experiments were repeated at a later time point to determine if a more developed 
injury would result in increased platelet adhesion.  For these experiments CFDA-SE stained 
platelets were introduced systemically at 4 hours post-ConA or control treatment.  Similar 
results to those seen at 2 hours post ConA administration were obtained.  Compared to the 
controls, platelet adhesion was found to be significantly reduced in the ConA injured liver 
(Figure 5.7 A; p<0.001).  The difference was most significant at 10 minutes after platelet 
injection and narrowed as the experiment continued.  In ex vivo cross sections of the livers 
there were fewer platelets in ConA injured livers than controls but this difference was not 
significant (Figure 5.7 B; p>0.05). 
5.3.6. Lymphocytes Injected at 4 hours Post Treatment Adhere in Significantly Lower 
Numbers within the Livers of Mice Treated with ConA Compared to Vehicle Control 
Lymphocyte recruitment at this later time point was also investigated.  CMTMR stained T-cells 
and CFDA-SE stained B-cells were introduced into the circulation 4 hours after ConA or vehicle 
treatment and their trafficking within the liver was visualised using intravital microscopy.  The 
number of adherent T-cells was significantly reduced in the ConA injured liver compared to 
the control (Figure 5.8 A; p<0.001).  There was no significant difference in the number of free 
flowing T-cells between the Injured and control livers (Figure 5.8 B; p>0.05).  The numbers of 
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T-cells in ex vivo cross sections of the livers at 6 hours post treatment were lower in the ConA 
injured livers than the controls but this difference was not significant (Figure 5.8 E; p>0.05). 
The results for B-cells were similar to those obtained with T-cells.  The number of adherent B-
cells was quite significantly lower in the ConA injured livers than the controls (Figure 5.9 A; 
p<0.001).  There was no significant difference in the numbers of free flowing B-cells between 
the ConA injured livers and the controls (Figure 5.9 B; p>0.05).  The numbers of B-cells in ex 
vivo cross sections of the livers was slightly lower for the ConA injured livers than the controls 
but this difference did not reach significance (Figure 5.9 E; p>0.05).  
5.3.7. CD4+ T-cell Adhesion is Significantly Higher than CD8a+ T-cell Adhesion within the 
ConA Injured Liver 
CD4+ and CD8+ T-cells are known to play very different roles in inflammation.  In order to 
investigate whether one of these subsets adheres more than the other in ConA injury equal 
numbers of each subset were infused into the circulation of mice 2 hours after being given a 
dose of ConA.  CD4+ T-cells were found to adhere in significantly greater numbers than CD8a+ 
T-cells in ConA injured liver (Figure 5.10 A; p<0.05).  Ex vivo cross sections of the liver taken at 
4 hours post ConA administration also had lower numbers of CD8a+ cells than CD4+ cells but 
this difference was not significant (Figure 5.10 E; p>0.05).  There was no significant difference 
between the numbers of free flowing CD4+ and CD8a+ T-cells (Figure 5.10 B; p>0.05).
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Figure 5:7 Platelets injected at 4 hours post treatment adhere in significantly lower numbers within the livers 
of mice injected with ConA compared to vehicle control.  1x108 CFDA-SE stained platelets were injected into the 
carotid artery of mice 4 hours after administration of ConA or a vehicle control.  Using intravital microscopy the 
number of adherent platelets within the hepatic microcirculation was monitored in ConA injured  and control 
livers (A).  The numbers of platelets in a cross sections of the liver taken ex vivo 6 hours after treatment 
administration (B).  Images show platelets (green) in the control liver (C) and the ConA injured liver (D) at 250 
minutes post treatment administration.  Data presented a mean ±SEM, n≥3, ***p<0.001 (two-way ANOVA (A) 
and t-test (B)) scale bars=100µm. 
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Figure 5:8 T-cells injected at 4 hours post treatment adhere in significantly lower numbers within the livers of 
mice injected with ConA compared to vehicle control.  0.5x106 CMTMR stained T-cells were injected into the 
carotid artery of mice 4 hours after administration of ConA or a vehicle control.  Using intravital microscopy the 
number of adherent T-cells within the hepatic microcirculation was monitored in ConA injured and control livers 
(A). The number of free flowing cells within ConA injured and control livers (B)    Images show T-cells (red) in the 
control liver (C) and the ConA injured liver (D) at 330 minutes post treatment administration.  The numbers of T-
cells in a cross section of the liver taken ex vivo 6 hours after treatment administration (E).  Data presented a 
mean ±SEM, n≥3, ***p<0.001 (two-way ANOVA (A&B) and t-test (E)) scale bars=100µm. 
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Figure 5:9 B-cells injected at 4 hours post treatment adhere in significantly lower numbers within the livers of 
mice injected with ConA compared to vehicle control.  0.5x106 CFDA-SE stained B-cells were injected into the 
carotid artery of mice 4 hours after administration of ConA or a vehicle control.  Using intravital microscopy the 
number of adherent B-cells within the hepatic microcirculation was monitored in ConA injured and control livers 
(A).  The number of free flowing cells within ConA injured and control livers  (B)    Images show B-cells (green) in 
the control liver (C) and the ConA injured liver (D) at 280 minutes post treatment administration.  The numbers 
of B-cells in a cross section of the liver taken ex vivo 6 hours after treatment administration (E).  Data presented 
a mean ±SEM, n≥3, ***p<0.001 (two-way ANOVA (A&B) and t-test (E)) scale bars=100µm.  
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Figure 5:10 CD4+ T-cell adhesion is significantly higher than CD8a+ T-cell adhesion within the ConA injured 
liver.  Equal numbers of CMTMR or CFDA-SE stained CD4+ and CD8a+ were introduced into the circulation of 
mice 120 minutes after injection of 20mg/kg ConA.  Intravital microscopy was used to monitor adhesion of these 
cells within the hepatic microvasculature (A).  The number of free flowing CD4+ and CD8a+ T-cells in the ConA 
injured liver (B).  Images show CD4+ (C) and CD8a+ (D) T-cells within the liver at 140 minutes post ConA 
treatment.  Ex vivo analysis of the number of CD4+ and CD8a+ T-cells in a cross section of the liver taken at 240 
minutes post ConA treatment (E).  Data presented a mean ±SEM, n≥4, ***p<0.001 (two-way ANOVA (A&B) and 
t-test (E)) scale bars=100µm.  
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5.3.8. Lymphocyte Adhesion within the ConA Injured Liver is Significantly Reduced 
Following Platelet Depletion 
As was shown in the previous chapter, platelet depletion reduces lymphocyte adhesion within 
the IR injured liver.  With the aim of establishing whether the same was true in ConA induced 
liver injury, platelets were depleted prior to ConA administration using CD42b antibodies.  2 
hours after ConA or vehicle control injection, CMTMR stained T-cells and CFDA-SE stained B-
cells were infused into the circulation.  The number of adherent T-cells in the liver was 
significantly reduced in platelet depleted mice compared to non-platelet depleted mice 
(Figure 5.11 A; p<0.001).  Platelet depletion had no significant effect on the number of free 
flowing T-cells within the liver (Figure 5.11 B; p<0.001).  Platelet depletion also significantly 
reduced B-cell adhesion within the ConA injured liver (Figure 5.12 A; p<0.05).  Platelet 
depletion also had no significant effect on the number of free flowing B-cells in the ConA 
injured liver (Figure 5.13 B; p<0.05). 
5.3.9. Blocking CD162 on T-cells Significantly Reduces there Adhesion within the ConA 
Injured Liver 
As platelets express CD62P in ConA injury, platelet dependent T-cell recruitment may occur 
through T-cell expressed CD162 interacting with platelet CD62P.  T-cell CD162 was blocked 
using an antibody in order to elucidate its role in T-cell recruitment to the ConA injured liver.  
Incubation with the CD162 blocking antibody significantly reduced T-cell adhesion compared 
to an IgG control (Figure 5.13 A; p<0.01).  There was no significant difference in the number 
of free flowing T-cells between those treated with IgG and those treated with blocking 
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antibody (Figure 5.13 B; p>0.05).  Ex vivo cross sections showed no significant difference in 
cell number between the blocked and control cells (Figure 5.13 E; p>0.05).
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Figure 5:11 T-cell adhesion within the ConA liver is significantly reduced following platelet depletion.  Prior to 
ConA injection mice were depleted of platelets using an antibody.  120 minutes after administration of a 20mg/kg 
ConA dose 0.5x106 CMTMR stained T-cells were introduced into the circulation.  T-cell adhesion (A) and free 
flowing T-cells (B) within the injured liver were quantitated in platelet depleted mice.  Images show T-cells within 
liver 190 minutes after ConA injection in non-platelet depleted (C) and platelet depleted mice (D).  Data 
presented a mean ±SEM, n≥3, ***p<0.001 (two-way ANOVA) scale bars=100µm. 
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Figure 5:12 B-cell adhesion within the ConA liver is significantly reduced following platelet depletion.  Prior to 
ConA injection mice were depleted of platelets using an antibody.  120 minutes after administration of a 20mg/kg 
ConA dose 0.5x106 CFDA-SE stained B-cells were introduced into the circulation.  B-cell adhesion (A) and free 
flowing B-cells (B) were quantitated in the ConA injured livers of platelet depleted mice.  Images show B-cells 
within liver 200 minutes after ConA injection in non-platelet depleted (C) and platelet depleted mice (D).  Data 
presented a mean ±SEM, n≥3, ***p<0.001 (two-way ANOVA) scale bars=100µm. 
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Figure 5:13  Blocking CD162 on T-cells significantly reduces their adhesion within the ConA injured liver.  T-cells 
were incubated for 30 minutes with either CD162 blocking antibody or an IgG control.  Their trafficking within 
the liver 120 minutes after ConA administration was monitored using intravital microscopy.  T-cell adhesion (A) 
and free flowing T-cells (B) following incubation with either CD162 blocking antibody or IgG control. Images show 
T-cells incubated with an IgG control (C) and CD162 blocking antibody (D) in the liver 220 minutes after ConA 
administration.  The number of T-cells in a cross section of the liver taken ex vivo at 240 minutes post ConA 
treatment following incubation with either CD162 blocking antibody or IgG control (E).  Data presented as mean 
±SEM, n≥3, **p<0.01 (two-way ANOVA (A&B) and t-test (E)), scale bars=100µm. 
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5.4. Discussion  
ConA injury is a well-used, clinically relevant model for many forms of hepatitis.  When 
injected intravenously into mice, it triggers a T-cell dependant liver injury (Palacios, 1982, 
Tiegs et al., 1992).  This injury appears to be primarily mediated by CD4+ T-cells (Tiegs et al., 
1992) but a role for NKT cells has also been identified (Kaneko et al., 2000, Toyabe et al., 1997, 
Diao et al., 2004).  High levels of pro-inflammatory cytokines such as TNFα, IL-6, IFNγ and IL-1 
is the feature of ConA hepatitis.  They are released from resident and infiltrating activated 
lymphocytes, as well as other hepatic cells, and contribute to disease progression.  ConA liver 
injury was used as a model to study the role of platelets in mediating T-cell recruitment using 
thrombocytopenic mice – this is novel work and has not previously been explored. Indeed, 
limited intravital studies have been conducted to monitor the mechanisms of pathophysiology 
in this model.  In the current chapter we demonstrate that ConA has a highly detrimental 
effect on overall hepatic blood flow and induces significant decreases in the numbers of 
circulating endogenous red/white blood cells and platelets.   Although no increases in injected 
donor T- or B-cell adhesion was identified in ConA injured mice, their presence was remarkably 
absent in thrombocytopenic ConA injured mice.  The novel results presented in this chapter 
provide the first evidence that lymphocyte recruitment, including CD4+ T-cells, to the ConA 
injured liver is platelet dependant.   
ConA administration was associated with macroscopically visible injury to the liver and spleen.  
Previous studies have also shown a dose of 20mg/kg sufficient to induce significant 
inflammation of the liver within 2-4 hours (Tiegs et al., 1992). This was accompanied by a 
significant decrease in circulating endogenous leukocytes, erythrocytes and platelets.  The 
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large decrease in circulating platelet numbers does not appear to have been described before. 
It has previously been shown that many circulating cells, including platelets, accumulate 
within the liver and within the spleen, both of which were noticeably enlarged and engorged 
in the current study (Massaguer et al., 2002, Miyazawa et al., 1998).  Indeed, histological 
analysis has shown the hepatic sinusoidal lumens to be occluded by agglutinated erythrocytes 
and by aggregated platelets and leukocytes during ConA injury (Massaguer et al., 2002, 
Miyazawa et al., 1998).   This would explain the decreased full blood count.  Splenomegaly is 
a common feature of liver inflammation and is generally due to congestion of the spleen 
and/or cellular infiltration.  It is frequently accompanied by anaemia and thrombocytopenia 
(McCormick and Murphy, 2000). Blood counts also showed a significant increase in mean 
platelet volume following ConA treatment, seen in conjunction with thrombocytopenia this 
generally indicates destruction of platelets. 
A comparison of the injury suffered by the liver after ConA and IR injury has not previously 
been described.  Here we show that the survival of ConA treated mice was lower than that of 
IR injured mice despite serum ALT activity showing that the liver injury in ConA treated mice 
was less severe than that of IR injured mice (almost 4 fold lower).  This low survival may be 
linked to the anaemia seen in the ConA treated animals which is compounded by the mice 
being under ketamine anaesthetic (Sanford and Colby, 1980).   
Similarly to IR injury, ConA resulted in a disruption of hepatic blood flow, as shown intravitally 
by FITC-BSA injection.  Areas of poor blood flow were clearly seen interspersed between areas 
of good perfusion.  This has previously been described histologically as a feature of ConA 
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induced liver injury and is due to cell aggregation/congestion within the hepatic 
microvasculature mentioned above (Miyazawa et al., 1998).  Histologically, it has been shown 
that at 2 hours post-ConA treatment, almost 20% of the liver sinusoids appear to show 
intrasinusoidal occlusion ((Massaguer et al., 2002).  However, laser Doppler measurements 
did not detect a decrease in tissue perfusion as was demonstrated in the previous chapter 
following IR injury.  A mild increase in laser Doppler measurements above control values was 
seen at 60 minutes post-ConA administration which progressively declined by 4 hours - this 
was not statistically significant.  Laser Doppler most likely failed to (statistically) detect an 
overall decrease in blood flow due to the greatly increased speed of blood flow within the 
perfused areas.  This was assessed by the quantification of the velocity of free flowing donor 
platelets which was significantly increased between 2 and 4 hours post-ConA.   Indeed, the 
speed at which donor platelets circulated through the perfused regions was remarkably high, 
often making it difficult to even detect the individual platelet with only a fluorescent streak 
seen.  Such high speed cellular trafficking has not previously been observed by the Kalia lab.  
This platelet velocity / blood flow remained high for the entire duration of the experiment 
unlike in IR injury where flow decreased as the injury progressed.  The increased flow speed 
within hepatic capillaries is likely due to vascular congestion in many regions of the liver, which 
would have resulted in localised increases in blood pressure / blood flow within perfused 
areas.   
Although previous histological studies have shown significant endogenous platelet 
accumulation within the liver following ConA injury (Massaguer et al., 2002), donor platelet 
adhesion was significantly reduced in our model when quantitated intravitally.  This may be 
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explained by the reduced hepatic perfusion present at the point of platelet injection.      
Qualitatively and quantitatively, there was better blood perfusion in the liver at 2 hours than 
at 4 hours post-ConA treatment, indicating the damage to the liver became progressively 
worse with time.  The importance of adequate hepatic perfusion at the time of platelet 
injection in order to deliver these cells to the liver is highlighted by the fact that 50 donor 
platelets were adherent / field of view when injected at 2 hours rather than 25-30 platelets 
adherent when injected at 4 hours post-ConA administration.  Furthermore, platelet adhesion 
was only observed in areas of blood flow.  The increased blood velocity described earlier in 
these areas of flow where platelets could adhere is also likely to affect adhesion as local 
sinusoidal shear will be elevated.  Of course, any increase in shear due to increased velocity 
may have been at least partially offset by a reduction in blood viscosity as a result of the lower 
haematocrit of ConA treated animals.   
Similarly, ConA injury did not increase either donor T- or B-cell adhesion within the liver.  
Indeed when lymphocytes were injected at 4 hours post-ConA injection their adhesion was 
significantly lower than in un-injured controls.   The same explanations used above to explain 
poor platelet adhesion may apply for these cells too.   Again, adherent lymphocytes were only 
present in areas of flow – injection of Alexa 647-BSA to highlight areas of flow showed 
adherent donor lymphocytes only in perfused areas. These results somewhat contradict 
previous studies which have shown a significant increase in T-cell infiltration of the liver 
following ConA injury (Mizuhara et al., 1994, Bonder et al., 2005).   The current intravital 
observations of limited lymphocyte adhesion does not mean the ConA injury model cannot 
attract lymphocytes to the liver.  The current study assessed donor lymphocyte adhesion, but 
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it must not be forgotten that endogenous circulating lymhocytes are also simultaneously 
recruited to the injured liver.  Indeed, Massaguer and colleagues demonstrated histologically 
that 80 endogenous lymphocytes, identified by their nuclear morphology, were present in 
liver sinusoids 2 hours post-ConA as opposed to 19.1±0.7 lymphocytes/field in healthy 
mice(Massaguer et al., 2002).  It is therefore possible that the lack of donor lymphocytes 
adhering could also be explained by them having to compete with endogenous cells for 
endothelial adhesion molecules.   Although at 2 hours the numbers of T- and B-cells adhering 
is very similar to that observed in control mice, it is important to note that this is still probably 
biologically significant as this adhesion occurs in a greatly reduced area of blood perfusion.  It 
is also possible that to identify significant lymphocyte presence, we needed to image for 
longer and inject T-/ B-cells at 6 hours post-ConA.  Indeed others have shown histologically 
that the number of CD4+ T cells in the liver peaked 6 hours post-ConA injection, and remained 
high for 24 hours with peak ALT levels observed at 12 hours (Higashimoto et al., 2013). 
Of the T-cells adhering at 2 hours post-ConA, CD4+ T-cells were found to adhere in slightly 
greater numbers than CD8a+ T-cells.  This result is in line with previous work which has shown 
significantly higher CD4+ T-cell infiltration compared to CD8+ T-cell infiltration in the ConA 
injured liver (Mizuhara et al., 1994).  In the current experiments the difference in adhesion 
between CD4+ and CD8+ T-cells was not as pronounced.  This is likely due to injecting equal 
numbers of each subset. This is in contrast to studies in which peripheral blood lymphocytes 
infiltration was quantitated where CD4+ T-cells are present in greater numbers than CD8+ T-
cells (Chen and Harrison, 2002, Mizuhara et al., 1994).  Additionally the mice used in this study 
were male C57BL/6 whereas Mizuhara et al. (1994) used female BALB/c mice.  
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Since T- and B-cell adhesion was observed at 2 hours post-ConA, platelet depletion studies 
were conducted at this time point.  In ConA induced liver injury, as with hepatic IR injury, 
platelet depletion resulted in a significant decrease in lymphocyte adhesion within the 
inflamed liver.  This is the first study to present evidence that shows a role for platelets in 
recruitment of lymphocytes to ConA induced liver injury.  As platelet depletion did not affect 
perfusion within the ConA injured liver, this reduction in lymphocyte adhesion does not 
appear to be due to a reduction in entrapment due to vessel occlusion by platelets.  It would 
have been worthwhile to determine immunohistologically whether endogenous T-cell 
infiltration was also reduced in thrombocytopenic mice as this would have provided 
confirmation of the intravital results.  
Interestingly, platelet depletion and the subsequent large reduction in lymphocyte adhesion 
did not result in a concomitant reduction in liver injury.  Indeed platelet depletion was 
associated with a doubling in serum ALT activity following ConA injury.  Macroscopically the 
liver and spleen of platelet depleted animals looked similar to those of normal animals 
following ConA treatment. These results are somewhat surprising as preventing T-cell 
recruitment to the liver by depleting circulating T-cells has been shown in a number of studies 
to reduce the injury caused by ConA (Mizuta et al., 1999).  One possible explanation for the 
injury observed in these mice is that increased haemorrhage due to platelet depletion allowed 
for increased infiltration by inflammatory cells into the hepatic parenchyma.  It is also possible 
there is reduced recruitment of those subsets of lymphocytes that may play anti-inflammatory 
or protective roles in this injury.  Mitogens such as ConA are well known to stimulate T-
lymphocyte proliferation in vitro.  However, interestingly, this in vitro proliferation can be 
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significantly inhibited by adding resting intact platelets to these cultures.  Furthermore, co-
culture also reduces surface activation markers and cytokine secretion from 
lymphocytes(Wang and Niu, 2008). This increase may reflect the possibility that platelets 
could be involved in reducing immune responses in this model.   
Although the current study has proposed platelets may mediate lymphocyte recruitment to 
ConA injured liver, others have highlighted a key role for neutrophils (Bonder et al., 2004). 
Using a similar protocol, Bonder et al., showed intravitally that although there was a significant 
increase in leukocytes interacting and adhering in the postsinusoidal venules, only a small 
proportion (∼20%) of these cells were GFP-labelled endogenous T lymphocytes, which were 
found primarily adherent within the sinusoids.  Neutrophils appeared to be the main leukocyte 
infiltrating the liver after ConA damage as determined immunohistologically.  They further 
demonstrated that neutropenic animals had little CD4+ T lymphocyte presence in the liver 
after ConA.  This clearly suggests that the ConA mediated liver injury is a multi-faceted 
pathology involving many different circulating cells contributing to each other’s recruitment 
and eventually tissue injury.   
Following CD162 blockade on T-cells, adhesion of T-cells was significantly reduced.  This result 
is in agreement with previous work showing that T-cell recruitment within the ConA liver is 
dependent on the CD162 receptor CD62P (Massaguer et al., 2002).  As CD62P is expressed on 
platelets during ConA injury (Massaguer et al., 2002), these results suggest that T-cell CD162 
interacting with platelet P-selectin is partially responsible for the role of platelets in T-cell 
adhesion following ConA injury.  However, platelet depletion resulted in a far greater drop in 
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T-cell recruitment suggesting that other mechanisms are also involved.  An increase in shear 
as evidenced by the increased blood velocity in ConA mice may explain the CD62P dependent 
nature of ConA injury.  Cellular recruitment within the inflamed liver is generally selectin 
independent due to the low shear stresses within sinusoidal vessels which circumvents the 
need for ‘rolling’ molecules on circulating cells (Wong et al., 1997).  
We have shown here, for the first time a key role for platelets as mediators of lymphocyte 
recruitment following ConA induced liver injury.  In the case of T-cells this appears to occur 
partially through interactions between platelet CD62P and lymphocyte CD162.  However, we 
have also shown that platelet depletion does not have a protective effect and may even 
exacerbate the injury.  The results presented in this chapter show marked similarities to those 
obtained with IR injured mice, presented in the previous chapter.  Clearly the presence of 
lymphocytes within the injured liver, be it an acute inflammatory reperfusion injury or an 
immune T-cell dependent injury, requires platelets.  This novel body of research contained 
within this thesis is the first study to have identified a critical role for platelets in two very 
different models of liver injury. 
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6. GENERAL DISCUSSION 
6.1. Summary and Discussion of Main Findings 
The rise in deaths related to liver disease, underlines the importance of continued research 
into the mechanisms which govern liver inflammation (British Liver Trust, 2008).  Lymphocytes 
are known to be important mediators of pathogenesis in a wide range of inflammatory 
disorders of the liver including viral hepatitis (Chisari, 1997), alcoholic liver disease (Batey and 
Wang, 2002), autoimmune hepatitis (Eggink et al., 1982) and hepatic ischaemia reperfusion 
injury (Zwacka et al., 1997).  As such it is important to understand the factors which underlie 
recruitment of these cells to the inflamed liver.  Although the primary role of platelets is in 
haemostasis, it is becoming increasingly apparent that platelets can modulate inflammatory 
and immune responses either directly or indirectly.  It is perhaps unsurprising that platelets, 
although small anucleate cells, can interact with and influence the function of other blood 
cells considering their high circulating number and the diversity of inflammatory mediators 
released from them.  It has long been known that platelets can mediate the adhesion of 
lymphocytes both in vitro (Diacovo et al., 1996b, Sheikh et al., 2004) and in vivo (Diacovo et 
al., 1996c).  However, with the exception of work carried out by Iannacone et al. (2005), 
showing a platelet dependent mechanism for Tc cell recruitment to the liver following 
hepatitis B infection,  little is known about the involvement of platelets in recruitment of 
lymphocytes to the inflamed liver.  T-cells, particularly CD4+ T-cells, are key regulators of the 
immune system and so a better understanding of platelet and T-cell interactions would impact 
a number of inflammatory and immune conditions, especially of the liver.  The primary aim of 
203 
 
this thesis was to determine whether platelets play a role in lymphocyte adhesion in two non-
viral models of liver inflammation: hepatic IR injury and ConA induced liver injury.  
The major findings of this study are as follows: 
 Adhesion of lymphocytes to CD54 and MAdCAM is increased by adherent activated 
platelets. 
 Incubation with naïve platelets increases lymphocyte adhesion to MAdCAM and 
incubation with the releasate of activated platelets increases lymphocyte adhesion to 
CD54 and MAdCAM. 
 Incubation with platelets or platelet releasate does not significantly increase the 
adhesion of lymphocytes isolated from the inguinal lymph nodes to colonic endothelial 
cells in vitro.  Incubation with activated platelets increases adhesion of splenic T-cells 
and B-cells to activated colonic endothelium in vitro.     
 Incubation with PMPs increases lymphocyte adhesion to CD54, CD106 and MAdCAM 
in vitro but does not affect lymphocyte recruitment to the IR injured liver in vivo. 
 Adhesion of T-cells but not B-cells within the hepatic microvasculature was increased 
following hepatic IR injury.  
 Depletion of platelets reduces T-cell and B-cell adhesion within the IR injured hepatic 
microvasculature. 
 Depletion of platelets reduces B-cell but not T-cell adhesion in the uninjured liver. 
 Blocking CD162 on T-cells marginally reduces their adhesion within the IR injured liver. 
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 Adhesion of T-cells and B-cells within the hepatic microvasculature was not increased 
following 2 or 4 hours ConA injury.  
 Depletion of platelets reduces T-cell and B-cell adhesion within the ConA injured 
hepatic microvasculature. 
 Blocking CD162 on T-cells marginally reduces their adhesion within the ConA injured 
liver. 
In order to image lymphocyte and platelet recruitment in the liver in vivo, and characterise 
the spatial and temporal kinetics of their interactions, the technique of intravital microscopy 
was utilised.  Intravital studies on lymphocyte trafficking have typically involved the injection 
of fluorescently labelled donor cells (Bonder et al., 2005, Gunzer et al., 2004, Fujimori et al., 
2002).  In order to minimise the number of mice used we initially aimed to label endogenous 
lymphocytes and platelets in order to avoid the use of additional donor mice.  Also, handling 
of donor cells in vitro and the isolation procedure could perturb cell surface molecules and 
change the activation status of the cells. To avoid this, we used fluorescent antibodies 
targeted against cell specific markers on endogenous lymphocytes.   However, the results 
obtained using this technique were found to be unreliable due to high levels of non-specific 
binding within the liver.  Because of this we opted to use the fluorescent intracellular dyes 
CFDA-SE and CMTMR to label T-cells and B-cells from the spleens of donor mice and platelets 
form the whole blood.  Exogenously labelling cells in this way is advantageous as they 
fluoresce brightly making them easy to visualise in vivo.  For future studies the use of 
transgenic mice which have green fluorescent protein expressing lymphocytes may prove 
useful in reducing the overall number of mice used (Singbartl et al., 2001). Indeed, Singbartl 
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and colleagues developed a transgenic mouse that expressed enhanced GFP (EGFP) in T cells 
under a CD2 promoter.  These mice continued to express the GFP even when T-cells became 
activated.  They further used this mouse to demonstrate T-cell rolling and adhesion during 
TNFα-induced inflammation in the cremaster muscle intravitally.   
 
Although the focus of the work conducted in this thesis was to characterise lymphocyte-
platelet cross-talk, we also demonstrated that a key feature of both hepatic IR injury and ConA 
induced liver injury was a major disruption of blood flow within the hepatic microvasculature.  
These observations are difficult to make without using in vivo microcirculatory imaging 
techniques.  Large areas without flow were observed in the liver in both models, which was 
coupled with an increase in flow rate within the areas of flow although this increase was only 
transitory in IR injury.  These disruptions in flow have major implications for cellular 
recruitment within the liver.  Lack of flow causes localised hypoxia and also prevents invasion 
of the surrounding tissue by circulating cells.  In addition, higher rates of flow  result in higher 
shear rates which may lead to changes in the mechanisms of cellular adhesion.  For example 
selectins are not normally required for leukocyte adhesion within the liver (Wong et al., 1997) 
but may be involved at these higher shears.  Furthermore, high shear rates may lead to an 
inability for adhesive interactions to occur or be sustained.  Wall shear stresses confer an anti-
adhesive force on circulating cells that that opposes the pro-adhesive forces generated by 
leukocyte and endothelial adhesion molecules.  Therefore, when blood flow increases, less 
leukocyte adhesion occurs.  Indeed,  to ensure platelets are able to adhere to blood vessels at 
high shear, both the GPIb–VWF interactions as well as the α21–collagen interaction are used, 
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possibly serving as a physiologic safeguard if one of these mechanisms is defective (Moroi and 
Jung, 2007). Therefore, in the current study, the observed lymphocyte adhesion in IR injured 
mice, although small, is quite remarkable considering the higher blood flow velocity. 
 
Both injury models resulted in an expected increase in serum ALT, a specific biochemical 
marker of hepatic injury.  Interestingly, this increase was lower in ConA treated animals than 
IR injured animals despite the former having lower survival.  This implies that the reduced 
survival of ConA treated mice is not caused by liver damage per se and is most likely the result 
of severe anaemia that was observed in these animals.  It is possible that a lower dose of ConA 
such as the 13mg/Kg used by Bonder et al. (2004) may improve the survival of these animals 
for future experiments. Whether a change in dose (and hence overall survival) impacts on the 
lymphocyte and platelet events remains to be elucidated. 
 
We hypothesised that both hepatic IR injury and ConA induced liver injury would result in 
increased adhesion of both platelets and lymphocytes within the hepatic microvasculature.  
This however was found not to be the case.  In fact the only increase in adhesion observed 
was that of T-cells following hepatic IR injury.  Given the disrupted blood flow observed in our 
injury models this is perhaps not very surprising.  As at the point of cell introduction areas of 
no flow were already present and so the area in which cells could potentially adhere was 
greatly reduced.  The rate of blood flow within the hepatic sinusoids was also increased at the 
point of cell injection, which may have reduced the cells ability to form stable interactions 
with the endothelium.  
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The work we have presented here clearly shows that adhesion of T-cells and B-cells within the 
liver is platelet dependent in both hepatic IR injury and ConA induced liver injury.  Iannacone 
et al. (2005) previously showed that Tc cell recruitment to the liver following hepatitis B 
infection was platelet dependent but this is the first time that such a role for platelets has be 
described in non-viral liver inflammation.  It is also the first time that a platelet dependent 
mechanism for B-cell adhesion in the inflamed liver has been observed.  Interestingly although 
both T-cells and B-cells did adhere within the uninjured liver, platelet depletion only resulted 
in a small decrease in B-cell adhesion.  This suggests the mechanisms of lymphocyte adhesion 
differ between the inflamed and uninjured liver. Investigation of CD4+ and CD8+ T-cell 
revealed that both subsets adhered relatively equally within the IR injured liver and within the 
ConA injured liver although CD4+ T-cell adhesion was slightly higher.  Previous studies have 
shown that CD4+ T-cell infiltration into the liver is significantly higher than CD8+ T-cell 
infiltration in both injury models (Zwacka et al., 1997, Mizuhara et al., 1994).  These 
differences in results are likely due to the unequal ratio of CD4+ to CD8+ T-cells in the 
circulation in contrast to the equal numbers of donor cells injected in our experiments (Chen 
and Harrison, 2002).  As adhesion of T-cells was almost completely abrogated by platelet 
depletion in both models, and the T-cells used in these experiments were roughly 50% CD4+ 
and 42% CD8+, it can be concluded that both CD4+ and CD8+ T-cell recruitment is platelet 
dependent in both of these models. 
 
There are various possible mechanisms by which platelets could mediate lymphocyte 
adhesion within the inflamed liver.  The results of the work presented in this thesis 
investigating the possible mechanisms involved are summarised in Figure 6.1.  In vitro data 
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suggests that platelet releasate is a key mediator of lymphocyte adhesion.  One component 
of activated platelet releasate, PMPs, was shown to increase adhesion of lymphocytes to 
immobilised cell adhesion molecules.  These results were not replicated in vivo in the IR 
injured liver, however high levels of PMPs are present in the blood following injury and are 
likely to mask any effect of pre-incubation with PMPs.  The effects of two platelet released 
cytokines, CCL5 and CXCL12, were also investigated but were found to not significantly alter 
T-cell adhesion to immobilised cell adhesion molecules in vitro.  These results suggest that 
platelet released factors such as PMPs may play critical roles in recruitment of lymphocytes to 
the inflamed liver - this area certainly requires further study 
 
In addition to platelet released factors, T-cell recruitment in both hepatic IR injury and ConA 
induced liver injury was shown to be partially dependent on the T-cell expressed CD62P ligand 
CD162.  This is in line with previous studies showing that T-cells roll on immobilised activated 
platelets in a CD62P dependent manner (Diacovo et al., 1996b, Sheikh et al., 2004).  The B-cells 
used in this study did not express CD162 and, although expressed on around 30% of circulating 
B-cells, it appears to be inactive so is unlikely to be involved in B-cell adhesion (Vachino et al., 
1995).  Despite these findings the importance of direct lymphocyte-platelet interaction in 
recruitment of lymphocytes to liver in the two injury models remains unclear.  Although T-cell 
adhesion was lower in both injury models following CD162 blocking it was still higher than 
following platelet depletion. Additionally, in our in vitro studies, lymphocytes were only very 
rarely seen in direct contact with platelets.  However, a number of possible mechanisms of 
direct platelet-lymphocyte interactions, including lymphocyte expressed CD11a/CD18 and 
CD11b/CD18 interactions with platelet CD102 (Sheikh et al., 2004, Diacovo et al., 1994) and 
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lymphocyte expressed CD40 interactions with platelet expressed CD154 (Elzey et al., 2003), 
were not investigated here. 
 
Flow following injury was not improved following platelets depletion in either model. 
Therefore, it can be concluded, that the decrease in stationary (adherent) lymphocytes 
observed following platelet depletion was not due to a reduction in entrapment of 
lymphocytes by platelet aggregates occluding the vasculature.  These results are comparable 
to those of Iannacone et al. (2005) which showed that recruitment of Tc cells to the liver during 
acute viral hepatitis is independent of platelet coagulation. 
The similarities in the in vivo results observed between the two models used in this study are 
quite surprising as marked differences exist between the pathological mechanisms of the two 
injuries.  Hepatic IR injury is generally believed to be primarily mediated by neutrophils with 
CD4+ T-cells playing a role in neutrophil recruitment (Zwacka et al., 1997, Jaeschke et al., 
1990).  In contrast ConA induced liver injury is primarily mediated by CD4+ T-cells and 
NKT-cells with neutrophils playing a lesser role (Tiegs et al., 1992, Toyabe et al., 1997, Bonder 
et al., 2004).  Cytokines are important mediators of cell recruitment in both injury models, 
however the exact cytokines involved differ between the two.  For example IL-4 is required 
for ConA induced liver injury however it elicits anti-inflammatory effects in hepatic ischemia 
reperfusion injury (Toyabe et al., 1997, Kato et al., 2000).  In addition to cytokines ROS formed 
due to hypoxia are important in the development of hepatic IR injury (Zhang et al., 2007).  
Production of superoxide by Kupffer cells is also an important mediator of ConA induced liver 
injury (Nakashima et al., 2008). There is also likely to be a hypoxic element to the mechanism 
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of ConA induced liver injury due to the large areas of non-perfused liver. However, it is likely 
that there is far less hypoxia in ConA injury than hepatic IR injury therefore it is logical that 
ROS levels are lower in ConA injury than in hepatic IR injury.  
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Figure 6:1 Platelet dependent mechanisms of lymphocyte recruitment.  In this thesis we have shown that platelets (green) mediate lymphocyte (orange) adhesion 
following hepatic injury, this could occur through a number of mechanisms.  Evidence presented in this study suggests that mechanisms highlighted in green are 
involved, and that those highlighted in red are not involved, in lymphocyte recruitment to both the IR injured liver and ConA injured liver.  Mechanisms written in grey 
may be involved but were not investigated in this study.  PMP, platelet micro-particle; VEGF, vascular endothelial growth factor; PAF, platelet activating factor. 
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6.2. Future Work 
The work presented in this thesis opens a number of possible avenues for further research.  
We have shown a role for platelets in recruitment of lymphocytes in ConA induced liver injury 
and hepatic IR injury.  However the long-term effects of platelet depletion in these models 
remains unclear.  Platelet derived serotonin has been shown to be important in liver 
regeneration following IR injury (Nocito et al., 2007, Lesurtel et al., 2006); however, the effects 
of platelets on liver regeneration following ConA administration are unknown.  Allowing the 
injury to develop for a longer period would give a better idea of the effects of platelet 
depletion on injury severity, recovery and inflammatory cell infiltration at later time points.  
Indeed the peak of injury measured by serum ALT level occurs about 12 hours after ConA 
administration (Zhou et al., 2013) and about 6 hours following hepatic ischaemia (Yadav et al., 
1999) - far later than the time periods monitored in this study. 
Having shown here that platelets are involved in the recruitment of B-cells to the IR and ConA 
injured livers, it would be interesting to investigate the role of B-cells in these models.  This 
could be achieved using B-cell deficient mice (Kitamura et al., 1991) or through depletion of 
B-cells using antibodies (Uchida et al., 2004). It would be particularly interesting to investigate 
their effect on recovery in these models as they are known to mediate liver fibrosis in CCl4 
induced hepatitis (Novobrantseva et al., 2005). 
Although our novel studies have unravelled some of the mechanisms involved in platelet 
recruitment of lymphocytes, further work is required.  Interaction between platelet CD154 
and lymphocyte expressed CD40 have been suggested as a possible mechanism for 
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lymphocyte platelet interaction (Elzey et al., 2003) but has not been investigated here. This 
could be investigated through tracking lymphocyte recruitment to the inflamed liver in CD154-
/- mice infused with normal or CD154-/- platelets (Elzey et al., 2003). Although our in vitro 
studies have shown platelet released factors to increase lymphocyte adhesion their in vivo 
role was not determined.  The anti-platelet drug Clopidogrel was used by Nocito et al. (2007) 
to block aggregation but not release of inflammatory mediators by platelets in the IR injured 
liver. This could potentially be used to either confirm or rule out platelet released factors as 
mediators of lymphocyte recruitment in our models. The effect of aspirin and warfarin on 
lymphocyte recruitment in the models used in this thesis would also be of interest. Iannacone 
et al. (2005) Showed that both Clopidigrel and aspirin, but not warfarin, could reduce 
recruitment of CD8+ T-cells in models of viral hepatitis.  
Another possible mechanism not investigated here is platelet mediated activation of 
endothelial cells leading to lymphocyte recruitment.  Staining for adhesion molecules usually 
up-regulated following activation of hepatic endothelium, such as CD54 and CD106 (Steinhoff 
et al., 1993), in platelet depleted mice may show if this is important in mediating lymphocyte 
recruitment. 
It would also be of interest to examine the role that hyaluronic acid (HA) plays in these injury 
models. The lymphocytes used in this thesis do express the HA receptor CD44, as do platelets 
(Koshiishi et al., 1994). In addition to this high levels of HA expression occur in the liver under 
both basal and inflammatory conditions (McDonald et al., 2008). Indeed, high levels of HA are 
observed in the serum during liver fibrosis and may be useful clinical marker (Geramizadeh et 
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al., 2008). It is possible that HA may act as a bridge between CD44 on platelets and 
lymphocytes. HA is already known to act as a bridge between lymphocytes and endothelial 
cells (DeGrendele et al., 1996).  Another reason to investigate the role of HA is that platelet 
released growth factors have previously been shown to upregulate HA expression by 
fibroblasts and vascular smooth muscle cells (Papakonstantinou et al., 1995, Anitua et al., 
2007). HA could easily be rapidly broken down in the injury models used in this thesis through 
the injection of hyaluronidase (White, 2014). However, this would also effect neutrophil 
recruitment in these models as CD44-HA interactions have been shown to be important in 
neutrophil adhesion within the sinusoids (McDonald et al., 2008).      
Whilst our studies focused on the liver, platelets may also be required for lymphocyte 
recruitment to other inflamed organs.  There is evidence for platelet dependent lymphocyte 
recruitment following allergic pulmonary inflammation (Pitchford et al., 2004), although it is 
not known whether platelets are important in recruitment of lymphocytes to other inflamed 
organs.  Lymphocyte mediated inflammation that occurs with high levels of platelet 
recruitment are also observed in the IR injured kidney and so renal injury may be good models 
for further investigation (Chintala et al., 1994, Awad et al., 2006). 
6.3. Concluding Remarks 
Inflammation of the liver is a common clinical problem with limited treatment options.  In 
order to best treat hepatic inflammation we first require an understanding of the processes 
involved.  The mechanisms underlying recruitment of inflammatory cells to the liver are often 
poorly understood particularly in non-viral hepatitis.      
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Platelets have long been known to be involved in the maintenance of haemostasis but it is 
becoming increasingly clear that they are also important mediators of inflammation.  The work 
presented in this thesis adds to the growing body of evidence that platelets are vital in the 
recruitment of inflammatory cells to the inflamed liver.  Whether anti-platelet strategies can 
be of use in the treatment of liver inflammation remains to be seen but the work carried out 
to date makes it an intriguing avenue of research.   
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